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Abstract
The autosomal recessive inherited, metabolic disorder phenylketonuria (PKU) is caused by a deficiency
of the enzyme phenylalanine hydroxylase (PAH) - a key enzyme in the catabolism of phenylalanine.
PKU patients present with noxiously increased concentrations of the amino acid phenylalanine in the
plasma, leading to a so-called hyperphenylalaninemia. This disorder is treatable by avoiding uptake of
phenylalanine. As this amino acid is naturally ubiquitously present in normal nutrition, patients have to
follow a very strict and artificial diet in order to evade the grave consequences, such as severe mental
retardation, they would have to expect otherwise. In the 1970s it was realised that there exists another
cause of hyperphenylalaninemia which led to the detection of tetrahydrobiopterin deficiency. The
connecting link between these two disor-ders is tetrahydrobiopterin (BH4), the natural cofactor of
phenylalanine hydroxylase and other members of the aromatic amino acid hydroxylases, enzymes
pivotal for catecholamine and serotonin biosynthesis. BH4 serves also as an essential cofactor for other
enzymes (nitric oxide synthase and glyceryl-ether monooxygenase) and has additional functions on a
cellular level. In recent years an other new variant of hyperphenylalaninemia/PKU was described
(BH4-responsive HPA/PKU). Patients with this type of PKU are characterised by a marked reduction
and normalisation of the increased phenylalanine concentration after oral loading with BH4. This
finding opened a new perspective for a pharmacological treatment of so-called BH4-responsive
HPA/PKU, as an alternative to the phenylalanine restricted diet which has notoriously a low
compliance. With BH4 tested in medication of BH4-responsive HPA/PKU patients and being already
used to treat BH4-deficient patients, our interest in the effects of exogenous BH4 on the organism was
aroused. We started a project to study the influence of BH4, its metabolism and regulation.  In the
course of our study, we developed a new method for the measurement of different pterins (neopterin,
biopterin, and pterin) in dried blood spots, which could be of use as an alternative in the screening for
BH4 deficiencies. We identified new patients with GTP cyclohydrolase I deficiency,
6-pyruvoyl-tetrahydropterin synthase deficiency, and dihydropteridine reductase deficiency using this
method. Extensive pharmacokinetic studies of BH4 have been performed in animal models but only few
parameters are known from studies in humans. With the dried blood spots method we analysed the
pharmacokinetics of orally administered BH4 in 71 patients with hyperphenylalaninemia and calculated
a rapid absorption- (1.1 h) and distribution phase (2.5 h) and a slower elimination phase (46 h). Previous
findings of others, that BH4-responsiveness was higher among patients with mild PAH mutations, could
be confirmed.In a third part we looked at the molecular genetics of BH4 responsive HPA/PKU patients.
By virtue of data mining in the BIOPKU database we identified 60 different mutations associated with
BH4 responsiveness and analysed the frequency of potentially responsive genotypes and their dispersal
in Europe. We estimated an average of 55% responsive amongst HPA/PKU patients in Europe.  We also
studied the outcome and made a long-term follow-up of 36 patients with BH4 defi-ciency, 26 with a
6-pyruvoyl-tetrahydropterin deficiency and 10 with dihydropteridine reduc-tase deficiency, the two
most common forms of BH4-deficiency. Our data suggested that diagnosis within the first month of life
is essential for a good outcome and that low  5-hydroxyindolacetic acid and homovanillic acid values in
cerebrospinal fluid could be an indicator for the ongoing developmental impairment, even in absence of
neurological symptoms.  In a last part, we investigated in the effects of BH4 on the metabolism and
regulation of en-zymes, either directly involved in the biosynthesis and regeneration of BH4 or
otherwise associ-ated with BH4 metabolism. The experiments were performed employing various cell
lines, which were treated by supplementation of BH4 and other agents with either stimulating or
inhibiting effects. In most investigated cell lines, after supplementation with cytokines, a significant and
strong up-regulation (~50-fold) of the gene expression of GCH1 was found, the gene encoding for GTP
cyclohydrolase I, the first and rate limiting enzyme in BH4 de novo biosynthesis. Furthermore, the
expression of AKR1B1, involved in alternative pathway, was found to be upregulated (~4-fold). A slight
but significant reduction of the transcription of QDPR, coding for the enzyme dihydropteridine
reductase, was observed after supplementation with sepiapterin, known to be taken up quickly by cell
cultures and intracellularly converted to BH4.   
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 ABSTRACT 
 
The autosomal recessive inherited, metabolic disorder phenylketonuria (PKU) is caused by a 
deficiency of the enzyme phenylalanine hydroxylase (PAH) – a key enzyme in the catabolism 
of phenylalanine. PKU patients present with noxiously increased concentrations of the amino 
acid phenylalanine in the plasma, leading to a so-called hyperphenylalaninemia. This disorder is 
treatable by avoiding uptake of phenylalanine. As this amino acid is naturally ubiquitously 
present in normal nutrition, patients have to follow a very strict and artificial diet in order to 
evade the grave consequences, such as severe mental retardation, they would have to expect 
otherwise. 
In the 1970s it was realised that there exists another cause of hyperphenylalaninemia which led 
to the detection of tetrahydrobiopterin deficiency. The connecting link between these two disor-
ders is tetrahydrobiopterin (BH4), the natural cofactor of phenylalanine hydroxylase and other 
members of the aromatic amino acid hydroxylases, enzymes pivotal for catecholamine and 
serotonin biosynthesis. BH4 serves also as an essential cofactor for other enzymes (nitric oxide 
synthase and glyceryl-ether monooxygenase) and has additional functions on a cellular level. 
In recent years an other new variant of hyperphenylalaninemia/PKU was described (BH4-
responsive HPA/PKU). Patients with this type of PKU are characterised by a marked reduction 
and normalisation of the increased phenylalanine concentration after oral loading with BH4. 
This finding opened a new perspective for a pharmacological treatment of so-called BH4-
responsive HPA/PKU, as an alternative to the phenylalanine restricted diet which has 
notoriously a low compliance. 
With BH4 tested in medication of BH4-responsive HPA/PKU patients and being already used to 
treat BH4-deficient patients, our interest in the effects of exogenous BH4 on the organism was 
aroused. We started a project to study the influence of BH4, its metabolism and regulation.  
In the course of our study, we developed a new method for the measurement of different pterins 
(neopterin, biopterin, and pterin) in dried blood spots, which could be of use as an alternative in 
the screening for BH4 deficiencies. We identified new patients with GTP cyclohydrolase I 
deficiency, 6-pyruvoyl-tetrahydropterin synthase deficiency, and dihydropteridine reductase 
deficiency using this method. 
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 Extensive pharmacokinetic studies of BH4 have been performed in animal models but only few 
parameters are known from studies in humans. With the dried blood spots method we analysed 
the pharmacokinetics of orally administered BH4 in 71 patients with hyperphenylalaninemia 
and calculated a rapid absorption- (1.1 h) and distribution phase (2.5 h) and a slower elimination 
phase (46 h). Previous findings of others, that BH4-responsiveness was higher among patients 
with mild PAH mutations, could be confirmed.In a third part we looked at the molecular 
genetics of BH4 responsive HPA/PKU patients. By virtue of data mining in the BIOPKU 
database we identified 60 different mutations associated with BH4 responsiveness and analysed 
the frequency of potentially responsive genotypes and their dispersal in Europe. We estimated 
an average of 55% responsive amongst HPA/PKU patients in Europe.  
We also studied the outcome and made a long-term follow-up of 36 patients with BH4 defi-
ciency, 26 with a 6-pyruvoyl-tetrahydropterin deficiency and 10 with dihydropteridine reduc-
tase deficiency, the two most common forms of BH4-deficiency. Our data suggested that 
diagnosis within the first month of life is essential for a good outcome and that low  
5-hydroxyindolacetic acid and homovanillic acid values in cerebrospinal fluid could be an 
indicator for the ongoing developmental impairment, even in absence of neurological symptoms.  
In a last part, we investigated in the effects of BH4 on the metabolism and regulation of en-
zymes, either directly involved in the biosynthesis and regeneration of BH4 or otherwise associ-
ated with BH4 metabolism. The experiments were performed employing various cell lines, 
which were treated by supplementation of BH4 and other agents with either stimulating or 
inhibiting effects. In most investigated cell lines, after supplementation with cytokines, a 
significant and strong up-regulation (~50-fold) of the gene expression of GCH1 was found, the 
gene encoding for GTP cyclohydrolase I, the first and rate limiting enzyme in BH4 de novo 
biosynthesis. Furthermore, the expression of AKR1B1, involved in alternative pathway, was 
found to be upregulated (~4-fold). A slight but significant reduction of the transcription of 
QDPR, coding for the enzyme dihydropteridine reductase, was observed after supplementation 
with sepiapterin, known to be taken up quickly by cell cultures and intracellularly converted to 
BH4. 
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 ZUSAMMENFASSUNG 
 
Die autosomal-rezessiv vererbte Stoffwechselkrankheit Phenylketonurie (PKU) wird durch 
einen Defekt des Enzyms Phenylalaninhydroxylase (PAH) verursacht, das für den 
Katabolismus von Phenylalanin verantwortlich ist. Im Plasma von PKU Patienten wird eine 
gesundheitschädlich erhöhte Konzentration der Aminosäure Phenylalanin gefunden, was zu 
einer so genannten Hyperphenylalaninämie führt. Wird eine Aufnahme von Phenylalanin 
vermieden, lässt sich diese Krankheit gut kontrollieren, da diese Aminosäure aber omnipräsent 
in der normalen Nahrung vorliegt, müssen PKU Patienten eine spezielle, künstliche Diät halten. 
Wenn diese nicht strikt befolgt wird, drohen schwerwiegende Konsequenzen, wie 
Entwicklungsverzögerungen und geistige Behinderung. 
In den 1970er wurde mit der Entdeckung der Tetrahydrobiopterin-Defizienz eine weitere Ursa-
che für Hyperphenylalaninämien gefunden. Das verbindende Element dieser beiden Krankhei-
ten ist das Tetrahydrobiopterin (BH4), der natürliche Cofaktor der Phenylalaninhydroxylase und 
anderer Aromatischer-Aminosäure-Hydroxylasen, welche entscheidend an der Biosynthese von 
Katecholaminen und Serotonin beteiligt sind. BH4 dient auch anderen Enzymen als essentieller 
Cofaktor (NO-Synthase, Glycerl-Ether Monooxygenase) und hat weitere Funktionen auf Stufe 
der Zelle. 
In der jüngsten Vergangenheit wurde eine neue PKU Variante beschrieben (BH4-sensitive 
HPA/PKU). Patienten mit dieser Form PKU bzw. HPA zeichnen sich durch eine deutliche 
Reduktion und Normalisierung der Phenylalaninkonzentration nach einer oralen Verabreichung 
von BH4 aus. Diese Entdeckung eröffnete neue Perspektiven für eine medikamentöse 
Behandlung von PKU, als Alternative zur Diät mit reduziertem Phenylalaningehalt, die 
bekanntermassen eine schlechte Compliance aufweist. 
BH4 wird als Medikation von BH4-sensitiven HPA/PKU Patienten getestet und wird in der 
Behandlung von Patienten mit BH4-Mangel bereits seit einiger Zeit eingesetzt. Dies erweckte 
unser Interesse zu untersuchen, welche Einflüsse das exogen zugeführte BH4 auf den Organis-
mus hat und wir starteten ein Projekt, um die Effekte, den Metabolismus und die Regulation 
von BH4 zu untersuchen. 
Im Verlaufe unserer Studie entwickelten wir eine neue Methode zur Messung verschiedener 
Pterine (Neopterin, Biopterin und Pterin) in Trocken-Blut, die als alternative Methode im BH4-
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 Defizienzen-Screening dienen könnte. Es war uns möglich, neue Patienten mit GTP 
Cyclohydrolase I Defizienz, 6-Pyruvoyltetrahydropterin Synthase Defizienz und Dihydropteri-
din Reduktase Defizienz mit dieser Methode zu identifizieren.  
In früheren Studien wurden umfassende pharmakokinetische Untersuchungen mit BH4 an 
Tiermodellen durchgeführt aber nur wenige Parameter waren von Studien mit Menschen 
bekannt. Mit oben erwähnter Methode analysierten wir die Pharmakokinetik von oral 
verabreichtem BH4 in 71 Patienten mit Hyperphenylalaninämie und fanden eine schnelle 
Absorptions- (1.1 h) und Verteilungsphase (2.5 h), sowie eine etwas langsamere 
Ausscheidungsphase (46 h). 
In einem dritten Teil untersuchten wir die molekulare Genetik von BH4-sensitiven HPA/PKU 
Patienten. Mittels Data-Mining in der BIOPKU Datenbank identifizierten wir 60 verschiedene 
Mutationen, die wir mit einer BH4-Sensitivität assoziieren konnten. Wir untersuchten die 
Genfrequenz von potentiell sensitiven Genotypen und deren Verteilung in Europa. Wir 
berechneten einen Anteil von 55% BH4-sensitiven in der Gesamtheit der PKU Patienten in 
Europa. 
Andere Studien fanden, dass besonders Patienten mit milden PAH Mutationen auf eine BH4-
Gabe ansprechen. Diese Forschungsergebnisse konnten wir bestätigen. 
Weiter analysierten wir den Langzeit-Therapieerfolg von 36 Patienten mit einer BH4-Defizienz, 
26 davon litten an einem 6-Pyruvoyltetrahydropterin Synthase Mangel und 10 an einer 
Dihydropteridin Reduktase Defizienz, den zwei häufigsten Formen einer BH4-Defizienz. 
Aufgrund unserer Daten kamen wir zur Feststellung, dass eine Diagnose im ersten 
Lebensmonat entscheidend für einen positiven Therapieverlauf ist und dass eine tiefe 
Konzentration von 5-Hydroxyindolessigsäure und Homovanillinsäure im Liquor cerebrospinalis, 
auch bei fehlenden neurologischen Symptomen als Indiz für eine anhaltende Beeinträchtigung 
der Entwicklung dienen könnte.  
In einem letzten Teil haben wir die Effekte von BH4 auf den Metabolismus und die Regulation 
von Enzymen studiert, die entweder direkt an der Biosynthese bzw. Regeneration von BH4 
beteiligt sind oder aber sonst mit der BH4 Synthese assoziiert sind oder BH4 als Cofaktor für 
ihre enzymatische Aktivität nutzen. Wir wollten wissen, ob durch BH4-Gabe, wie das z.B. bei 
PKU Patienten der Fall ist, andere Stoffwechselsysteme beeinflusst werden. Zur Durchführung 
der Experimente machten wir von diversen Zelllinien Gebrauch, die wir durch Zugabe von BH4 
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 und anderer Reagenzien beeinflussten, was entweder zu stimulierenden oder inhibierenden 
Effekten des BH4-Systems führte. In den meisten der untersuchen Zelllinien fanden wir, nach 
Zugabe von Zytokinen, eine starke, signifikante Erhöhung (~50-fach) der Expression von 
GCH1, dem Gen der GTP Cyclohydrolase I, die das erste und geschwindigkeitsbestimmenden 
Enzym der BH4 de novo Biosynthese darstellt. Weiter wurde gefunden, dass die Expression des 
Gens AKR1B1, involviert im alternativen Stoffwechselweg von BH4, ebenfalls induziert wurde. 
Nach Zugabe von Sepiapterin, das von Zellen rasch aufgenommen und in BH4 umgewandelt 
wird, fanden wir tendenziell eine leichte Reduktion der Expression von QDPR, dem Gen, das 
die Dihydropteridin Reductase codiert. 
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 C h a p t e r  1  
INTRODUCTION 
 
Phenylketonuria and hyperphenylalaninemia 
Phenylketonuria: from discovery to therapy 
Phenylketonuria (PKU) is a widespread autosomal recessive genetic disorder (OMIM 261600) 
which results from a deficiency of the hepatic enzyme phenylalanine-4-hydroxylase (PAH). It is 
characterised by mental retardation if untreated. Nowadays most developed countries routinely 
perform newborn screening to detect PKU (Scriver 2007). 
The discovery of PKU was made in the year 1934 by the Norwegian physician Asbjørn Følling, 
when a mother of two mentally retarded children came to him for advice. Her seven-year-old 
daughter was only capable of speaking a few words, and had a purposeless way of moving 
around, the four-year-old son did not walk, was unable to fix his eyes on anything and his stool 
and urine habits were those of a baby. They both had a fair complexion and somewhat spastic 
extremities. A peculiar mousy odour was emanating from their body and urine. By classical, 
organic-chemical means, Følling proved that these two children and eight additional patients, 
suffering from mental retardation, excreted phenylpyruvic acid in their urine. Based on these 
observations he named the disease imbecillitas phenylpyrouvica (Følling 1994). 
The following year this disease was renamed to phenylketonuria by S.L. Penrose (Hendriksz 
and Walter 2004; Penrose 1998) and in 1947 G.A. Jervis could prove that phenylketonuria is 
based on the deficiency to metabolise the amino acid phenylalanine to tyrosine (Jervis 1953). 
Some years later Woolf and Vulliamy (Woolf and Vulliamy 1951) suggested that a 
phenylalanine-restricted diet might be beneficial in preventing patients from neurological 
damage. This hypothesis was first successfully tested in 1953 by German paediatrician H. 
Bickel, who treated effectively a patient with phenylalanine low diet (Bickel 1996; Woolf et al. 
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1955). These two characteristics made phenylketonuria a paradigm for treatable genetic 
diseases (Scriver and Waters 1999). 
 
Hyperphenylalaninemia 
In the 1960s the introduction of newborn screening for PKU started, using then a simple 
bacterial growth test with bacillus subtilis, not until then it was considered that classification in 
PKU might become necessary one day (Guthrie and Susi 1963). Ever since, PKU has proven to 
be a disorder with a broad spectrum of different phenotypes (Marsden and Levy 2006). The 
most severe form, the classical PKU, shares with the other, less grave forms, the fact that blood 
phenylalanine levels are increased. This condition is called hyperphenylalaninemia (HPA); 
today serum concentrations above 120 µM are regarded as pathologically increased. In the 
following years, it was found that HPA is genetically a heterogeneous disorder; 98% of the 
patients suffering from HPA present with a defect of hepatic enzyme PAH. To date (2007) over 
500 different mutations in the encoding gene PAH have been detected and recorded in the 
locus-specific PAHdb database (http://www.pahdb.mcgill.ca/). Most patient are compound 
heterozygous, and the vast number of possible combinations, of alleles with grave or less 
serious mutations, partially explains the variety in degree of severity of this disorder. 
In the 1970s it became recognised that in the remaining 2%, HPA was caused by a lack of 
sufficient tetrahydrobiopterin (BH4), the natural cofactor of the enzyme PAH (Kaufman et al. 
1975, 1978; Tada et al. 1970). 
The classification of the grade of HPA is mainly based on the plasma concentrations of 
phenylalanine in the untreated patient. There is no world wide consensus on cut-off values, but 
generally following classification, in descending order in respect of phenylalanine (Phe) 
concentration, applies: 1) classical PKU (Phe >1200 µM), 2) moderate/mild PKU (Phe 600-
1200 µM), and 3) non-PKU/mild HPA (Phe <600 µM) (Table 1). Besides of these, there are 
also the BH4 deficiency and transient forms of HPA due to: prematurity, iatrogenesis, neonatal 
liver disease, and maternal hyperphenylalaninemia (Marsden and Levy 2006). 
HPA as a metabolic consequence of PAH deficiency can have a toxic effect on the brain due to 
a drastic increase of plasma phenylalanine, which may even exceed concentrations of 1200 µM, 
but there is evidence that levels below 600 µM in untreated patients may not be harmful for the 
cognitive development (Scriver and Kaufman 2001; Scriver et al. 1994). Patients with a mild 
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HPA do not need to follow a phenylalanine restricted diet; nevertheless a thoughtful approach 
to intake of protein-rich nutrition is recommended (Matalon and Michals-Matalon 2006). 
PKU/HPA is, as mentioned before, an autosomal recessive disorder, inherited in a Mendelian 
fashion, with an average incidence of about 1:10’000 newborns in Europe. The occurrence can 
vary considerably between different countries, for example on Ireland an incidence of approx. 
1:4500 was stated, whereas in Finland the ratio was estimated to be below 1:100’000 (Guldberg 
et al. 1995; Zschocke 2003). 
The name phenylketonuria was coined in recognition of the unusual metabolic by-products 
resulting from the inability of HPA patients to metabolise dietary phenylalanine to tyrosine. 
Instead phenylalanine is accumulated in the blood and partly degraded to phenylpyruvate, 
phenylacetate and phenyllactate, which all can be found in the patient’s urine. In addition to the 
toxic effects of phenylalanine, it can outcompete other large neutral amino acids (such as 
tyrosine, tryptophan and branched chain amino acids etc.) in the transport through the blood-
brain barrier into the brain, as the responsible carrier protein has the lowest Km for 
phenylalanine. This leads to an increased influx of phenylalanine into the brain and to a 
reduction of the already decreased concentrations of tyrosine. It was suggested that these two 
factors cause brain protein synthesis to decrease, and stimulate myelin turnover on the other 
hand, besides of the occurrence of further abnormalities in the amine neurotransmitter systems, 
explaining brain damages seen in untreated patients (Matsuo and Hommes 1987; Surtees and 
Blau 2000). 
 
Phenylalanine-4-hydroxylase 
The cause of the disorder discovered by Følling, is a deficiency of the enzyme phenylalanine-4-
hydroxylase (PAH; EC 1.14.16.1). It is encoded by the gene PAH on chromosome 12q22-q24.2. 
It contains 13 exons, spanning about 171 kb, which translate into a 52 kDa protein with a 
primary sequence of 452 amino acids (Scriver 2007). 
PAH catalyses the para-hydroxylation of L-phenylalanine to L-tyrosine using BH4 as a cofactor, 
and O2 as additional substrate. In addition to this, PAH shows a strict requirement for a non-
heme iron. Under physiological conditions, PAH consumes about 75% of the phenylalanine 
taken up from food or gained through protein catabolism (Scriver and Kaufman 2001). It is 
functionally active as a homotetramer, and in solution it is present in equilibrium with dimers 
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(Kaufman 1993; Pey and Martínez 2006). Its monomeric subunit (52 kDa) displays three 
different domains: the regulatory domain, located at the N-terminus, providing a serine residue 
(Ser16) as a phosphorylation site, and responsible for positive cooperativity induced by 
phenylalanine, respectively for an negative regulatory effect by BH4; second, the catalytic 
domain, containing the active site with a coordinated iron atom, and the binding sites for 
phenylalanine and BH4; third, the tetramerization domain, facilitating oligomerisation via 
interaction of coiled-coil motifs (Pey and Martínez 2006). 
PAH together with tyrosine-3-hydroxylase (TH; EC 1.14.16.3), and the two isoforms of 
tryptophan-5-hydroxylase (TPH1, peripheral; TPH2, neuronal; EC 1.14.16.4) belongs to the 
family of the aromatic amino acid hydroxylases (Fitzpatrick 2000; Walther and Bader 2003). 
The major pool of PAH activity in mammals is the liver, controlling the overall phenylalanine 
homeostasis. In humans, also other organs have been reported to show PAH activity or at least 
to express PAH mRNA, as there are the kidney, brain, pancreas and melanocytes (Pey and 
Martínez 2006). 
It has been proposed that there would be enough PAH activity present in the liver to deplete 
plasma phenylalanine levels within several minutes if the enzyme was constantly and fully 
active. In order to maintain the phenylalanine homeostasis in vivo, the activity of PAH is tightly 
regulated by several mechanisms. Aforementioned positive cooperativity of PAH and 
phenylalanine (Hill coefficient, h ≈ 2) is thought to be of major physiological relevance in the 
control mechanism of phenylalanine homeostasis in the blood (Kappock and Caradonna 1996; 
Kaufman 1993). Upon binding of phenylalanine in concert with phosphorylation, the enzyme 
undergoes conformational changes, which moves the autoregulatory sequence away from the 
active site, and becomes thereby activated (Kappock and Caradonna 1996; Kobe et al. 1999; 
Miranda et al. 2004; Thórólfsson et al. 2003). On the other hand BH4 acts as an allosteric 
inhibitor, keeping the enzyme in a low-activity state. This PAH·BH4 complex is thought to keep 
the enzyme in a latent form, to allow for a rapid activation in response to increased intra- and 
extracellular (plasma) phenylalanine concentrations. Binding of BH4 leads to a conformational 
change, which triggers a closing of the entrance to the active site by the N-terminal regulatory 
domain (Mitnaul and Shiman 1995; Pey and Martínez 2006; Pey et al. 2004). The third major 
contributor to PAH regulation is phosphorylation at Ser16 in the N-terminal regulatory domain. 
It was found to be mediated by cAMP and Ca2+/calmodulin dependent protein kinase and leads 
to an increased basal activity and apparent affinity for the substrate (Kaufman 1993; Miranda et 
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al. 2002). As showed in vitro, the rate of the phosphorylation is increased in the presence of 
phenylalanine and decreased by BH4 
 
Phenylalanine restricted diet 
The genetic disorder PKU or HPA is treatable with a special diet, low in phenylalanine content. 
Even patients with severe PKU can develop normal cognitive abilities, when the diet treatment 
is started at early infancy and the blood phenylalanine concentration in the blood is controlled 
and maintained on a close to normal level (Waisbren et al. 2007). 
Nevertheless there are several drawbacks to the phenylalanine restricted diet: To prevent 
progressive loss of intellectual functions it has to be followed for a lifetime (Smith et al. 1978). 
Adding to this, it is drastically interfering with a normal lifestyle and demands a high level of 
discipline, as patients are not allowed to eat meat, fish, eggs, dairy products, pasta, and bakery 
products. Sweets and vegetables are permitted to a certain degree. The diet consists of a 
phenylalanine free protein substitution, minerals, vitamins, trace elements, protein reduced 
special products and other nourishments with low protein content, and is mostly regarded as not 
being savoury at all (MacDonald et al. 1997; Harding 2000; 2001). In the light of these 
obstacles, it is no surprise that compliance is in general rather low, and patients tend to be more 
prone for psychological problems like depressions (Smith and Knowles 2000; Walter et al. 2002; 
Weglage et al. 1996). 
 
Maternal PKU 
An international study in the 1980s (Lenke and Levy 1980) showed a high frequency of mental 
retardation (92%), microcephaly (73%) low birth weight (40%), and congenital heart disease 
(12%) in offspring of mothers with PKU, as they suffered, when still being a foetus, from the 
high concentrations of phenylalanine from the maternal metabolism. Therefore, treatment 
strategies had to be developed for pregnant women with PKU. For them dietary restrictions had 
become an absolute requirement during pregnancy to prevent the occurrence of this so-called 
maternal PKU, leading to developmental abnormality and mental impairment of the unborn due 
to increased phenylalanine levels in the foetus’ body (Koch et al. 2003; Platt et al. 2000; Sheard 
2000). 
  5 
 
CHAPTER 1 
 
Alternative treatment 
Several strategies have been developed as alternatives to treatment with phenylalanine restricted 
diet. One of the most promising ways is somatic gene therapy. Recent publications reported for 
the first time successful application of adeno-associated virus vectors, targeted to the liver, 
leading to complete correction of hyperphenylalaninemia in a PKU mouse model. The viral 
vectors were used to deliver PAH cDNA into the liver cells, leading to a long-lasting expression 
of PAH activity in these otherwise PAH-deficient mice. Different similar strategies have been 
employed (Chen and Woo 2007; Ding et al. 2004, 2006; Harding et al. 2006; Oh et al. 2004). 
To eliminate the potential risk of side-effects due to the nature of the vector, other techniques to 
deliver the gene construct are now object of ongoing research. 
A totally different approach to reduce phenylalanine in patients is the so-called enzyme 
substitution therapy. Sarkissian and others (Sarkissian and Gámez 2005; Sarkissian et al. 1999) 
and similarly Liu and others (Liu et al. 2002) investigated in the feasibility of replacing PAH by 
the non-mammalian, recombinant phenylalanine ammonia lyase (PAL). This enzyme converts 
phenylalanine to the harmless metabolites, trans-cinnamic acid and trace ammonia. Taken orally 
and when non-absorbable and protected, PAL lowered plasma phenylalanine in a mutant 
hyperphenylalaninemic mouse model. Subcutaneous administration of PAL was also tested 
with an even more substantial lowering of plasma levels and significant reduction in brain 
phenylalanine levels; however the metabolic effect was not sustained following repeated 
injections due to an immune response.  
A third alternative or supplementation to the low phenylalanine diet to treat PKU patients, is the 
oral administration of large neutral amino acids (LNAA, i.e. valine, isoleucine, leucine) 
competing with phenylalanine for the transport across the blood-brain barrier, thereby 
preventing excessive influx of phenylalanine to the brain. The benefit applying LNAA is still a 
matter of controversial debate but they may be of some use for patients not complying with the 
diet treatment (Matalon et al. 2003; Schindeler et al. 2007). 
The discovery of a new variant of PKU opened up new vistas for pharmacological treatment of 
PKU with BH4, the natural cofactor of the defective enzyme PAH. See next paragraph. 
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Tetrahydrobiopterin responsive hyperphenylalaninemia 
The disorder PKU manifests itself in a broad spectrum of phenotypes, from severe classical 
PKU to less malignant forms, such as mild hyperphenylalaninemia. In the year 1999 a new 
variant named BH4 responsive HPA/PKU, was described for the first time by Kure (Kure et al. 
1999). He described four patients with hyperphenylalaninemia who responded to oral 
administration of BH4 with a reduction of their plasma levels of phenylalanine. Soon thereafter 
other studies suggested that BH4 can be successfully used in the long-term treatment of HPA 
patients as an alternative to phenylalanine restricted diet (Bélanger-Quintana et al. 2005; Cerone 
et al. 2004; Hennermann et al. 2005; Lambruschini et al. 2005; Muntau et al. 2002; Shintaku et 
al. 2004; Steinfeld et al. 2004; Trefz et al. 2001; 2005) 
Patients are defined as BH4-responsive if they reduce their phenylalanine plasma levels after a 
BH4 loading test. There is no strict norm determining cut-off levels of responsiveness or the 
exact amount of BH4 used for the test. It seems generally acceptable to use a 30%-reduction 
within 24 hours as cut-off, after oral administration of 20 mg/kg BH4. As shown in (Fiege and 
Blau 2007) also within shorter timeframes or higher cut-off values, responsible patients can be 
identified. Furthermore this study suggested that BH4 responsive patients are mostly found 
amongst mild HPA to mild PKU patients. Nevertheless also several patients with classical PKU 
responded to BH4 loading. 
Apparently in these patients, the super-physiological concentration of BH4 activates the 
deficient enzyme PAH (Pey and Martínez 2005). There are several hypotheses concerning the 
exact mechanism of BH4 responsiveness. For instance, high dose of BH4 may compensate for 
decreased affinity of the deficient PAH. BH4-responsive patients display a high degree of 
heterogeneity at the genetic level but only in some cases so-called Km mutants could be 
identified. A recent study (Pey et al. 2007) attributes the main molecular mechanism underlying 
BH4 responsiveness to a chaperone-like effect, by which BH4 increases the stability of mutant 
PAH proteins (thermal stability and protection against proteolytic degradation and oxidative 
inactivation). Considerable residual activity is further proposed as being an important 
characteristic. On the whole BH4 responsiveness appears to be multifactorial (Aguado et al. 
2006; Blau and Erlandsen 2004; Erlandsen and Stevens 2001; Erlandsen et al. 2003; Kure et al. 
2004; Pey et al. 2004; Steinfeld et al. 2003; Thöny et al. 2004). 
Since the first report on patients with BH4-responsive HPA/PKU, it hast been shown that a 
considerable percentage of patients with HPA respond to pharmacological doses of BH4 
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(Bernegger and Blau 2002). Mainly patients with mild clinical phenotypes benefit most from 
treatment with the cofactor, which allows more than 80% of them to discontinue their 
phenylalanine low diet. But there is also evidence that some patients suffering from severe 
forms of PKU respond to BH4. For this group of patients – who often show a partial response to 
pharmacological therapy – a combined treatment of a less stringent diet together with 
administration of BH4, might be valuable (Muntau and Gersting 2006). 
 
Tetrahydrobiopterin deficiencies 
With the detection in the 1970s of several patient apparently suffering from PKU, but who did 
not respond to diet treatment, it was speculated that these formally called untypical PKU 
patients might be affected by a new form of HPA caused by a deficiency of the BH4 metabolism. 
Features they had in common were that they, regardless of an early diagnosis for HPA, did not 
react with a reduction of the phenylalanine levels upon treatment with phenylalanine restricted 
nutrition. They developed progressive neurological symptoms and many died at early age 
(Bartholomé 1974; Bartholomé et al. 1977; Brewster et al. 1979; Danks et al. 1979; Kaufman et 
al. 1975, 1978; Smith and Lloyd 1974; Smith et al. 1975; Tada et al. 1970). 
Nowadays several variants of these BH4 deficiencies are known and characterised, and have 
been catalogued in the databases BIODEF and BIOMDB, respectively (www.bh4.org). The first 
one lists worldwide data from screening over the last 30 years. It includes information on 
patient’s age, ethnic origin, information about the parents, siblings, laboratory values, treatment, 
clinical symptoms, and so on. This database is linked with the second one, the BIOMDB, where 
all the gene mutations of the corresponding patients are mapped. More than 500 patients have 
been diagnosed as a result of selective screening during the last 30 years. 58% of them 
presented with PTPS deficiency, 30% with DHPR deficiency, and each about 4% suffered from 
PCD- or GTPCH-deficiency (for definition of the different deficiencies see below) (Blau and 
Dhondt 2006). 
 
Nomenclature of tetrahydrobiopterin deficiencies 
BH4 deficiencies, previously termed “atypical PKU”, form a very heterogeneous group of 
different disorders (Table 1). They present with diverse clinical and biochemical characteristics 
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(Blau et al. 2001). The affected enzyme in the first place, the type of the mutation, its severity, 
the outcome of a BH4 challenge and the response to therapy are all criteria to be considered 
when defining as a specific variant. Accordingly to the actual need for treatment with 
neurotransmitter precursors, the terms severe, mild or peripheral should be used to describe the 
severity (Blau 2006). 
Two principle distinctions can be made: BH4 deficiencies with HPA and BH4 deficiencies 
without HPA. The first can all be detected by neonatal screening for PKU or HPA. Selective 
screening for BH4-deficiency is of great importance in every newborn with plasma 
phenylalanine levels higher than 120 µM and in older children showing neurological symptoms 
of unclear origin (Blau et al. 1996; Zurflüh et al. 2005). 
 
Tetrahydrobiopterin (BH4) deficiencies with hyperphenylalaninemia (HPA) 
Four autosomal-recessively inherited enzyme defects belong to the group of BH4 deficiencies 
with HPA: GTP cyclohydrolase I (arGTPCH) deficiency, 6-pyruvoyl-tetrahydropterin synthase 
(PTPS) deficiency, carbinolamine-4α-dehydratase (PCD) deficiency and dihydropteridine 
reductase (DHPR) deficiency. They can be further divided into two groups, mild or severe, 
depending on the presence or absence of normal CNS monoamine neurotransmitter metabolism. 
In the latter group, patient are treated with a combination therapy with carbidopa, L-dopa, and 
5-hydroxytryptophan additionally to a phenylalanine restricted diet and administration of BH4 
(Ponzone et al. 2006). 
 
GTP cyclohydrolase I (GTPCH) deficiency 
GPTCH deficiency (OMIM 233910), also termed arGTPCH due to its autosomal recessive trait, 
is a rare form of HPA, characterised by low urine and blood concentrations of pterins as the 
BH4-biosynthesis is blocked at an early step in the pathway. Accordingly there are very low 
levels of neopterin, biopterin, isoxanthopterin and pterin detectable in the urine, but the ratio of 
the different pterins is normal. Also in the CSF, neopterin and biopterin, together with 
neurotransmitter precursors (5HIAA and HVA), are found in very low concentrations. The 
clinical picture of GTPCH deficiency is variable, but patients share some common symptoms 
like mental retardation, convulsions, disturbance of tone and posture, abnormal movements, 
hypersalivation and swallowing difficulties (Blau et al. 2001; Blau 2006). 
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6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency 
Patients with a PTPS deficiency (OMIM 261640) cannot convert dihydroneopterin triphosphate 
(NH2TP), the substrate of PTPS, to 6-pyruvoyl-tetrahydropterin (6PTP), which leads to an 
accumulation of the substrate. In the tissue, NH2TP is dephosphorylated by pyrophosphatases to 
dihydroneopterin and cleared from the body in high concentration via urine, where it can be 
detected, respectively its oxidation product neopterin, together with monapterin and  
3’-hydroxysepiapterin. Biopterin is present only in traces. PTPS is the most frequent and 
heterogeneous BH4-deficiency. Untreated patients show generally plasma phenylalanine 
concentration of approximately 1200 µM. About 80% of the PTPS-deficient present with a 
severe, or typical form. Their neurotransmitter levels are similarly low as in patients with 
GTPCH deficiency, in contrast to patients with a mild (atypical, peripheral/partial) variant, 
whose concentration of neurotransmitter metabolites in the CSF appears to be normal. But 
neopterin levels are increased as well (Blau et al. 2001; Blau 2006). 
 
Pterin-4α-carbinolamine dehydratase (PCD) deficiency 
PCD deficiency, also known as primapterinuria (OMIM 126090 and 264070) was initially often 
misdiagnosed as a mild form of PTPS deficiency. Newborns show variably elevated 
phenylalanine levels, which may increase transiently to concentration between 1200 µM and 
2000 µM. Biopterin levels in the urine are in the subnormal range but neopterin is higher than 
normal values. Remarkable is that about 30% to 50% of the total biopterin are excreted as 7-
biopterin (or primapterin), the substance that clearly distinguishes PCD from PTPS deficiency 
(Blau et al. 2001; Blau 2006). 
 
Dihydropteridine reductase (DHPR) deficiency 
DHPR deficiency (OMIM 261630) is characterised by excretion of extremely high 
concentrations of total biopterin, but in the newborn period urinary pterins pattern can be 
completely normal. The enzyme DHPR is responsible for the conversion of the highly unstable 
intermediate quinoid dihydrobiopterin (qBH2), formed via hydroxylation from BH4 through 
PCD, to BH4. In cases where this enzyme is defective, qBH2 readily tautomerises to 7,8-
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dihydrobiopterin which is excreted in the urine as its oxidised product biopterin in very high 
quantities together with normal to slightly increased neopterin. Additionally DHPR deficient 
patients suffer from a defective folate metabolism in the CNS.  
Most patients with such a deficiency are detected through screening of the urinary pterins, but 
some neonates can be missed, especially when under low-phenylalanine diet. Therefore, when 
DHPR deficiency is suspected, an additional DHPR enzyme assay, using dried blood spots, is 
performed to confirm (Blau et al. 2001; Blau 2006). 
 
Tetrahydrobiopterin (BH4) deficiencies without hyperphenylalaninemia (HPA) 
Historically, defects of BH4 metabolism have been identified as a cause of follow-up studies to 
unravel the reason of an HPA found during newborn screening or in the course of clarification 
of neurological signs of unclear origin in older children. The latter is especially true for a 
number of BH4-deficiencies presenting without HPA, namely dopa-responsive dystonia (DRD, 
an autosomal dominant adGTPCH deficiency), and sepiapterin reductase (SR) deficiency (Blau 
et al. 2001; Blau 2006). 
 
Dopa-responsive dystonia (DRD) 
Dopa-responsive dystonia (OMIM 128230) also known as autosomal dominantly inherited GTP 
cyclohydrolase I (adGTPCH) deficiency or Segawa disease is characterised, as its name 
suggests, by a fast response to low dose L-dopa. Patients show often diurnal variation of 
dystonia getting worse towards the evening. First symptoms generally affect the posture of the 
feet. Within several years, the muscle dystonia is spreading to the other extremities including 
further symptoms like parkinsonism (Segawa et al. 2003). 
Most informative biochemical measurements come from analysis of neopterin and biopterin, 
and neurotransmitter metabolites like HVA and 5HIAA in the CSF. Compared to arGTPCH 
deficiency, CSF levels of neopterin and biopterin are higher; nevertheless patients of both forms 
of a GTPCH deficiency can be clearly distinguished from patients with other types of a BH4 
deficiency or controls. 
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Analysis of large DRD pedigrees revealed a highly variable expressivity in clinical symptoms 
despite of the same mutation. Asymptomatic carriers are more frequently men than women, and 
the penetrance in patients was reported to be 90-100% in females and 40-55% in males, 
potentially due to sexual differentiation of mesencephalic dopaminergic neurons (Blau et al. 
2001; Blau 2006; Ichinose and Nagatsu 2006). 
 
Sepiapterin reductase (SR) deficiency 
The autosomal recessively inherited SR deficiency (OMIM 182125) is the latest detected BH4-
deficiency affecting a different enzyme of the BH4 metabolism and was first described by 
Bonafé et al. in 2001. In contrast to other BH4-deficiencies it cannot be detected by the neonatal 
screening for PKU, as it presents without hyperphenylalaninemia, also urinary pterin excretion 
is normal. Analysis of CSF neurotransmitter metabolites and pterins, e.g. sepiapterin, as well as 
enzyme activity in fibroblasts are used for the diagnosis of this disorder. The discovery of SR 
deficiency led to new insights into alternative pathways of the cofactor BH4, its clinical features 
comprise common but variable symptoms, seen also in other variants of autosomal recessive 
BH4 deficiencies like disturbed tonus and posture, abnormal movements, hypersalivation, and 
swallowing difficulties. Besides of progressive psychomotor retardation, spasticity, and 
dystonia; microcephaly, tremor, seizures, and other neurological signs can be observed (Blau et 
al. 2001; Blau 2006; Bonafé et al. 2001; Bonafé 2006). 
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Table 1. 
Laboratory parameters found in patients with various forms of PKU and BH4-deficiency 
 
Disorder Phe (blood) 
Neo 
(urine) 
Bio 
(urine) 
Neo 
(CSF) 
Bio 
(CSF) 
5HIAA 
(CSF) 
HVA 
(CSF) 
5MTHF 
(CSF) 
 µM mM/mol creat. nM 
PKU >1200 1.2-19.8 0.5-7.9 9-118 15-143 14-471 47-174 n 
Mild PKU 600-1200 1.2-14.5 0.6-5.3 9-118 15-143 n n n 
MHPA 120-600 <0.2 <0.2 n n n n n 
arGTPCH 120-1200 <0.2 <0.2 0.05-3.0 1.5-7.5 61-183 15-48 n 
PTPS 250-2500 5.0-51.2 <0.5 47-402 1.0-16.0 5-113 5-223 n 
Mild PTPS 240-2200 5.0-51.2 <0.5 25-230 13-56 n n n 
PCD 180-1200 4.1-22.5 0.7-1.5* 43-117 16-96 n n n 
DHPR 180-2500 0.5-23.2 3.8-25.6 11-70 43-117 4-75 19-204 ↓ 
Mild DHPR 280-600 0.5-23.2 3.8-25.6 11-70 43-117 21-66 n ↓-n 
DRD n n n 1.1-6.2 3.1-7.6 48-97 120-239 n 
SR n n n 14-51 72-102** 3-15 49-111 n 
Controls <120 1.0-15.5 0.5-7.6 15-35 20-70 310-1100 150-800 64-182 
*Primapterin in urine ↑; **7,8-dihydrobiopterin and sepiapterin in CSF ↑; n = normal; PKU = phenylketonuria; 
MHPA = mild hyperphenylalaninemia; arGTPCH = autosomal recessive GTP cyclohydrolase I deficiency; 
PTPS = pyruvoyl-tetrahydropterin synthase deficiency; PCD = pterin-4α-carbinolamine dehydratase 
deficiency; DHPR = dihydropteridine reductase deficiency; DRD dopa-responsive dystonia; SR = sepiapterin 
reductase deficiency; Phe = phenylalanine; Neo = neopterin; Bio = biopterin; 5HIAA = 5-hydroxyindolacetic 
acid; HVA = homovanillic acid; 5MTHF = 5-methyltetrahydrofolic acid; CSF = cerebrospinal fluid. 
Adapted from (Blau 2006). 
 
Tetrahydrobiopterin metabolism 
(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (tetrahydrobiopterin, BH4), the molecule that links 
PKU and BH4-deficiencies, is crucial for several processes in the organism and is ubiquitously 
found in all tissues. It is either produced by de novo biosynthesis or via regeneration of pterin-
4α-carbinolamine (4α-hydroxy-tetrahydrobiopterin), the oxidation product of different aromatic 
amino acid hydroxylases (AAAH) (Fig.1). The de novo biosynthesis starts with the conversion 
of guanosine triphosphate (GTP) to NH2TP by GTPCH, followed by a redox reaction and a 
dephosphorylation carried out by PTPS. This reaction leads to 6PTP, which is then reduced to 
the final product BH4 by SR. The biosynthesis of BH4 via the two intermediates is a Mg2+-, 
Zn2+-, and NADPH-dependent reaction. 
Subsequently BH4 is primarily consumed by aromatic amino acid hydroxylases, i.e. PAH, TH;, 
and TPH (TPH1, peripheral and TPH2, neuronal). Furthermore, BH4 serves as cofactor for all 
three forms of nitric oxide synthase (NOS; nNOS, neuronal; iNOS, inducible; eNOS, 
endothelial; EC 1.14.13.39) and for the enzyme glyceryl-ether monooxygenase (GEMO; EC 
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1.14.16.5). Besides functioning as a cofactor, BH4 has several less defined functions at the 
cellular level (see below, page 22). 
As mentioned before, when used as a cofactor, BH4 is converted to pterin-4α-carbinolamine, 
which is thereafter dehydrated in the first step of the regeneration to quinoid-dihydrobiopterin. 
This reaction is catalysed by the enzyme PCD/DCoH. And finally, under consumption of 
NADH, q-dihydrobiopterin is converted back to BH4 by the action of DHPR.  
The regulation of the BH4 biosynthesis, controlled by GTPCH feedback regulation protein 
(GFRP) and other factors, appears to be complex (see below), and a complete picture of the 
pathway control does not exist yet. 
In the further paragraph the different enzymes, involved in the de novo biosynthesis and the 
regeneration of BH4, will be closer portrayed. 
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 Fig. 1. BH4-biosynthesis, consumption by aromatic amino acid hydroxylases (phenylalanine-, tyrosine-, 
tryptophan-hydroxylase) or similarly by nitric oxide synthase and glyceryl-ether monooxygenase, and 
regeneration of BH4. Alternative pathway and salvage pathway are as well integrated into figure 1. For 
explanation see paragraph Alternative and salvage pathway (below).  
GTPCH = GTP cyclohydrolase I; PTPS = pyruvoyl-tetrahydropterin synthase; SR = sepiapterin reductase; 
AKR1C3 = aldo-keto reductase family 1, member C3; CR = carbonyl reductase (CBR); AR aldose 
reductase (AKR1B1); DHFR = dihydrofolate reductase; AAAH = aromatic amino acid hydroxylase, Phe = 
phenylalanine; Tyr = tyrosine; Trp = tryptophan; L-dopa = levodopa (3,4-dihydroxy-L-phenylalanine); 5-
OH-Trp = 5-hydroxy-L-tryptophan; PCD/DCoH = pterin-4α-carbinolamine dehydratase/dimerisation 
cofactor of HNF1-α; DHPR = dihydropteridine reductase. 
Adapted from (Blau et al. 2002; Thöny 2006) 
 
 
GTP cyclohydrolase I 
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The enzyme GTP cyclohydrolase I (GTPCH; EC 3.5.4.16), the first enzyme in the biosynthesis 
of BH4 (Fig. 2.), is encoded by a single copy gene, GCH1, containing 6 exons, spanning about 
30 kb and is located on chromosome 14 (14q21.1-22.2) (Ichinose et al. 1995). Its expression can 
be modulated on a transcriptional level by various stimuli of the immune system such as 
INTRODUCTION 
 
cytokines (interferon-γ, tumour necrosis factor-α, stem-cell factor, interleukin-1β, glial cell line-
derived neurotrophic factor GDNF and specific combinations of these), phytohemagglutinin, 
and endotoxin (lipopolysaccharide) in a cell- and tissue-specific manner. Furthermore in some 
human cell lines (HUVEC) increased levels of GCH1 mRNA were also observed after 
stimulation with phenylalanine, and after application of arginine or H2O2 (endothelial cells) 
(Thöny 2006; Werner-Felmayer et al. 2002). Post-translational modification of GTPCH include 
cleavage of the 11 N-terminal amino acids (shown in rats) and phosphorylation of the enzyme, 
most likely through protein kinase C (PKC) or casein kinase II (at least in vitro). 
Phosphorylation increases the enzymatic activity of GTPCH and leads to higher cellular BH4 
levels (Hesslinger et al. 1998; Lapize et al. 1998; Thöny 2006). Further effectors controlling the 
enzyme activity are, GTP – the substrate of GTPCH – and the pathway end-product, BH4 
(together with other reduced pteridines), via a negative feedback regulation involving GFRP 
(see paragraph below) as well as phenylalanine (positive feedback regulation via GFRP), and 
intracellular Ca2+ influx, which was shown to up-regulate GTPCH expression in cell culture 
models. 
The enzyme GTPCH is functionally active as a homodecamer, with monomers of 250 amino 
acids and of 27.9 kDa. Crystal structure data is available for several organisms (recombinant 
human, E. coli and rat), and for the GTPCH·GFRP complex of rat protein (Auerbach et al. 2000; 
Maita et al. 2002, 2004; Nar, Huber, Meining, et al. 1995; Nar, Huber, Auerbach, et al. 1995). 
The homodecameric enzyme is composed of two dimeric pentamers lying face-to-face building 
a barrel with a cavity of 30 Å ×30 Å ×15 Å. There are ten equivalent active sites with a 
complexed Zn2+ ion per functional unit (Thöny 2006). 
 
GTPCH feedback regulation protein 
GTPCH feedback regulation protein (GFRP) is the product of the gene GCHFR, which is 
located on chromosome 15q15. It spans roughly 4 kb and codes for 3 exons. Expression 
analysis showed that up to three different transcripts are produced in all investigated human 
tissues, including brain (Gesierich et al. 2003; Milstien et al. 1996; Werner et al. 2002). 
The 84-amino-acid protein has a weight of 9.7 kDa and forms a propeller-like homopentameric 
disc. Two such pentamers sandwich one GTPCH decamer and build a 360 kDa GTPCH·GFRP 
complex; the contact between GTPCH and GFRP is mediated mainly by van der Waals 
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interactions and salt bridges. The association between the two is enhanced by binding of five 
phenylalanine molecules at the contact surface. This seems to increase the GTPCH activity by 
locking the enzyme in an active state (Thöny 2006). 
 
6-pyruvoyl-tetrahydropterin synthase 
6-pyruvoyl-tetrahydropterin synthase (PTPS; EC 4.6.1.10) is expressed from the gene PTS 
which spans a region of about 6-7 kb on chromosome 11q22.3-23.3 (Thöny et al. 1992). It 
contains six exons, whereof 23 bp of the exon 3 are occasionally skipped at least in some cell 
types. This splicing polymorphism, causing aberrant protein expression, was not only observed 
in patients but also in normal controls. The amount of exon-3-skipping could be closely 
correlated with PTPS activity, leading to the conclusion that this is a major mechanism to 
regulate protein expression in different human cell types (Leitner et al. 2003). Furthermore 
phosphorylation of PTPS was shown to be essential for the activity of the enzyme (Oppliger et 
al. 1995) 
PTPS forms homohexamers, consisting of 2 trimers which are arranged in a head-to-head 
fashion building a barrel of the overall dimensions of 60 Å ×60 Å ×60 Å. The complex harbours 
six putative active sites, one per subunit. The monomer consists of 145 amino acids, weighing 
16.4 kDa, and binds a Zn2+-ion, crucial for catalysis, coordinated by three histidine residues 
(Ploom et al. 1999; Thöny 2006). 
 
Sepiapterin reductase 
Sepiapterin reductase (SR; EC 1.1.1.153) located on chromosome 2p13 and encoded by the 
gene SPR spans a region of approximately 4-5 kb with three exons. The genomic organisation 
of this gene is very similar in mouse and human and they are highly homologous (Lee et al. 
1999; Ohye et al. 1998). 
SR, a member of the short-chain dehydrogenase/reductase family, forms homodimers out of 
261-amino-acid, and 28.0 kDa monomers, and seems ubiquitously expressed in all mammalian 
tissues, also throughout all brain regions in contrast to GTPCH or PTPS which are mainly 
expressed in monoamine neurons (Thöny 2006). In vitro experiments showed that SR is 
phosphorylated by calmodulin-dependent protein kinase II and by protein kinase C. 
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Phosphorylation changed the kinetic properties and might also play a role in the regulation of 
SR in vitro (Fujimoto et al. 2002; Katoh et al. 1994). 
 
Pterin-4α-carbinolamine dehydratase 
Pterin-4α-carbinolamine dehydratase (PCD; EC 4.2.1.96) is also known as pterin-4α-
carbinolamine dehydratase/dimerisation cofactor of hepatocyte nuclear factor 1-α (HNF1-α) or 
short: PCD/DCoH. PCD is encoded by the genes PCBD1 on chromosome 10q22, spanning four 
exons (Citron et al. 1993; Thöny et al. 1994, 1995) and as a paralogue enzyme (also known as 
DCoH2) by PCBD2 located on chromosome 5q31.1, equally spanning 4 exons 
(http://www.ncbi.nlm.nih.gov/ Entrez gene) (Rose et al. 2004). 
A PCD monomer weighs 11.9 kDa (104 amino acids) but the functional enzyme with 
dehydratase activity consists in a homotetramer with an overall size of 60 Å ×60 Å ×60 Å. 
Primary sequence of the mature protein is identical in human and rat, and differs only by one 
amino acid from the one of the mouse. The mammalian PCD/DCoH and DCoH2 exist in two 
oligomeric states; in the cytoplasm they adopt a homotetrameric conformation with dehydratase 
activity, and in the nucleus they can be found as an α2β2 heterodimer associated with HNF1-α, 
enhancing thereby as a coactivator the transcriptional activity of HNF1-α. DCoH2 can only 
partially complement PCD/DCoH activity in the regeneration of BH4, but the two paralogues 
are able form homotetramers and mixed heterotetramers in solution. 
PCD activity was found in human liver, kidney, brain, skin and hair follicles. Patients with the 
chronic skin condition vitiligo showed dramatically reduced PCD activity (Schallreuter 1999; 
Thöny 2006). 
 
Dihydropteridine reductase 
Dihydropteridine reductase (DHPR; EC 1.6.99.7) is encoded by the gene QDPR, located on 
chromosome 4p15.3. This 7-exon gene spans over more than 20 kb, the coding sequence 
consisting of 732 bp. 
The protein counts 244 amino acids, leading to a molecular weight of 25.8 kDa. DHPR forms 
dimers of a dimension of 34 Å ×50 Å ×73 Å. Crystal structure is available for the rat protein at 
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a 2.3 Å resolution (Varughese et al. 1992). DHPR is an α/β protein with a Rossmann-type 
dinucleotide fold for NADH binding; the human enzyme was found to bind two NADH 
molecules per dimer. 
DHPR has an essential role in the hydroxylation systems of phenylalanine, tyrosine, and 
tryptophan and is widely distributed in the tissue. In addition to its expression in the adrenal 
medulla, the principal site of the conversion of tyrosine to catecholamines, and the brain 
(conversion of tyrosine and tryptophan in the biosynthesis of the neurotransmitters serotonin 
and dopamine), it is also found in tissues with no or only little aromatic amino acid 
hydroxylation activity, like in the heart or the lung. Its function in those tissues is unclear but it 
might be involved in other metabolic processes (Blau et al. 2001; Thöny 2006). 
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 Fig. 2. Three-dimensional structures of BH4-metabolising enzymes. Shown 
are ribbon-type representations of the main-chain foldings of the enzymes 
involved in the de novo BH4-biosynthesis and BH4-regeneration. Substrates 
are shown in ball-and stick representation, with atoms in standard colours. 
On the right side the enzymes are shown rotated by 90° around the x-axis. 
The crystal structure co-ordinates used are: GTPCH from E. coli, PTPS 
from rat liver, SR from mouse, PCD/DCoH from rat, and DHPR from rat 
liver. GTPCH = GTP cyclohydrolase I; PTPS = pyruvoyl-tetrahydropterin 
synthase; SR = sepiapterin reductase; PCD = pterin-4α-carbinolamine 
dehydratase; DHPR = dihydropteridine reductase. Figure taken from 
(Thöny et al. 2000). 
 
 
Alternative and salvage pathway 
Besides the de novo biosynthesis and the regeneration by PCD and DHPR, BH4 can also be 
produced through the so-called salvage pathway involving the enzyme SR (Fig. 1); i.e. SR 
catalyses the conversion of sepiapterin to 7,8-dihydrobiopterin which is subsequently reduced to 
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BH4 by dihydrofolate reductase (DHFR; EC 1.5.1.3), in both steps NADPH is consumed 
(Nichol et al. 1985). Even though SR is enough to complete the BH4 synthesis, there exist 
alternative pathways for the production of BH4 and especially the detection of the SR deficiency, 
due to its lack of hyperphenylalaninemia provided, deeper insight into these pathways of BH4 
metabolism. It involves a family of NADPH-dependent aldo-keto reductases, and carbonyl 
reductases (CR), aldose reductases and the 3α-hydroxysteroid dehydrogenase type 2 (AKR1C3). 
They are able to convert 6-pyruvoyl-tetrahydropterin via different routes to BH4 in the 
interaction with SR but also without. Moreover CR is able to catalyse the conversion of 
sepiapterin to 7,8-dihydrobiopterin like the SR (Iino et al. 2003). It is assumed that due to a low 
expression or activity of DHFR and AKR1C3 in the brain, the BH4 synthesis starting from 6-
pyruvoyl-tetrahydropterin via alternative pathway is not sufficient in the case of a SR deficiency 
and leads to a central BH4-deficiency without HPA. 
Furthermore, both sepiapterin and 7,8-dihydrobiopterin can be taken up and metabolised by the 
salvage pathway to replenish the BH4 pool in the body. Studies with mice showed that these 
two compounds are taken up even more efficiently than natural BH4 (Blau et al. 2001; Sawabe 
et al. 2005; Thöny 2006). 
 
Tetrahydrobiopterin as a cofactor and other functions 
The history of BH4, respectively of pterins, dates back to the end of the 19th century, when in 
1889 the later Nobel Laureate and butterfly fancier Sir Frederick Gowland Hopkins partially 
characterised a yellow purine-like pigment from the wings of the common English brimstone 
butterfly and some years later, a white pigment from the wings of the cabbage butterfly, now 
known as xanthopterin and leucopterin (Curtius 2006). In 1963 Pfleiderer proposed the trivial 
name pterin for the compound 2-amino-1H-pteridin-4-one and its derivatives and in same year 
Kaufman recognised BH4 as the natural cofactor of PAH (Curtius 2006; Kaufman 1963). 
To date, the function of BH4 as cofactor for the aromatic amino acid hydroxylases PAH, TH, 
and TPH1, TPH2 is the most investigated and understood. Furthermore it is used by all three 
forms of the nitric oxide synthase and the enzyme glyceryl-ether monooxygenase (Kappock and 
Caradonna 1996; Taguchi and Armarego 1998; Werner et al. 2007). 
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Enzymatic reactions of AAAH have intensively been studied and revealed a strict requirement 
not only for BH4 but also for O2, and iron-ions. The oxidation product of BH4, tetrahydro-4α-
carbinolamine, is released after each catalytic turnover to be regenerated by PCD and DHPR. In 
the course of the reaction two electrons are transferred from BH4, one to reduce the iron from 
Fe3+ to Fe2+ and the second goes apparently to the oxygen (Hufton et al. 1995). In contrast to 
this, the role BH4 plays in reactions of NOS seems to be a different. BH4 appears not to 
dissociate from NOS during the turnover and only a one-electron transfer takes place. 
Besides serving as a cofactor for PAH, BH4 together with phenylalanine has a major regulatory 
function for this enzyme. BH4 works a negative effector, forming a dead-end complex 
PAH·BH4; on the other hand phenylalanine is a positive allosteric effector, competing with BH4 
to turn the inactivated enzyme into an enzymatically active state. In the liver, the site of the 
highest PAH activity, BH4 concentrations were found to be around 5-10 µM, but the Km value 
for the cofactor of PAH was estimated to be approximately 20-30 µM, leaving BH4 in sub-
saturating concentrations and making it a limiting factor in the catabolism of phenylalanine in 
the liver (with important implications for BH4-responsive HPA/PKU). Recently it was 
recognised that BH4 has an additional protecting role for PAH as a chemical chaperone, 
preventing the protein from misfolding and inactivation during dimer/tetramer formation and 
protecting it against proteolytic cleavage (Pey et al. 2004; Thöny et al. 2004). 
All three isoforms of the NOS use BH4 as redox cofactor; each monomer has a C-terminal 
reductase domain, where NADPH, FAD, FMN, and calmodulin can bind and an N-terminal 
oxygenase domain with binding sites for the cofactor BH4, the prosthetic group heme and for 
the substrate arginine. But NOS are functionally active as dimers and carry therefore two 
molecules of BH4 at the interface between the two monomers. BH4 is not only required for the 
catalysis serving as a one-electron donor in the conversion of arginine to citrulline but has also 
structural functions, including stabilisation of the NOS dimer, and protecting it against 
proteolysis. Additionally BH4 facilitates the binding of arginine (Stuehr et al. 2004; Wei et al. 
2003). Compared with PAH, NOS’ need for BH4 is, according to its Km value, two orders of 
magnitude smaller. Nevertheless, when the concentration drops too low, as it might be the case 
in BH4 deficiency, BH4 becomes a limiting factor for the activity of NOS, which becomes 
uncoupled and produces peroxides instead of nitric oxide; furthermore the available NO can 
react with superoxide to form neurotoxic peroxinitrate (Zorzi et al. 2002). 
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Besides serving as a cofactor, BH4 has different functions in humans but also in other organisms. 
One of the earliest discovered was its role as growth factor for Crithidia fasciculata. This fact 
was initially used to measure biopterin in different body fluids and tissues (Leeming and Blair 
1974). BH4 has also a proliferative activity in haematopoietic cells as newer observations do 
indicate (Kerler et al. 1989; Tanaka et al. 1989). DNA synthesis was found to be stimulated by 
BH4 in some mouse erythroleukemia clonal cell line. In these cells proliferation was induced, as 
it was the case SV40 transformed human fibroblasts, rat C6 glioma cells, and PC12 cells. As 
sepiapterin is readily taken up by cells and converted to BH4, it has similar effects on the cells 
like BH4. Further involvement of BH4 comprises an increased proliferation of PC12 cells 
through epidermal growth factor, nerve growth factor, and insulin-like growth factor. 
BH4 not only plays a role in proliferation but also seems to act as a self-protecting factor for 
nitric oxide toxicity as it shows a strong scavenging activity against superoxide anion radicals. 
On the base of this, it was suggested application of BH4 might be a useful treatment of various 
diseases, which pathogenesis is actively oxygen-related (Kojima et al. 1995). Others observed 
that in cytotoxicity due to nitric oxide involving H2O2 production and scavenging of H2O2 by 
BH4 may be at least one of the mechanisms by which BH4 reduces NO-induced endothelial cell 
death (Shimizu et al. 1998). On the other hand, it was suggested that ischemia raises the 
intracellular BH4 concentration and that the increased BH4 has a pivotal responsibility in 
selective neuronal injury via NOS activation. They showed a distinct reduction of BH4 
concentrations accompanied by a delayed neuronal injury in the parts of the hippocampus by 
using a selective GTPCH inhibitor in an animal model exposed to transient forebrain ischemia 
(Cho et al. 1999). A further function of BH4 is enhancing dopamine- and serotonin-release in 
the striatum and frontal cortex as shown in rats (Wolf et al. 1991; Koshimura et al. 1990).  
Recent findings suggested that BH4 is also a key modulator of peripheral neuropathic and 
inflammatory pain through the action of GTPCH. After axonal injury, concentrations of BH4 
rose in primary sensory neurons, and in dorsal root ganglia. Inhibiting the de novo BH4 
synthesis in rats attenuated neuropathic and inflammatory pain and prevented excess nitric 
oxide production in the ganglia evoked through nerve injury (Tegeder et al. 2006). 
The role of BH4 was also discussed in connection with cofactor administration in BH4-
responsive HPA/PKU patients. For these patients BH4 presents a possible alternative to the 
phenylalanine restricted diet treatment. Recent studies on the mechanism of the BH4-
responsiveness unravelled a multifactorial base, including the chemical chaperon effect of BH4, 
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preventing inactivation and degradation of mutant PAH protein or providing certain Km-mutants 
with sufficient BH4-cofactor. PAH enzyme activity was increased by BH4 but neither gene 
expression nor mRNA stability of PAH was changed in feeding experiments with BH4 in 
normal mice (Kure et al. 1999; Scavelli et al. 2005; Thöny 2006; Thöny et al. 2004). 
 
Aims of the thesis 
In the light of BH4 becoming a potential pharmacological treatment in PKU and already being 
used in the medication of BH4 deficient patients, we were interested in the effects of exogenous 
BH4 or increased BH4 biosynthesis on the organism. Therefore, we started a project aiming to 
study the BH4 metabolism and regulation, and the influence of BH4 on other genes and proteins, 
either directly participating in BH4 biosynthesis and regeneration or otherwise involved in the 
BH4 metabolism; and the potential influence of BH4 on other pathways. To reach our goal we 
intended to employ different cell models in a first approach and study the effects in patients 
with BH4-responsive HPA/PKU and BH4 deficiency. 
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To study effects of BH4 orally administered to patients or healthy controls, we developed a new 
method assessing the pharmacokinetics of BH4, described in Chapter 2, which not only 
provided an insight into the absorption, distribution, metabolism, and elimination time of the 
cofactor but also allowed for a rapid diagnosis of BH4 deficient patients amongst newborns with 
hyperphenylalaninemia in the differential screening. An early onset of the correct therapy is 
imported for patients with hyperphenylalaninemia, therefore a method to discern the cause of 
the increased phenylalanine levels is essential. Until now, in screening for BH4 deficiencies, 
mostly urine samples were analysed. We present here an inexpensive, easy and safe to handle 
alternative method, employing dried blood spots. This method was used to determine basic 
pharmacokinetic parameters for BH4 in blood after administration of BH4 or following 
combined phenylalanine and BH4 loading of PAH deficient patients as described in Chapter 3. 
Extensive pharmacokinetic studies of BH4 have been performed in animal models, but only a 
few parameters are known from studies in human. The pharmacokinetics was suggested being 
a factor affecting BH4 loading tests and might provide details on pharmacological response to 
BH4 therapy. In Chapter 4 we aimed to identify mutations and genotypes associated with BH4 
responsiveness and estimated the dispersal of such mutations within the population of PKU 
patients in Europe by exploiting the BIOPKU database, an international data collection of 
published BH4-responsive HPA/PKU cases, and other sources. Chapter 5 presents a study on 
CHAPTER 1 
 
the outcome and long-term follow-up of patients suffering from a cofactor deficiency. These 
patients are under treatment with BH4 and further medication. The aim was to recognise 
parameters determining a successful outcome of long-term treatment. In the final section, 
Chapter 6, preliminary results from gene expression analysis in cell models are presented. 
Using BH4, respectively sepiapterin which is readily taken up by cells and converted to BH4, 
and other stimulating or inhibiting agents, we manipulated and analysed the regulation of the 
BH4 metabolism. To reach this goal we systematically tested several cell lines for activity of 
enzymes involved in the metabolism of BH4, and a few cell lines were further investigated to 
study the influence of increased BH4 concentrations on the metabolism.  
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Chapter 2 is published in Mol Genet Metab (Zurflüh et al. 2005) 
Chapter 3 in J Inherit Metab Dis (Zurflüh et al. 2006) 
Chapter 4 in Hum Mutat (Zurflüh et al. 2008) 
Chapter 5 in Mol Genet and Metab (Jäggi et al. 2008) 
Chapter 6 is intended for publication (Zurflüh et al. 2008) 
Appendix is published in Eur J Pediatr (Opladen et al. 2005) 
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Abstract 
Tetrahydrobiopterin (BH4) deficiency among newborns with hyperphenylalaninemia must be 
rapidly diagnosed and distinguished from classical phenylketonuria (PKU) to initiate immedi-
ately specific treatment and to prevent irreversible neurological damage. The characteristic pat-
tern of urinary pterins makes it possible to differentiate between PKU and BH4 deficiencies, and 
to identify different variants of BH4 deficiency. However, collection, storage, and shipment of 
urine samples for pterin analysis is cumbersome. A method for the measurement of different 
pterins (neopterin, biopterin, and pterin) in blood collected on filter paper was developed as a 
potential alternative to the screening for BH4 deficiencies in urine and for the monitoring of 
BH4 pharmacokinetics. Pterins pattern in blood spots was comparable with those in plasma and 
urine. We thus established reference values for pterins in blood spots in patients with 
hyperphenylalaninemia and identified new patients with GTP cyclohydrolase I deficiency, 6-
pyruvoyl-tetrahydropterin synthase deficiency, and dihydropteridine reductase deficiency using 
dried blood spots on filter paper. 
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Introduction 
Tetrahydrobiopterin (BH4) is the essential co-factor/co-substrate of phenylalanine hydroxylases 
(PAH) and several other monooxygenases (Thöny et al. 2000). Measurement of pterins in 
different biological fluids is the most common method for the screening and differential 
diagnosis of inborn errors of BH4 metabolism. Five distinct genetic defects are known to cause 
hyperphenylalaninemia (HPA), including the classical form of Phenylketonuria (PKU) with a 
defect in the apo-enzyme PAH or a defect in four out of five BH4 co-factor-synthesizing or 
regenerating enzymes (Blau et al. 2001). Either of two defects in biosynthesis of BH4, i.e., GTP 
cyclohydrolase I (GTPCH) or 6-pyruvoyl-tetrahydropterin synthase (PTPS) or defects in 
regeneration, i.e., pterin-4α-carbinolamine dehydratase (PCD) and dihydropteridine reductase 
(DHPR) may be responsible for BH4 deficiency. BH4 deficiency is a severe but treatable disease 
and early detection in newborns is essential to avoid irreversible brain damage. 
According to the current protocol, the following investigations should be performed in all new-
borns with HPA (blood phenylalanine >120 µmol/L): 1. analysis of pterins (neopterin, biopterin, 
and primapterin) in urine; 2. measurement of DHPR activity in dried blood spots from Guthrie 
card; and 3. analysis of phenylalanine and tyrosine in plasma or blood before and after BH4 
loading with 20 mg/kg body weight. Tests 1 and 2 are essential for all newborns and identify 
primarily variants of BH4 deficiency in older children due to characteristic pterin patterns: 
GTPCH deficiency with low neopterin and biopterin, PTPS deficiency with high neopterin and 
only traces of biopterin, PCD deficiency with high neopterin, moderately biopterin and high 
primapterin, and DHPR deficiency with normal or moderate elevated neopterin and high bio-
pterin. Test 2 identifies patients with DHPR deficiency, which can sometimes be missed by 
test 1 if the urine is collected under low-protein diet. Test 3 is useful in all forms of BH4 
deficiency and can also detect patients with BH4-responsive PAH deficiency (Blau et al. 2002). 
With the introduction of tandem mass-spectrometry (TMS) in newborn screening, blood sample 
collection on filter paper became a routine procedure. The aim of this study was to test the use 
of filter paper blood spots (Guthrie cards) instead of urine for screening of BH4 deficiencies and 
  29 
 
CHAPTER 2 
 
to study the pharmacokinetics of BH4 by monitoring blood concentrations of pterins following 
oral loading test in patients with HPA. The new method should enable simultaneous measure-
ment of pterins (neopterin, biopterin, isoxanthopterin, and pterin), DHPR activity, and amino 
acids from a single Guthrie card specimen. The main advantage of using Guthrie cards instead 
of urine is the easy handling and sample collection, and the less expensive shipping of the sam-
ples at room temperature. 
 
Materials and Methods 
Pterins were purchased from Schircks Laboratories (Jona, Switzerland). All other chemicals 
were of the highest quality available. 
 
Sample preparation 
Pterins were eluted from dried blood spots on filter paper (Guthrie cards). For every single 
measurement four blood spots (∅ 6 mm) were cut out and pterins were extracted with 250 µL 
of 20 mmol/L HCl and placed in an ultrasonic bath (Sonorex RK31, Bandelin) for 30 s. Extrac-
tion was continued for 10 min by mixing the filter spots solution five times for 5 s at room 
temperature. The extract was centrifuged at 1800g for 5 min at room temperature. Sixty microli-
ters of the clear supernatant were used for analysis of haemoglobin on the haematology analyzer 
Sysmex KX-21N (Sysmex, Japan). The remaining supernatant was ultra-filtrated on Ultrafree 
(NMWL 10000; Millipore) at 5000g for 5 min. Pterins were analyzed in clear filtrate by HPLC 
and fluorescence detection without prior oxidation. 
 
HPLC of pterins 
HPLC of pterins (neopterin, biopterin, isoxanthopterin, and pterin) was performed as described 
previously (Curtius et al. 1991) with some modifications. Separation was performed on a C8 
Spherisorb, 5 µm pre-column (40 × 4.6 mm) and ODS-1 Spherisorb, 5 µm analytical column 
(250 × 4.6 mm) (both from Stagroma, Rheinach, Switzerland), using 1.5 mmol/L potassium 
hydrogen phosphate buffer, pH 4.6, with 8% (v/v) methanol at a flow rate of 1.2 mL/min. Pter-
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ins were detected by their native fluorescence at λEX: 350 nm, λEM: 450 nm using a fluorescence 
Detector FP-920 (Jasco, Tokyo, Japan). 
 
Patients 
Seventy patients with HPA (age 1 week to 15 years) were either tested for BH4 responsiveness 
(BH4 loading test with 20 mg/kg) or on treatment with BH4 (Schircks Laboratories, Jona, 
Switzerland). Blood sampling was a part of the routine screening for BH4 deficiency and was 
approved by corresponding boards. 
 
Controls 
Healthy adult controls (authors of this work) were administered BH4 (2 mg/kg, orally or sublin-
gually) as described previously. 
 
Statistical analyses 
WinSTAT for Excel (v. 2003.1) was used for descriptive statistics and for regression analysis. 
Correlation between blood spots, plasma, and urine was evaluated by debiased regression analy-
sis according to the method of Passing and Bablok. 
 
Results 
BH4 is extremely unstable in collected blood and about 30–40% is readily decomposed to pterin. 
Thus, in this study total biopterin was calculated as the sum of biopterin and pterin (bio-
pterin + pterin). 
 
Extraction of pterins from filter paper 
Neopterin, biopterin, and pterin were eluted from filter paper with 20 mmol/L HCl. Addition of 
10 or 20% (v/v) methanol did not improve the efficiency (Fig. 1A). Extending the sonification 
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time from 30 s to 5 min and extraction time from 10 to 30 min, and increasing the volume of 
solvent from 250 to 500 µL also did not change the elution profile significantly (Figs. 1B and 
C). 
 
Recovery 
Recovery of pterins from Guthrie cards, calculated by spiking blood samples with neopterin 
(20 nmol/L), biopterin (20 nmol/L), and pterin (5 nmol/L) standards, yielded 63–69%. 
 
Stability 
The stability of pterins in dried blood spots was tested by storing Guthrie cards at room 
temperature in the dark for a period of up to 16 days. This time was estimated to be sufficient to 
send samples by ordinary mail to the laboratory. Pterins were analyzed on 5 different days, and 
as shown in Fig. 2, the profile did not change significantly during the first 16 days. For long-
time storage, Guthrie cards were kept at −20 °C and retested after 6 and 18 months. Compared 
with initial values, neopterin was 102%, biopterin 105%, pterin 67%, and biopterin + pterin 
80% (data not shown). 
 
Reproducibility 
The run-to-run imprecision was determined with 20 identical blood samples from a patient with 
HPA (high value) and of an adult healthy control (low value). The rather high coefficient of 
variation (CV) in the control sample (low value) may be explained by the fact that concentra-
tions of pterins were close to detection limit of the HPLC system (around 0.02 nmol/g Hb). The 
within-run imprecision was measured in the same fashion but samples were measured in the 
same series (Table 1). 
 
Comparison with plasma and urine 
Concentrations of pterins in dried blood spots were compared with those in plasma obtained at 
same time points from four healthy persons loaded with 2 mg BH4/kg and regression was calcu-
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lated using the method of Passing–Bablok (Table 2). A relatively good correlation was found 
between two methods for biopterin + pterin and neopterin (Figs. 3A and D) and less good but 
still acceptable for biopterin and pterin alone (Figs. 3B and C). Analysis of pterins in dried 
blood spots and plasma of healthy persons loaded with BH4 (2 mg/kg) showed identical profiles 
for biopterin + pterin and neopterin (data not shown). 
Comparison of pterins from Guthrie cards with those from urine specimen from both control 
persons and patients with HPA revealed a similar correlation as between blood spots and 
plasma (Table 2 and Figs. 4A–D). Furthermore, the percentage of biopterin + pterin (of the sum 
of all pterins) in two patients with HPA were found to be comparable for all three methods 
(Fig. 5). The first patient underwent an extended loading test with BH4 (2 × 20 mg/kg BH4 at T0 
and T24) (Fig. 5A) and in the second patient a combined loading test (100 mg/kg phenylalanine 
at T−3 and 20 mg/kg BH4 at T0) was performed (Fig. 5B). The pterins profile showed that bio-
pterin + pterin levels peaked 3–4 h after BH4 administration in both cases (Figs. 6A and B), 
while neopterin concentrations remained unchanged (data not shown). The maximal BH4 
concentrations in blood spots were found to be extremely variable (3.6–96.4 nmol/g Hb) in a 
group of patients loaded with the same amount of BH4 (20 mg/kg). In one patient who was, 
based on the genotype, suggested to be BH4-responsive, pterins were measured in blood spots 
on two occasions (Fig. 7). In the first loading test, he was found to be a non-responder and at 
that time the blood spot biopterin + pterin concentration was rather low (9.7 nmol/g Hb). In the 
second test, the patient was found to be a BH4-responder and the maximal biopterin + pterin 
concentration was much higher (33.2 nmol/g Hb). 
 
Pterins profile in dried blood spots 
To be able to screen for BH4 deficiency in patients with HPA, reference values for neopterin 
and biopterin + pterin were established (Table 3). For this purpose, blood spots from 70 patients 
with various degrees of HPA in whom BH4 deficiency was excluded by standard tests were 
analyzed. Values were corrected for the reported recovery of ~65%. 
In a heterogeneous group of patients with HPA, two patients with PTPS deficiency, one with 
DHPR deficiency, and one with GTPCH deficiency were identified by analysis of the pterins 
profile in blood spots. Fig. 8A shows a patient suffering from classical PKU with a PAH defi-
ciency. Neopterin and biopterin levels are slightly increased, with the profiles fitting well those 
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in urine. A patient with a PTPS deficiency shows increased neopterin and no biopterin (Fig. 8B) 
and a patient suffering from DHPR deficiency has normal to increased neopterin and increased 
biopterin levels in blood spots (Fig. 8C). The patient with GTPCH deficiency is characterized 
by reduced neopterin and biopterin levels (Fig. 8D). We also investigated blood spots and urine 
samples from an older patient previously diagnosed with PCD deficiency, but primapterin was 
very low in urine and was not detected in blood spots (data not shown). 
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Figures and Tables 
Table 1. 
Run-to-run and within-run imprecision of identical 20 samples with low- 
value pterins (adult control) and high-value pterins (patient with HPA) 
 
 n = 20 Low value High value  
 Neo Bio Pte Bio + Pte Neo Bio Pte 
Bio + 
Pte 
Run-to-run   
x 0.08 0.26 0.22 0.33 2.81 12.44 14.86 27.29 
SD 0.02 0.08 0.08 0.17 0.40 2.12 2.52 4.58 
CV(%) 24.0 28.4 36.0 52.9 14.3 17.0 17.0 16.8 
Within-run   
x 0.05 0.21 0.41 0.62 0.32 54.23 84.69 138.92 
SD 0.004 0.01 0.05 0.06 0.041 1.812 3.619 4.652 
CV(%) 9.1 5.5 12.2 8.8 13.1 3.34 4.27 3.35 
For details, see Materials and methods. Values are expressed in nmol/g Hb 
(not corrected for the recovery). Neo, neopterin; Bio, biopterin; Pte, pterin. 
 
Table 2. 
Regression analysis of pterins in blood spots, plasma, and urine according to 
Passing-Bablok 
 
 n r Slope (95%-range) Intercept (95%-range) 
Blood spots vs. plasma 
Bio+Pte 72 0.883 0.006 (0.005 to 0.007) -0.026 (-0.056 to 0.012) 
Bio 72 0.773 0.004 (0.003 to 0.005) -0.003 (-0.038 to 0.020) 
Pte 72 0.728 0.010 (0.008 to 0.012) 0.000 (-0.019 to 0.037) 
Neo 72 0.842 0.010 (0.009 to 0.011) -0.025 (-0.042 to -0.012) 
Blood spots vs. urine 
Bio+Pte 84 0.852 0.261 (0.217 to 0.350) -0.062 (-0.171 to -0.021) 
Bio 84 0.788 0.182 (0.152 to 0.242) -0.019 (-0.084 to 0.016) 
Pte 84 0.502 0.520 (0.341 to 0.703) -0.005 (-0.035 to 0.000) 
Neo 84 0.874 0.163 (0.151 to 0.195) 0.026 (0.009 to 0.036) 
See also Figs.3 and 4. 
 
Table 3. 
Reference values for neopterin and biopterin + pterin in blood spots (nmol/g Hb) of patients 
with HPA, corrected for the reported recovery (65%) 
 
n = 70 Neo Bio+Pte %Bio+Pte 
Median 1.08 0.77 31.3 
5 – 95 percentile 0.31 – 4.45 0.15 – 2.91 13.9 – 78.3 
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 Fig. 1. Concentrations of neopterin, biopterin, and pterin in 
blood spots on filter paper investigated at: (A) different 
content of methanol in eluent; (B) different sonification times; 
and (C) different extraction times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 2. Stability of neopterin, biopterin, and pterin in blood 
spots on filter paper after storage at room temperature. 
n = 3 
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 Fig. 3. Regression analysis between blood spot and plasma: (A) biopterin plus pterin (Bio + Pte), (B) bio-
pterin (Bio), (C) pterin (Pte), and (D) Neopterin (Neo). 
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Fig. 4. Regression analysis between blood spots and urine: (A) biopterin plus pterin (Bio + Pte), (B) biop-
terin (Bio), (C) pterin (Pte), and (D) neopterin (Neo). 
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Fig. 5. Percentage of biopterin plus pterin (100 × (Bio + 
Pte)/(Neo + Bio + Pte)) in blood spots, plasma, and urine of two 
patients with HPA loaded with (A) 2 × 20mg/kg of BH4 at T0 
and T24 hours (extended loading test); and (B) 100 mg/kg 
phenylalanine at T-3 and 20 mg/kg BH4 at T0 (combined loading 
test). 
 
 
 
 
 
 
 
  
Fig. 6. Concentrations of biopterin plus pterin (Bio + Pte) in blood 
spots and plasma of two patients with HPA loaded with (A) 2 × 20 
mg/kg of BH4 at T0 and T24 hours (extended loading test); and (B) 
100 mg/kg phenylalanine at T-3 and 20 mg/kg BH4 at T0 (combined 
loading test). 
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Fig. 7. Effect of oral administration of BH4 (20 mg/kg) on blood 
phenylalanine levels in a patient with BH4-responsive PAH 
genotype (A403V/S411X) on two separate loading tests. During the 
first test (slow response) T4 blood spot BH4 levels were 6.3 nmol/g 
Hb while during the second test (good response) BH4 levels were ~3 
times higher (33.2 nmol/g Hb). 
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Fig. 8. HPLC profiles of pterins in blood spots and urine from patients with PKU and PTPS, DHPR, and 
GTPCH deficiencies. N: neopterin; B: biopterin; I: isoxanthopterin; P: pterin. 
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Discussion 
Dried blood spots on filter paper (Guthrie cards) were introduced in the early 1960s for the new-
born screening of few common and treatable inherited metabolic diseases, including PKU 
(Guthrie and Susi 1963). With the introduction of TMS, a number of new tests were developed 
for blood spots and blood collection on filter paper became a practical alternative for measure-
ment of metabolites such as amino acids and acylcarnitines in serum, plasma, or even urine. A 
minimal sample volume is required and samples can be transported at room temperature in an 
envelope. In addition to measurement of phenylalanine and tyrosine, blood spots are used for 
measurement of DHPR activity in patients with HPA (Arai et al. 1982). These are routine tests 
for the screening of disorders in BH4 metabolism and diagnosis is completed with the analysis 
of BH4 metabolites in urine. Dried blood spots on Guthrie cards were also used for simultane-
ous measurement of total biopterin and DHPR activity. It used the Crithidia fasciculata bioas-
say, which may not detect biopterin levels in patients with partial or peripheral defects and was 
never tested for other BH4 disorders (Leeming et al. 1984). 
Depending on the profile of neopterin and biopterin in urine, enzyme defects in BH4 metabo-
lism can be localized. However, urine samples need to be oxidized or sent frozen on dry ice. We 
developed a method that allows measuring amino acids, DHPR activity, and pterins from a 
single Guthrie card (eight 6 mm diameter spots). 
One of the main problems with the analysis of pterins in body fluids is their sensitivity to oxy-
gen and light. Particularly, BH4 is readily oxidized and degraded to biopterin and pterin, and 
depending where the degradation takes place, pterin is further oxidized to isoxanthopterin and 
xanthopterin by the xanthine dehydrogenase (Niederwieser et al. 1986). BH4 is present in blood, 
CSF, and urine mainly in tetrahydro form (Fukushima and Nixon 1980) and in the circulating 
blood it is probably bound to albumin. In solutions, BH4 is stable at acidic pH while at basic pH 
the side chain of BH4 is split off, producing a pterin ring (Fukushima and Nixon 1980). We 
have previously shown that addition of ascorbic acid and DTE to plasma samples prevents BH4 
from both oxidation and degradation to pterin (Fiege et al. 2004). Using differential oxidation of 
plasma samples with iodine at acidic and basic pH, we were able to show that about 80% of 
total biopterin is present as BH4. In dried blood spots on filter paper, BH4 is already fully oxi-
dized to biopterin and partially degraded to pterin. While the percentage of pterin is rather low 
in patients who are not on BH4, it can be up to 50% after administration of BH4. Once oxidized, 
pterins are stable in blood spots for up to 16 days at room temperature, which is the time esti-
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mated to be sufficient to send samples to the laboratory. Over longer period of time (up to 18 
months), neopterin (102%) and biopterin (105%) are more stable than pterin (67%). There was 
a positive correlation between plasma and blood spots for biopterin + pterin (r = 0.883) and 
neopterin (r = 0.842) and similar correlation was found between urine and blood spots 
(r = 0.852 for biopterin + pterin and r = 0.874 for neopterin). 
Elution and extraction of neopterin, biopterin, and pterin was optimized with respect to the elu-
ent and time. Pterins are generally well soluble in hydrochloric acid and at the acidic pH and 
when stored in the dark, they are stable over a longer period of time. Addition of organic sol-
vent, as used for the extraction of amino acids or acylcarnitines, did not improve extraction of 
pterins from dried blood spots. Recovery was calculated to be 63–69%. Concentrations of pter-
ins in blood spots were expressed per haemoglobin content because of a relative high amount of 
neopterin and biopterin in red blood cells. We have previously shown that concentrations of 
biopterin are about two times higher in red blood cells than in plasma and this ratio is even 
higher for neopterin (eight times higher in red blood cells) (Ponzone et al. 1993). 
Reproducibility is similar to those found for plasma pterins with a relative high run-to-run 
imprecision (24.0–52.9%) for the low-value sample, while the high-value run-to-run impreci-
sion (14.3–17.0%) and both low (5.5–12.2%) and high-value (3.34–13.1%) within-run impreci-
sion fulfil all diagnostic criteria. 
Blood spots biopterin + pterin were used to monitor BH4 pharmacokinetics in healthy controls 
and patients with HPA. Preliminary pharmacokinetic of BH4 was already done in healthy volun-
teers by monitoring biopterin concentrations in plasma following oral administration of BH4 
(Fiege et al. 2004). As already mentioned, about 80% of total biopterin was found as BH4 when 
analyzed immediately in antioxidant pre-treated plasma and without antioxidants no BH4 was 
detected. Maximal BH4 concentrations were found 1–4 h after BH4 administration and the 
elimination half-life time was estimated to be 3.3–5.1 h (Fiege et al. 2004). We investigated 
blood spot pterins during the course of loading test with BH4 in 53 patients with HPA (to be 
published elsewhere). Two loading tests are presented in this paper and blood spot bio-
pterin + pterin were compared with plasma biopterin (Fig. 6). In the first loading test, two dos-
ages of BH4 (2 × 20 mg/kg) were administered and biopterin + pterin was monitored up to 48 h 
after administration. As expected, maximal levels were found at T4 and T32 hours and blood 
spots and plasma levels were comparable. Similarly, in the second loading test (combined 
100 mg/kg phenylalanine and 20 mg/kg BH4 challenge) biopterin + pterin slightly increased in 
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blood spots and plasma 3 h after phenylalanine administration and peaked 4 h after BH4 
administration. Thus, measurement of pterins in blood spots seems to be useful for monitoring 
BH4 pharmacokinetics. This was also demonstrated in a patient who was based on the genotype 
(A403V/S411X) predicted to be a BH4-responder. As shown in Fig. 7, there was only slow de-
crease in blood phenylalanine concentration after administration of BH4 (20 mg/kg). At that 
time, blood spot biopterin + pterin levels were 9.7 nmol/g Hb. The test was repeated several 
weeks later and the patient was found to be a good BH4-responder with blood spot bio-
pterin + pterin levels of 33.2. Obviously, intra-individual variation in BH4 absorption may 
contribute to BH4 blood levels as documented by monitoring blood spot biopterin + pterin. 
In a pilot study of more than 70 patients with HPA, we measured blood spot pterins before the 
BH4 loading test and compared results with the standard screening in urine. Four patients were 
detected to be BH4-deficient; one patient with the GTPCH deficiency, two with PTPS defi-
ciency, and one with DHPR deficiency. The profile of pterins in blood spots was identical with 
that found in urine collected at the same time (Fig. 8). Although, the number of patients tested is 
rather small and no patients with PCD deficiency were detected so far, preliminary results sug-
gest that blood spots on filter paper may be a practical alternative option for the differential 
diagnosis of common forms of BH4 deficiency. Eight 6 mm spots are sufficient for the analysis 
of pterins (four spots), DHPR activity (two spots), and amino acids (two spots). 
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Summary 
The oral loading test with tetrahydrobiopterin (BH4) is used to discriminate between variants of 
hyperphenylalaninaemia and to detect BH4-responsive patients. The outcome of the loading test 
depends on the genotype, dosage of BH4, and BH4 pharmacokinetics. A total of 71 patients with 
hyperphenylalaninaemia (mild to classic) were challenged with BH4 (20 mg/kg) according to 
different protocols (1 × 20 mg or 2 × 20 mg) and blood BH4 concentrations were measured in 
dried blood spots at different time points (T0, T2, T4, T8, T12, T24, T32 and T48 h). Maximal BH4 
concentrations (median 22.69 nmol/g Hb) were measured 4 h after BH4 administration in 63 out 
of 71 patients. Eight patients presented with maximal BH4 concentrations ∼44% higher at 8 h 
than at 4 h. After 24 h, BH4 blood concentrations dropped to 11% of maximal values. This pro-
file was similar using different protocols. The following pharmacokinetic parameters were 
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calculated for BH4 in blood: t max = 4 h, AUC (T0−32) = 370 nmol × h/g Hb, and t 1/2 for absorp-
tion (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases. Maximal BH4 blood 
concentrations were not significantly lower in non-responders and there was no correlation be-
tween blood concentrations and responsiveness. Of mild PKU patients, 97% responded to BH4 
administration, while one was found to be a non-responder. Only 10/19 patients (53%) with Phe 
concentrations of 600–1200 µmol/L responded to BH4 administration and of the patients with 
the severe classical phenotype (blood Phe > 1200 µmol/L) only 4 out of 17 patient responded. 
An additional 36 patients with mild hyperphenylalaninaemia (HPA) who underwent the com-
bined loading test with Phe+BH4 were all responders. Slow responders and non-responders 
were found in all groups of HPA. 
© SSIEM and Springer 2006 
 
Abbreviations 
AUC area under the curve 
BH4 tetrahydrobiopterin 
HPA hyperphenylalaninaemia 
PAH phenylalanine hydroxylase 
PKU phenylketonuria 
t1/2 half-life 
 
 
Introduction 
The loading test with tetrahydrobiopterin (BH4) is an essential and integral part of the differen-
tial diagnosis for hyperphenylalaninaemia (HPA) (Blau et al. 2001). This test discriminates be-
tween BH4 responders and non-responders and is particularly important for detection of patients 
with BH4-responsive phenylalanine hydroxylase (PAH; EC 1.14.16.1) deficiency (Blau and 
Erlandsen 2004). In BH4 responders, blood phenylalanine (Phe) declines 4–24 h after BH4 
administration (20 mg/kg body weight), with almost complete normalization after 4–8 h in pa-
tients with BH4 deficiency. BH4-responsive PAH patients were initially defined as showing a 
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decrease of blood Phe concentrations of 30% after 8 h and 30–50% after 24 h (Bernegger and 
Blau 2002) and most of them belong to the group of mild HPA and mild and moderate 
phenylketonuria (PKU; OMIM 262600) (Desviat et al. 2004; Fiori et al. 2005; Kure et al. 1999; 
Lässker et al. 2002; Lindner et al. 2003; Lücke et al. 2003; Matalon et al. 2004; Mitchell et al. 
2005; Muntau et al. 2002; Pérez-Dueñas et al. 2004; Spaapen et al. 2001; Steinfeld et al. 2003; 
Trefz and Blau 2003). Sensitivity of the test was further improved by multiple administrations 
of BH4 and by longer observation time (Fiege et al. 2005; Shintaku et al. 2004). Efficiency and 
interpretation of the loading test depends on several factors such as amount of administered BH4, 
severity of HPA, dietary management, and genotype. The pharmacokinetics of BH4 was sug-
gested as an additional factor affecting the loading test; however, this was never investigated in 
patients with PKU (Fiege et al. 2004). 
The aim of this study was to estimate basic kinetic parameters for BH4 in blood after 
administration of BH4 and following the combined Phe+BH4 loading test, and to correlate the 
BH4 concentrations in blood with the outcome of the test. 
 
Materials and Methods 
Patients 
A total of 71 HPA patients in whom BH4 deficiency had been excluded were loaded with a sin-
gle dose of BH4 (20 mg/kg); 35 of them presented with basal blood Phe concentrations 
<600 µmol/L, 19 with Phe concentrations of 600–1200 µmol/L, and 17 with Phe concentrations 
>1200 µmol/L. In 11 patients with blood Phe concentrations of 278–1575 µmol/L the standard 
test was extended by the administration of another 20 mg/kg BH4 after 24 h. An additional 36 
patients with basal Phe concentrations of 384–739 µmol/L underwent a combined Phe 
(100 mg/kg) and BH4 (20 mg/kg) loading test. 
Mutation analysis was done in only a few patients and was not included in this study. The study 
was performed after a formal consensus of patients or their parents and in accordance with the 
Helsinki recommendations 1989. 
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Loading test. 
The single BH4 test, the extended test, and the combined Phe+BH4 loading test were performed 
as described previously using the 6R-BH4 (Schircks Laboratories, Jona, Switzerland) (Blau and 
Erlandsen 2004; Fiege et al. 2005). In patients loaded with a single dose of BH4 (20 mg/kg), 
blood was collected at times T0, T4, T8 and T24 h. In 45 of them additional blood collections were 
done at T2, T12 and T48 h. In patients loaded with 2 × 20 mg/kg BH4, blood was collected at T0, 
T4, T8, T24, T32 and T48 h, and in patients loaded with Phe+BH4 the following blood collections 
were performed: T-3 (Phe administration), T0 (BH4 administration), T4, T8 and T24 h. 
The following criteria were used to define BH4-responsiveness over 24 h (Fiege et al. 
2005): ’rapid responder’, reduction of blood Phe by ≥30% at T8, and ≥50% at T24; ’moderate 
responder’, reduction of blood Phe by ≥20% at T8, and ≥30% at T24; ’slow responder’, reduc-
tion of blood Phe by <20% at T8, and ≥20% at T24 (Fig. 1). 
 
BH4 and Phe in blood 
BH4 was measured in dried blood spots according to the method of Zurflüh and colleagues 
(Zurflüh et al. 2005) and calculated as the sum of total biopterin and pterin (nmol BH4/g Hb). 
The following protocol was used: For each measurement, four blood circles (Ø6 mm) were cut 
out and pterins were extracted with 250 µL of 20 mmol/L HCl and placed in an ultrasonic bath 
for 30 s. Pterins were extracted by mixing the filter spot solution for 10 min at room tempera-
ture. The extract was centrifuged at 1800×g for 5 min at room temperature. Clear supernatatant 
(60 µL) was used for analysis of haemoglobin on the haematology analyser Sysmex KX-21N 
(Sysmex Corporation, Japan). The remaining supernatant was ultrafiltered on Ultrafree (NMWL 
10000; Millipore) at 5000×g for 15 min. Pterins were analysed in clear filtrate by HPLC and 
fluorescence detection without prior oxidation (Zurflüh et al. 2005). 
Phe was measured using standard ion-exchange chromatography of amino acids or tandem-
mass spectrometry. 
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Statistical analyses 
WinSTAT for Excel (v. 2003.1) was used for descriptive statistics and for regression analysis. 
Pharmacokinetic parameters were calculated using the PK Solutions software, v. 2.0 (Summit 
Research Services, Montrose, CO). 
 
Results 
BH4 kinetics in blood 
In 63 out of 71 patients with HPA loaded with 20 mg/kg BH4, blood BH4 concentrations 
reached highest values after 4 h (median = 22.65 nmol/g Hb; 5th–95th percentiles = 10.07–
49.97 nmol/g Hb). Four hours later (T8) BH4 concentrations decreased by 42% (median = 
13.61 nmol/g Hb; 5th–95th percentiles = 5.25–31.63 nmol/g Hb) and after 24 h BH4 concentra-
tions were only 11% of maximal values (median = 2.29 nmol/g Hb; 5th–95th percentiles = 
0.67–5.35 nmol/g Hb). In 8 out of 71 patients, blood BH4 concentrations were ~44 % higher at 
8 h than values at 4 h after administration and the highest single BH4 value was 96.39 nmol/g 
Hb at T4 h. 
In 45 of the above patients the blood BH4 profile was investigated over 32 h after BH4 
administration (20 mg/kg) with additional time points at T2, T12 and T32 h (Fig. 2). Two hours 
after BH4 administration (median = 16.30 nmol/g Hb; 5th–95th percentiles = 6.84–28.44 nmol/g 
Hb) blood concentrations reached about 70% of the maximal concentrations found after 4 h. At 
12 h (median = 6.15 nmol/g Hb; 5th–95th percentiles = 2.90–12.38 nmol/g Hb) and 32 h (median 
= 2.03 nmol/g Hb; 5th–95th percentiles = 0.51–5.47 nmol/g Hb) BH4 blood concentrations were 
lower than those at 8 h (47% and 15%, respectively). 
In 11 patients the protocol was extended to a second administration of BH4 (20 mg/kg) after 
24 h (Fig. 3). Blood was collected 8 (T32) and 24 (T48) hours after the second administration and 
compared with T8 concentrations for BH4 in blood (median = 15.37 nmol/g Hb; 5th–95th percen-
tiles = 7.05–54.02 nmol/g Hb); T32 values were 17% lower (median = 12.80 nmol/g Hb; 5th–95th 
percentiles = 7.41–38.54 nmol/g Hb). There was no significant difference in BH4 concentrations 
at T24 and T48 h. 
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Thirty-six patients with blood Phe concentrations of <336 µmol/L were loaded first with Phe 
(100 mg/kg) and three hours later with BH4 (20 mg/kg), and blood samples were collected be-
fore Phe administration (T-3), before BH4 administration (i.e. 3 h after Phe loading; T0), and 4, 8 
and 24 h after BH4 administration (T4-24) (Fig. 4). BH4 concentrations in blood increased in 
26/36 patients after Phe administration by 111% (BH4 at T-3, median = 0.30 nmol/g Hb; 5th–95th 
percentiles = 0.12–2.77 nmol/g Hb; BH4 at T0, median = 0.52 nmol/g Hb; 5th–95th percentiles = 
0.16–4.43 nmol/g Hb). The following profile of BH4 kinetics was similar as the one described 
for a single BH4 administration, with maximal blood concentrations at T4 (median = 
22.01 nmol/g Hb; 5th–95th percentiles = 10.40–46.58 nmol/g Hb), 25% lower concentrations at 
T8 (median = 16.46 nmol/g Hb; 5th–95th percentiles = 66–33.49 nmol/g Hb), and 90% lower 
concentrations at T24 (median = 2.09 nmol/g Hb; 5th–95th percentiles = 0.55–6.84 nmol/g Hb). In 
6 subjects maximal BH4 concentrations were reached after 8 h. 
Based on data obtained over 32 h after a single BH4 administration (20 mg/kg) in 45 patients 
with HPA, basic pharmacokinetic parameters were calculated: tmax was 4 h, AUC (T0-32) was 
370 nmol × h/g Hb, and t1/2 for absorption, distribution, and elimination phases was 1.1, 2.5, and 
46.0 h, respectively.  
 
Responsiveness to BH4 
Table 1 summarizes the results of the loading test with 20 mg/kg BH4 in patients with HPA. 
Responsiveness was calculated according to criteria defined in Fig. 1. 34/35 patients (97%) with 
basal blood Phe concentrations <600 µmol/L responded to BH4 administration, one patient was 
found to be a non-responder. Only 10/19 patients (53%) with basal blood Phe concentrations of 
600–1200 µmol/L responded to BH4 administration, and of the patients with the severe classical 
phenotype (blood Phe >1200 µmol/L) only four patients responded (24%), and two of them 
were slow responders (Fig. 5). The lower the Phe at T0 the higher the probability that a patient 
will respond to BH4. Two patients could not be assigned to the above-mentioned criteria; one 
would have been positioned somewhere between moderate and slow responder and the other 
was at the level of a rapid responder after 8 h but dropped at 24 h below the level of a slow re-
sponder. 
All 36 patients who underwent the combined loading test with Phe+BH4 were classified as 
responders (data not shown). 
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In order to demonstrate whether absorption of BH4 may affect the outcome of the loading test, 
maximal blood BH4 concentrations were compared with responsiveness to BH4, but no correla-
tion was found (Fig. 6). Highest maximal blood BH4 concentrations were found in two rapid 
responders. 
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Figures and Tables 
Table 1. 
Summary of BH4 loading tests (20 mg/kg) in 71 patients with PAH deficiency 
 
  Initial blood Phe concentrations 
 n <600 µmol/L (n = 35) 600–1200 µmol/L (n = 19) >1200 µmol/L (n = 17) 
Responder (total) 48 34  10  4  
Rapid responder 34 26  6  2  
Moderate responder 10 7  3  0  
Slow responder 4 1  1  2  
Non-responder 21 1  8  12  
Not defined 2 0  1  1  
 
 
 
 
 
 
 
  
Fig. 1. Definition of the BH4 responsiveness after oral administration of BH4 (20 mg/kg). RR: rapid 
responder; MR: moderate responder; SR: slow responder; NR: non-responder; ND not defined 
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Fig. 2. BH4 concentrations in blood after oral administration of BH4 
(20 mg/kg) in 47 patients with HPA. — Median, □ 25th–75th percentiles; ┴ 5th 
percentile; ┬ 95th percentile; + min/max 
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Fig. 3. BH4 concentrations in blood after oral administration of BH4 
(2 × 20 mg/kg) in 11 patients with HPA. Second dosage of BH4 was adminis-
tered 24 h after the first application. — Median, □ 25th–75th percentiles; ┴ 5th 
percentile; ┬ 95th percentile; + min/max 
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Fig. 4. BH4 concentrations in blood after oral administration of Phe 
(100 mg/kg) and BH4 (20 mg/kg) in 36 patients with mild HPA. BH4 was 
administered 3 h after Phe application. — Median, □ 25th–75th percentiles; 
┴ 5th percentile; ┬ 95th percentile; + min/max 
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Fig. 5. Correlation between Phe decline in blood 24 h after administration of BH4 (20 mg/kg) and basal 
Phe levels in 71 patients with HPA. ■ Rapid responder; ▲ moderate 
Responder, * slow responder; ● non-responder 
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Fig. 6. Correlation between Phe decline in blood 24 h after administration of BH4 (20 mg/kg) and 
maximal BH4 levels in 71 patients with HPA 
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Discussion 
Extensive pharmacokinetic studies of BH4 have been performed in animal models (Hayashi et 
al. 1992), but only a few parameters are known from studies in humans (Følling 2006). Some 
pharmacokinetic parameters are known from oral administration of BH4 tablets to healthy adult 
human volunteers and might provide details on pharmacological response to BH4 therapy (Fiege 
et al. 2004). Plasma concentrations of BH4 and total biopterin were assessed after oral 
administration of 6R-BH4 at different doses to different healthy subjects and preliminary 
pharmacokinetic parameters have been determined (Fiege et al. 2004). The plasma profile of 
total biopterin after oral administration exhibited first-order kinetics, showing a fast absorption 
phase (T0–T4), a rapid decline (T4–T10) corresponding to the absorption and distribution phase, 
followed by a slower decline in the final elimination phase (T10–T33 h). Total biopterin 
concentrations in plasma have been studied after administration of different doses (10 and 
20 mg/kg) to one healthy adult subject (Fiege et al. 2004). Maximal plasma concentrations in 
this subject were reached 4 h after the 10 mg/kg dose and 3 h after the 20 mg/kg dose, at 
concentrations of 258.7 and 441.7 nmol/L, respectively. The AUC0-10 after administration of 
20 mg/kg was 1.6 times higher than the AUC after the 10 mg/kg dosage (3046 vs. 
1958 nmol h/L). Based on these data, the elimination kinetics seem to be only slightly faster at 
higher plasma concentrations (tmax = 4.2 h vs. 5.1 h) (Fiege et al. 2004). 
Very little is known about BH4 pharmacokinetics in patients with HPA. Shintaku and col-
leagues (Shintaku et al. 2005) reported plasma biopterin concentrations in two patients with 
HPA who underwent a single BH4 loading test (10 mg/kg) at different ages. In both patients 
plasma biopterin concentrations were ~100% higher at an early age (<1 month) compared with 
concentrations measured at the age of 2 months. Also, biopterin concentrations peaked at 4 h at 
the age of 1 month, compared with maximal concentrations at 2 h at the age of 2 months. The 
authors suggested that BH4-responsiveness in the same individual or the same genotype may 
correlate with biopterin concentration, but in different genotypes this might not be the case 
(Shintaku et al. 2005). 
We were not able to see any statistical difference between different age groups in our patients 
(data not shown). Similarly to what was described for healthy controls (Fiege et al. 2004), blood 
BH4 peaked at 4 h in 90% of patients with HPA. This profile was consistent regardless of 
whether patients were loaded with one or two BH4 doses or after Phe administration (Figs. 2–4). 
Two hours after BH4 administration, blood concentrations were about 70% of the maximal BH4 
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concentrations, indicating a very fast absorption phase (t1/2 = 1.1 h). In our patients, oral 
administration of BH4 resulted in a fast distribution phase (t1/2 = 2.5 h), followed by a slow 
elimination phase (t1/2 = 46.0 h). Thus, although a single BH4 administration may be sufficient 
for the interpretation of the loading test, additional dosages can potentate the effect and increase 
the sensitivity (Fiege et al. 2005; Shintaku et al. 2004). 
Data from the combined Phe+BH4 loading test show that administration of Phe (100 mg/kg) 
almost doubled blood BH4 concentrations after 3 h in 72% of patients (Fig. 4). This is consistent 
with previous findings that biopterin concentrations in urine or plasma correlate with blood 
phenylalanine concentrations (Dhondt and Farriaux 1982; Ponzone et al. 1993) but have no 
consequences on the outcome of the loading test. Phenylalanine administration does not influ-
ence BH4 concentrations upon oral BH4 administration. As expected, all patients in this group 
were classified as responders and one should question how useful this test is. Factors such as 
spontaneous Phe elimination (Desviat et al. 2004) or daily fluctuations (Leuzzi et al. 2006) may 
influence the interpretation, and from our experience the combined loading test is not recom-
mended. It can be only used in patients who are already on a strict low-phenylalanine diet with 
normalized blood phenylalanine concentrations.  
One of the main goals of this study was to evaluate the effect of blood BH4 concentrations on 
the outcome of the loading tests. Recently we described a single case with HPA (BH4-respon-
sive genotype) showing intra-individual variations in BH4 absorption on two occasions, which 
resulted in different BH4 blood concentrations and influenced the responsiveness (Zurflüh et al. 
2005). We were not able to repeat the loading test in non-responders in this study, but maximal 
BH4 blood concentrations were not significantly lower in this group of patients. Indeed, maxi-
mal BH4 blood concentrations were only 3% lower in non-responders than in all responders, and 
slow responders had 7% and 42% higher concentrations than moderate or rapid responders, 
respectively (data not shown). 
With regard to the responsiveness to BH4, our data confirm previous observations that rapid 
responders belong mainly to the groups of mild HPA and mild PKU, and that patients with 
classical PKU show either only a slow response or none at all (Fig. 5). Nevertheless, slow 
responders and non-responders were found in all groups of HPA. 
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Abstract 
Mutations in the phenylalanine hydroxylase (PAH) gene result in phenylketonuria (PKU). 
Tetrahydrobiopterin (BH4)-responsive hyperphenylalaninemia has been recently described as a 
variant of PAH deficiency caused by specific mutations in the PAH gene. It has been suggested 
that BH4-responsiveness may be predicted from the corresponding genotypes. Data from BH4 
loading tests indicated an incidence of BH4-responsiveness of >40% in the general PKU 
population and >80% in mild PKU patients. The current project entailed genotype analysis of 
315 BH4-responsive patients tabulated in the BIOPKUdb database and comparison with the data 
from the PAHdb locus-specific knowledgebase, as well as with previously published PAH 
mutations for several European countries, Northern China, and South Korea. We identified 60 
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mutations, presenting with a substantial residual PAH activity (~47%), presumed to be associ-
ated with BH4-responsiveness. More than 89% of patients are found to be compound heterozy-
gotes. The three most common mutations found in >5% of BH4-responsive patients are 
p.A403V, p.R261Q, and p.Y414C. Using the Hardy-Weinberg formula the predicted average 
frequency of BH4-responsiveness in European populations was calculated to be 55% (range 17-
79%, lowest in Baltic countries and Poland and highest in Spain), 57% in Northern China, and 
55% for South Korea. The genotype-predicted prevalence of BH4-responsiveness was higher 
than prevalence data obtained from BH4 loading tests. Inconsistent results were observed for 
mutations p.L48S, p.I65T, p.R158Q, p.R261Q, and p.Y414C. Our data suggest that BH4-
responsiveness may be more common than assumed and to some extent may be predicted or 
excluded from the patient’s genotype. 
© 2008 Wiley-Liss, Inc. 
 
 
Introduction 
Phenylketonuria (PKU; OMIM# 261600) is an autosomal recessive genetic disorders caused by 
a deficiency of the hepatic phenylalanine-4-hydroxylase (PAH; EC 1.14.16.1) (Scriver and 
Kaufman 2001). PAH is a mixed function oxidase that catalyzes hydroxylation of phenylalanine 
(Phe) to tyrosine, the rate-limiting step in phenylalanine catabolism. The reaction is dependent 
on BH4 as cofactor, molecular oxygen, and iron. PAH deficiency causes hyperphenylalaninae-
mia (HPA) of variable degree. A distinction is made between PKU which requires a phenyla-
lanine-restricted diet, and mild hyperphenylalaninaemia (MHP), a variant that does not require 
treatment. Depending on the phenylalanine tolerance, PKU may be divided into mild PKU, 
moderate PKU, and classical PKU (Guldberg et al. 1998); some centers only distinguish be-
tween mild and classical PKU. The PAH-mutation genotype is the main determinant of the 
metabolic phenotype. Recently Kure et al. (Kure et al. 1999) described patients who responded 
to oral administration of BH4 by lowering their blood phenylalanine levels and subsequently 
several groups documented that BH4 can be successfully used for the long-term treatment of 
HPA patients as an alternative to a dietary treatment (Bélanger-Quintana et al. 2005; Cerone et 
al. 2004; Hennermann et al. 2005; Lambruschini et al. 2005; Muntau et al. 2002; Shintaku et al. 
2004; Steinfeld et al. 2004; Trefz et al. 2001; 2005). It has been estimated that, depending on 
the criteria selected, more than 30% of all HPA patients respond to BH4 (20 mg/kg) (Bernegger 
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and Blau 2002) and that the main target for BH4 administration are patients with mild to 
moderate PKU (Fiege and Blau 2007).  
Molecular mechanisms responsible for BH4-responsiveness in patients with PKU are 
multifactorial (Aguado et al. 2006; Blau and Erlandsen 2004; Erlandsen et al. 2003, 2004; Kure 
et al. 2004; Pey et al. 2004; Steinfeld et al. 2003; Thöny et al. 2004) and depend on mutations in 
the PAH gene. Chaperon-like activity of BH4 and stabilization of PAH protein and a 
considerable residual activity as well as an increase in intracellular BH4 concentrations required 
for the full enzyme activity are some of the proposed mechanisms. Mutations so far described in 
patients with BH4-responsive HPA are tabulated in the BIOPKU database (BIOPKUdb) and 
many of them have been shown to be associated with a significant residual PAH activity, when 
recombinantly expressed in different cell systems.  
In order to estimate the frequency of BH4-responsiveness in different populations based on 
genotype information, we calculated the allele and genotype frequencies for the BIOPKUdb and 
compared them with data published for different countries, including the PAHdb locus 
knowledgebase (Scriver et al. 2003). 
 
Subjects and Methods 
Source of data 
Data from 315 patients who responded to the BH4 loading test (10-20 mg/kg) by lowering their 
blood phenylalanine levels by >30% after 8-24 hours, were tabulated in the International Data-
base of Patients and Mutations Causing BH4-Responsive HPA/PKU (BIOPKUdb, 
http://www.bh4.org/BH4DatabasesBiopku.asp, programmed in Access 2003, Microsoft, Red-
mond, WA). The minimal requirement for inclusion in the database was a 30% blood phenyla-
lanine reduction 8 hour after administration of 10 mg/kg BH4. It is assumed that patients loaded 
with 20 mg/kg BH4 over 24 hours would have the same or even better responsiveness. There-
fore, data were not stratified in separate groups. Dietary intake of phenylalanine and initial 
blood phenylalanine levels were different, depending on the actual phenotype. BIOPKUdb in-
cludes detailed information on genotype (mutation name, systemic name, location in gene, PAH 
domain, residual activity, and HPA type), BH4 loading test data (amount of BH4 used and 
percentage of responsiveness), and references.  
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Both protein and cDNA numbers follow standard recommendations with nucleotide +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence, and 
the initiation codon denoted codon 1. Reference sequences: GenBank cDNA = NM_000277.1; 
protein = NP_000268.1. 
PAHdb, http://www.pahdb.mcgill.ca, a locus-specific knowledgebase (Scriver et al. 2006) 
tabulates a total of 3137 alleles (regardless of BH4-responsiveness) from countries all over the 
world. In 633 patients the genotype is defined (last access April 2007). In addition to molecular 
data, information about the source of alleles, polymorphic haplotype backgrounds, and effect of 
the allele on the enzyme activity is provided. Little information is provided about BH4-
responsiveness. 
Allele frequencies of common PKU mutations in Europe were previously published (Zschocke 
and Hoffmann 1999); we included studies only if the mutation detection rate exceeded 80%. 
Full genotype data were available for 119 patients from Northern Ireland (60 different geno-
types) (Zschocke et al. 1995) and 275 patients from Germany (165 different genotypes) 
(Zschocke and Hoffmann 1999). Information on BH4-responsiveness was not available for 
those cohorts. In addition to European patients we also included published patients from Korea 
and China with fully characterized genotypes in our study. There were 58 patients with 48 
different genotypes from Korea (the original study comprised 79 patients, but achieved only a 
mutation detection rate of 75%) (Lee et al. 2004). There were 155 patients with 97 different 
genotypes from China (the original study comprised 185 patients and achieved a mutation 
detection rate of 94 %) (Song et al. 2005). 
 
Data limitation 
Excluded from the study are patients with only one allele detected (13 patients) and those with 
two null alleles (no residual activity) (3 patients).  
 
Criteria for BH4-responsiveness 
The criteria of BH4-responsiveness in patients with PAH deficiency have been previously de-
scribed (Blau and Erlandsen 2004); briefly, patients were classified as BH4-responsive if they 
responded to the oral administration of BH4 (10-20 mg/kg body weight) by lowering their blood 
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Phe levels by at least 30% within 8 to 24 hours. A mutation/an allele was regarded as associated 
with BH4-responsiveness if it was present either in homozygous form or compound heterozy-
gous associated with a known null mutation. Mutations were also regarded as null mutations 
when in vitro residual activity was below 10% and the second mutation in a compound 
heterozygous BH4-responsive patient had a substantial residual PAH activity (>10%). In vitro 
enzymatic activities (mutant PAH as a percentage of wild-type PAH) are generally higher than 
those reported in liver biopsies (Waters et al. 1998).  
Alleles that could not be classified using these criteria were labeled unclear. 
 
Population genetics 
In order to estimate the frequency of BH4-responsiveness in different populations we regarded 
BH4-responsive mutations as dominant in compound heterozygous patients. BH4-responsive-
ness was expected in all patients with a BH4-responsive mutation on at least one PAH gene 
copy. For populations without available genotypes, the expected frequency of genotypes associ-
ated with BH4-responsiveness was estimated using the Hardy-Weinberg formula, as follows. 
We first calculated the combined allele frequencies for BH4-responsive mutations and non-
responsive mutations (including unclear alleles), respectively. Subsequently, squared combined 
frequency of non-responsive alleles was taken as the frequency of non-responsive genotypes, 
whilst the other genotypes were regarded as BH4-responsive.  
 
Results 
BIOPKUdb 
The BIOPKUdb comprises genotypes information from 315 BH4-responsive patients. 115 
different PAH gene mutations were found, 57% of which were present in more than one patient 
(Table 1). About 50% of the mutations described in the BIOPKUdb were previously expressed 
recombinantly in eukaryotic cell systems or in E. coli, and many were found to have substantial 
residual activity (>10%). The average residual PAH activity calculated for the 40 most common 
BH4-responsive mutations was 46.8% (data not shown).  
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Using the criteria outlined 57 mutations were classified as BH4-responsive (Figure 1), 20 were 
classified as non-responsive and 38 mutations were termed unclear. The most common BH4-
responsive mutations in the database are p.A403V (56 alleles), p.R261Q (49 alleles), p.Y414C 
(44 alleles), p.A300S and p.V245A (26 alleles each), p.L48S (24 alleles), p.E390G (23 alleles), 
and p.R241C (20 alleles) (Table 1). 32 out of 315 patients were homozygous, 102 had two 
different BH4-responsive alleles, and 173 had one BH4-responsive allele and one either non-
responsive or unclear allele. Eight patients (2.5%) were compound heterozygous for two un-
clear alleles. The most common BH4-responsive genotypes are listed in the Supplementary Ta-
ble S1. 
The mutations collected in the BIOPKUdb are spread all over the PAH gene (Figure 1). Only 
two out of 60 BH4-responsive mutations were located in the cofactor binding domain CBR1 
(p.V245A and p.R261Q). The overall distribution of the different mutations (responsive and 
non-responsive) tabulated in the BIOPKUdb is as follows: 64% are found in the catalytic do-
main, 14% are in the regulatory domain, 10% in the tetramerization domain, and 12% are in-
tronic. In comparison to non-responsive mutations, responsive mutations are located with an 
increased percentage in the tetramerization (14% vs. 1%) and the regulatory domains (16% vs. 
1%). Most of the responsive mutations were found in the catalytic domain (68%) (Table 2). 
There was a small number of splicing mutations that are BH4-responsive, contrary to the usual 
experience that they represent null mutations. This phenomenon may be caused by residual nor-
mal splicing with low efficiency or the generation of novel transcripts with in-frame insertions 
or deletions compatible with residual enzyme function (Jennings, et al., 2000). Nevertheless, it 
remains to be seen whether BH4 sensitivity associated with splicing mutations can be confirmed 
in other patients and how this effect is mediated by BH4. 
 
PAH database and BH4-responsiveness 
Based on the information in the BIOPKUdb, mutations tabulated in the PAHdb were assigned 
as BH4-responsive, non-responsive, or unclear (see Materials and Methods for the definition) 
and predicted frequencies are calculated using the Hardy-Weinberg equation. 
The 3173 mutations in the PAHdb were classified into responsive alleles (32%) and non-
responsive alleles (68%, incl. unclear and mutations not found in the BIOPKUdb). For 633 pa-
tients, genotypes were defined and it was found that within this group of patients responsive 
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alleles make up 36% of the mutations (Table 3). Study of the genotypic distribution revealed 
that out of 633 patients, 355 (56%) carried either one or two responsive alleles and thus are 
potential BH4-responders. Based on the allele frequency (AF), we calculated the theoretical 
distribution of BH4-responsive patients using the Hardy-Weinberg equation to be 58%, which 
corresponds well with the result of the genotype analysis. (Table 4). 
 
BH4-responsiveness in Europe, Northern China, and South Korea 
The data from Germany and Northern Ireland contained genotype information, those from the 
remaining European countries only allele frequencies.  
Based on the genotype information, 159 out of 275 (58%) potentially responsive patients were 
counted in Germany and 78 out of 119 (73%) in Northern Ireland. Using the Hardy-Weinberg 
formula a similar distribution was observed: 58% BH4-responders in Germany and 76% in 
Northern Ireland (Table 4). The calculation of the expected proportion of potentially responsive 
patients using the Hardy-Weinberg formula gave greatly different results ranging from 17% in 
the Baltic countries (Estonia, Latvia, and Lithuania) and Poland to a high 79% in Spain. Rela-
tive lower numbers of potentially responsive patients were found in Eastern Europe, mainly due 
to the high frequency of severe PKU mutations, in particular p.R408W, whilst higher numbers 
of responders are expected in the genetically heterogeneous Southern Europe populations. The 
average of potentially responsive patients in Europe was estimated to be 55% (Table 3). Data 
from Northern China comprised 155 fully defined genotypes with 310 alleles whereof 106 were 
according to our classification assigned as responsive (Table 3). Approximately 54% of the 
genotypes are found to be potentially BH4-responsive (57% using the Hardy-Weinberg formula) 
(Table 4). A total of 58 patients from South Korea with fully characterized mutations were used 
to calculate the expected frequency of BH4-responsiveness. We found 38/116 (33%) of respon-
sive alleles (Table 3), which leads to 31/58 (53%) potentially BH4-responsive patients (55% 
according to the Hardy-Weinberg formula) (Table 4). 
 
Genotype-phenotype correlation 
Most patients tabulated in the BIOPKUdb belong to the group of MHP (42%) or mild PKU 
(37%). As classical PKU is frequently associated with homozygosity or compound heterozygos-
ity for null mutations it is not surprising to find only 7% of moderate PKU and 13% of classical 
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PKU in the BIOPKUdb. Of 173 patients with only 1 responsive allele 39% are MHP and 38% 
mild PKU, while of 134 patients with 2 responsive alleles (either homozygote or compound 
heterozygote) 47% are MHP and 35% mild PKU. Only 14% of the patients with 1 responsive 
allele and 10% of the patients with 2 responsive alleles belong to classical PKU. 
We compared the BIOPKUdb information with two studies performed in PKU patients and 
faced a similar problem. Based on the loading test performed in 74 PKU patients, Fiori et al. 
(Fiori et al. 2005) detected 85% of patients to be BH4 responders. Using the genotype analysis 
we found five more responders (p.R261Q/p.L48S, p.L48S/p.L48S, p.L48S/p.L48S, 
p.L48S/p.R408W, and p.R261Q/p.R53H), raising predicted BH4-responsiveness to 92% (+7%). 
Pérez-Dueñas et al. (Pérez-Dueñas et al. 2004) loaded 42 PKU patients with BH4 and found 
44% of them to be responders. We confirmed BH4-responsiveness in 18 out of 20 patients who 
were initially defined as responders; two were non-responders according to the genotype 
(IVS2+5G>C/p.P362T and IVS4+5G>T/ IVS4+5G>T). 11 out of the 22 initially assigned non-
responders were BH4-responders according to the genotype information (p.R261Q/p.S349P, 
p.R243Q/p.I65T, p.L48S/p.S349P, IVS4+5G>T/p.R158Q, p.R261Q/p.R243X, 
p.V388M/p.S349P, IVS1+5G>T/p.R158Q, p.I65T/p.I65T, IVS4+5G>T/p.R243Q, 
p.I65T/IVS8+1G>A, and p.V388T/p.P279fsdelC). Thus, according to the BIOPKUdb 
classification by genotype, 69% (+25%) of patients described in this study are expected to be 
responders. 
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Figures and Tables 
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Table 1. 
Summary of the BIOPKUdb mutations. Alleles frequency, location in the protein, and residual 
PAH activity. 
 
Allele  
Nucleotide aberra-
tion 
Number of 
alleles (AF) 
Residual 
activity* Domain (CBR) (AS) 
BH4-responsive mutations    
p.A403V c.1208C>T 56 (8.9%) 32 catalytic 
p.R261Q c.782G>A 49 (7.8%) 38.5 catalytic (CBR1) 
p.Y414C c.1241A>G 44 (7.0%) 36 tetramerization 
p.A300S c.898G>T 26 (4.1%) 31 catalytic 
p.V245A c.734T>C 26 (4.1%) 50 catalytic (CBR1) (AS) 
p.L48S c.143T>C 24 (3.8%) 39 regulatory 
p.E390G c.1169A>G 23 (3.7%) 72.5 catalytic 
p.R241C c.721C>T 20 (3.2%) 25 catalytic 
p.I65T c.194T>C 18 (2.9%) 25.3 regulatory 
p.R158Q c.473G>A 14 (2.2%) 10 catalytic 
p.V388M c.1162G>A 14 (2.2%) 27.5 catalytic 
p.D415N c.1243G>A 8 (1.3%) 93 tetramerization 
p.R408Q c.1223G>A 7 (1.1%) 49.7 catalytic 
p.R243Q c.728G>A 6 (1.0%) 23 catalytic 
p.R413P c.1238G>C 6 (1.0%) 66 tetramerization 
IVS4-5c>g c.442-5C>G 5 (0.8%) ? intronic 
p.E178G c.533A>G 5 (0.8%) 39 catalytic 
p.F39del c.115_117delTTC 5 (0.8%) 20 regulatory 
p.F39L c.117C>G 5 (0.8%) 49 regulatory 
p.R68S c.204A>T 5 (0.8%) 87 regulatory 
p.A395P c.1183G>C 4 (0.6%) 15.5 catalytic 
p.L348V c.1042C>G 4 (0.6%) 41 catalytic 
p.M276V c.826A>G 4 (0.6%) ? catalytic 
p.P211T c.631C>A 4 (0.6%) 72 catalytic 
p.P407S c.1219C>T 4 (0.6%) 94 catalytic 
p.R241H c.722G>A 4 (0.6%) 23 catalytic 
p.Y417H c.1249T>C 4 (0.6%) ? tetramerization 
IVS10-3c>t c.1066-3C>T 3 (0.5%) ? intronic 
p.A104D c.311C>A 3 (0.5%) 26 regulatory 
p.A309V c.926C>T 3 (0.5%) 44 catalytic 
p.K320N c.960G>C 3 (0.5%) ? catalytic 
p.T380M c.1139C>T 3 (0.5%) ? catalytic (AS) 
p.V230I c.688G>A 3 (0.5%) 63 catalytic 
p.D222G c.665A>G 2 (0.3%) ? catalytic 
p.H170D c.508C>G 2 (0.3%) 43 catalytic 
p.I94del c.283_285delATC 2 (0.3%) 27 regulatory 
p.I94S c.281T>G 2 (0.3%) ? regulatory 
p.T92I c.275C>T 2 (0.3%) 76 regulatory 
p.V190A c.569T>C 2 (0.3%) 110 catalytic 
p.A313T c.937G>A 1 (0.2%) 76 catalytic 
p.A373T c.1117G>A 1 (0.2%) 56 catalytic 
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Table 1 cont.     
Allele  
Number of 
alleles (AF) 
Residual 
activity* Domain (CBR) 
p.D129G c.386A>G 1 (0.2%) ? 
p.D338Y c.1012G>T 1 (0.2%) ? catalytic 
p.E76G 1 (0.2%) 47 regulatory 
p.I269L c.805A>C 1 (0.2%) ? 
p.L308F c.922C>T 1 (0.2%) 49 catalytic 
p.L41F 1 (0.2%) 10 regulatory 
p.P122Q c.365C>A 1 (0.2%) 22 
p.P147S c.439C>T 1 (0.2%) ? catalytic 
p.P244L 1 (0.2%) 51 catalytic 
p.P275S c.823C>T 1 (0.2%) ? 
p.P314S c.940C>T 1 (0.2%) ? catalytic 
p.S110L 1 (0.2%) ? regulatory 
p.S310Y c.929C>A 1 (0.2%) ? 
p.S87R c.261C>A 1 (0.2%) 82 regulatory 
p.R176L 1 (0.2%) 31.5 catalytic 
p.V177M c.529G>A 1 (0.2%) ? 
Unclear mutations   
IVS10-11g>a c.1066-11G>A 27 (4.3%) intronic 
IVS4+5g>t c.441+5G>T 5 (0.8%) ? intronic 
c.168+5G>C 4 (0.6%) ? intronic 
p.F55>Lfs c.165delT 4 (0.6%) regulatory 
IVS7+1g>a c.842+1G>A 3 (0.5%) ? intronic 
c.1084C>A 3 (0.5%) ? catalytic 
IVS1+5g>t c.60+5G>T 2 (0.3%) intronic 
IVS4+4g>a c.441+4A>G 2 (0.3%) ? intronic 
Nucleotide aberra-
tion 
regulatory 
c.227A>G 
catalytic 
c.121C>T 
regulatory 
c.731C>T 
catalytic 
c.329C>T 
catalytic 
c.527G>T 
catalytic 
? 
IVS2+5g>c 
? 
p.P362T 
? 
IVS4-1g>a c.442-1G>A 2 (0.3%) ? intronic 
IVS10+1g>a c.1065+1G>A 2 (0.3%) ? intronic 
p.F55del c.163_165delTTT 2 (0.3%) ? regulatory 
p.F55L c.165T>G 2 (0.3%) ? regulatory 
p.I95_K96delinsK c.284_286delTCA 2 (0.3%) ? regulatory 
p.R53H c.158G>A 2 (0.3%) ? regulatory 
IVS1+5g>a c.60+5G>A 1 (0.2%) ? intronic 
IVS10del546 ? 1 (0.2%) ? intronic 
IVS2-13T>g c.IVS2-13T>G 1 (0.2%) ? intronic 
IVS3-22g>a c.353-22G>A 1 (0.2%) ? intronic 
IVS7+5g>a c.842+5G>A 1 (0.2%) ? intronic 
p.A132V c.395C>T 1 (0.2%) ? regulatory 
p.G188D c.563G>A 1 (0.2%) ? catalytic 
p.H201Y c.601C>T 1 (0.2%) ? catalytic 
p.I65S/p.H170Q c.194T>G/c.510T>A 1 (0.2%) ? regulatory/catalytic 
p.I65V c.193A>G 1 (0.2%) ? regulatory 
p.L287V c.859C>G 1 (0.2%) ? catalytic 
p.L367>Pfs c.1099_1100insC 1 (0.2%) ? catalytic 
p.P119S c.355C>T 1 (0.2%) ? regulatory 
p.P275L c.824C>T 1 (0.2%) ? catalytic 
p.P275R c.824C>G 1 (0.2%) ? catalytic 
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Table 1 cont.     
Allele  
Nucleotide aberra-
tion 
Number of 
alleles (AF) 
Residual 
activity* Domain (CBR) 
p.P281A c.841C>G 1 (0.2%) ? catalytic (CBR2) 
p.P366H c.1097C>A 1 (0.2%) ? catalytic 
p.R158W c.472C>T 1 (0.2%) ? catalytic 
p.S16>XfsX1 c.47_48delCT 1 (0.2%) ? regulatory 
p.S67P c.199T>C 1 (0.2%) ? regulatory 
p.T193I c.578C>T 1 (0.2%) ? catalytic 
p.Y168H c.502T>C 1 (0.2%) ? catalytic 
p.Y386C c.1157A>G 1 (0.2%) ? catalytic 
 
BH4-non-responsive mutations   
p.R408W c.1222C>T 35 (5.6%) 1.85 catalytic 
IVS12+1g>a c.1315+1G>A 14 (2.2%) 0 intronic 
p.P281L c.842C>T 12 (1.9%) 1 catalytic (CBR2) 
p.R261X c.781C>T 7 (1.1%) 1 catalytic (CBR1) 
p.S349P c.1045T>C 6 (1.0%) 1 catalytic 
p.G272X c.814G>T 4 (0.6%) 1 catalytic 
p.R252W c.754C>T 4 (0.6%) 1 catalytic (CBR1) 
p.R243X c.727C>T 3 (0.5%) 1 catalytic 
p.A259T c.775G>A 2 (0.3%) 0.3 catalytic (CBR1) 
p.E280K c.838G>A 2 (0.3%) 1.95 catalytic (CBR2) 
p.K274_Y277>Nfs c.822_832del11 2 (0.3%) ? catalytic 
p.R176X c.526C>T 2 (0.3%) 1 catalytic 
p.Y356X c.1068C>G 2 (0.3%) 1 catalytic 
p.D222>Efs c.663_664delAG 1 (0.2%) 1 catalytic 
p.L311P c.932T>C 1 (0.2%) 1 catalytic 
p.R111X c.331C>T 1 (0.2%) 1 regulatory 
p.R270K c.809G>A 1 (0.2%) 2.1 catalytic 
p.S411X c.1232C>A 1 (0.2%) 1 tetramerization 
p.T278I c.833C>T 1 (0.2%) 1 catalytic 
p.W187X c.561G>A 1 (0.2%) 0 catalytic 
*average PAH activity (%) calculated for different cell systems; AF: allele frequency; CBR: 
cofactor binding region;  
AS: active site 
Both protein and cDNA numbers follow standard recommendations with nucleotide +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence, and the 
initiation codon denoted codon 1. Reference sequences: GenBank cDNA = NM_000277.1; pro-
tein = NP_000268.1. 
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Table 2. 
Distribution of BIOPKUdb mutations in different PAH domains 
 
 Domain 
Number of 
alleles 
Percentage 
alleles 
No. of different 
genotypes 
catalytic 401 63.7 66 
regulatory 90 14.3 26 
tetramerization 63 10.0 5 
intronic 75 11.9 17 
regulatory/catalytic 1* 0.2 1* 
al
l a
lle
le
s 
total 630 100 115 
catalytic 300 67.9 36 
regulatory 72 16.3 15 
tetramerization 62 14.0 4 
intronic 8 1.8 2 
regulatory/catalytic 0 0.0 0 r
es
po
ns
iv
e 
total 442 100 57 
catalytic 86 84.3 17 
regulatory 1 1.0 1 
tetramerization 1 1.0 1 
intronic 14 13.7 1 
regulatory/catalytic 0 0.0 0 no
n-
re
sp
on
si
ve
 
total 102 100 20 
catalytic 15 17.4 13 
regulatory 17 19.8 10 
tetramerization 0 0.0 0 
intronic 53 61.6 14 
regulatory/catalytic 1* 1.2 1* 
un
cl
ea
r 
total 86 100 38 
*patient with two mutations on the same allele 
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Table 3. 
Allele frequencies and BH4-responsiveness in different countries and within PAHdb. 
 
Database* All alleles Responsive Unclear 
Non-re-
sponsive 
Not in the 
BIOPKUdb 
Potentially 
responsive 
patients** 
 
BIOPKUdb 630 442 86 102 - 315 (100%) 
PAHdb genotype 1266 450 104 456 256 370 (58%) 
PAHdb 3173 1008 323 796 1046 848 (53%) 
Northern Ireland (NI) 238 121 4 88 25 90 (76%) 
South Korea 116 38 17 26 35 32 (55%) 
Northern China 310 106 13 49 142 88 (57%) 
Europe 3655 1200 246 2023 186 1003 (55%) 
Spain 177 95 43 39 0 70 (79%) 
Sicily 108 55 27 26 0 41 (76%) 
France 186 90 18 78 0 68 (73%) 
The Netherlands 39 16 1 22 0 13 (65%) 
UK (without NI) 351 139 10 181 21 111 (64%) 
Belgium 195 74 12 109 0 60 (61%) 
Republic of Ireland 464 172 9 258 25 140 (60%) 
Germany 550 192 65 220 73 158 (58%) 
Norway 201 66 2 99 34 55 (55%) 
Croatia 67 21 3 43 0 18 (53%) 
Denmark 281 70 17 191 3 61 (44%) 
Bulgaria 46 7 15 24 0 6 (28%) 
Czech Republic 213 32 9 171 1 30 (28%) 
Iceland 16 2 0 10 4 2 (23%) 
Romania 28 3 0 25 0 3 (20%) 
Baltic States 319 29 2 288 0 28 (17%) 
Poland 176 16 9 151 0 15 (17%) 
*source data adapted from the PAHdb (http://www.pahdb.mcgill.ca), (Zschocke and Hoffmann 1999), 
and (Zschocke 2003); **calculated using Hardy-Weinberg equation. 
 
 
Table 4. 
Estimated and predicted BH4-responsive genotype frequencies in different countries 
and within PAHdb. 
 
Database* 
Number of 
patients 
Number of estimated 
responsive patients 
Number of predicted 
responsive patients** 
Germany 275 159 (58%) 158 (58%) 
Northern Ireland 119 87 (73%) 90 (76%) 
South Korea 58 31 (53%) 32 (55%) 
Northern China 155 84 (54%) 88 (57%) 
PAHdb 633 355 (56%) 370 (58%) 
*source data adapted from the PAHdb (http://www.pahdb.mcgill.ca), (Zschocke and 
Hoffmann 1999), and (Zschocke 2003). 
**calculated using Hardy-Weinberg equation 
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Table S1. 
Most abundant genotypes in the BIOPKUdb 
(Supplementary Online). 
 
Number of 
patients allele 1 allele 2 
8 p.Y414C p.R408W 
7 p.A403V IVS10-11G>A 
6 p.R261Q p.L48S 
6 p.R261Q p.R261Q 
6 p.A403V p.A300S 
5 p.L48S p.L48S 
5 p.R241C p.R413P 
5 p.V245A p.R261Q 
5 p.A403V p.V245A 
5 p.Y414C IVS10-11G>A 
4 p.R261Q p.Y414C 
4 p.E390G IVS12+1G>A 
4 p.A403V p.A403V 
3 p.R158Q p.R261Q 
3 p.R241C p.R241C 
3 p.V245A IVS10-11G>A 
3 p.A300S p.R261X 
3 p.A300S p.P281L 
3 p.A403V p.P281L 
3 p.A403V p.R408W 
3 p.A403V IVS12+1G>A 
Non-responsive or unknown alleles in bold 
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 Fig. 1. BH4-responsive mutations found in PKU patients are mapped in the 3D crystal structure of the 
PAH monomer. In the active site, iron atom and BH4 cofactor are shown in red. The N-terminus starting 
over the active site as well as the rest of the regulatory domain are highlighted in red; catalytic domain 
in blue; tetramer domain is in purple. In the top right corner is the native tetramer form of the enzyme. 
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Discussion 
We tabulated biochemical and molecular data from 315 patients with BH4-responsive PAH 
deficiency in the BIOPKUdb. Alleles and genotypes defined as BH4-responsive were compared 
with data previously reported for PKU patients in some European countries, in Northern China, 
and in South Korea. Furthermore, the PAHdb knowledgebase compiling 3171 mutant alleles 
from all over the world was analyzed using the BIOPKUdb information. Comparison of differ-
ent databases with the BIOPKUdb allowed us to estimate both allele and genotype frequencies 
of BH4-responsiveness and to compare them with data obtained from BH4 loading tests. 
Kure et al. (Kure et al. 1999) proposed that the mechanism of BH4-responsiveness may be ex-
plained by distinct mutations in the PAH gene and that the composition of the PAH subunits 
may be critical for BH4-responsiveness. Based on the BIOPKUdb information, we estimated 
that about 90% of BH4-responsive PAH alleles are producing heterotetramers and depending on 
the type of mutation (truncated or not), the ratio between hetero and homopolymers may be the 
predicting factor for the responsiveness.  
Erlandsen and Stevens (Erlandsen and Stevens 2001) calculated the location and proximity of 
some of the mutations to the BH4-binding site in the three-dimensional structure of PAH and 
predicted that some of them result in mutant enzymes that are Km variants (with a lower binding 
affinity for BH4) compared to the normal phenotype. The p.V388M mutation (BIOPKUdb AF 
2.2%) was shown to result in a kinetic variant form of PAH by increasing Km values for BH4 
from 22 µM to 82 µM (Leandro et al. 2000). Further BIOPKUdb mutations reported with de-
creased binding affinity for BH4 are p.F39L (AF 0.8%), p.I65T (AF 2.9%), p.R68S (AF 0.8%), 
p.129G (AF 02%), p.P244L (AF 0.2%), p.L308F (AF 0.2%), and p.A309V (AF 0.5%). 
(Aguado et al. 2007; Pérez-Dueñas et al. 2005) 
The second and most probably major mechanism proposed for BH4-responsiveness, a PAH-
stabilizing effect of BH4 (chaperon-like activity), has been confirmed by a number of investiga-
tions (Aguado et al. 2006; Erlandsen et al. 2004; Pey et al. 2004; Thöny et al. 2004). BH4 can 
prevent mutant PAH from both misfolding and inactivation. This has been shown for several 
common BH4-responsive mutations: e.g. p.R261Q (AF 7.8%), p.Y414C (AF 7.0%), p.I65T (AF 
2.9%), p.V388M (AF 2.2%), p.R68S (AF 0.8%), p.A309V (AF 0.5%), and p.P244L (AF 0.2%) 
(Pey et al. 2004). In addition, BH4 is able to enhance the wild-type enzyme activity without 
affecting PAH gene expression (Thöny et al. 2004). A similar effect of BH4 on the wild-type 
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PAH activity was demonstrated by Kure et al. (Kure et al. 2004). They proposed that the 
responsiveness to BH4 in patients with PAH deficiency is probably due to suboptimal 
physiological concentrations of BH4 in hepatocytes and that enhancement of the residual activ-
ity by BH4 supplementation may be associated with a wide range of mutations. 
Initial information about the frequency of BH4-responsiveness within patients with PAH defi-
ciency originates from a large retrospective study of over 1900 loading tests (Bernegger and 
Blau 2002). Of the patients with baseline phenylalanine levels of 120-400, 400-800, 800-1200, 
1200-1600, 1600-2200, and >2200 µmol/L, 65%, 74%, 33%, 17%, 0%, and 10% of patients, 
respectively, were defined as responders.  This study, however, used data obtained with both the 
old 33% less active formulation of BH4 and the new fully active 6R-BH4 compound. In another 
study a total of 557 patients diagnosed with HPA were loaded with the active 6R-BH4 (20 
mg/kg) and blood phenylalanine was monitored over 8 to 24 hours (Fiege and Blau 2007). The 
overall prevalence of BH4-responsiveness within patients with PKU for blood phenylalanine 
reduction of 20%, 30%, 40%, and 50% was 48%, 38%, 31%, and 24%, respectively, using the 
8-hour modus, and 55%, 46%, 41%, and 33%, respectively, using the 24-hour modus. Using the 
standard 30% cut-off, BH4-responsiveness was similar regardless of the modality in patients 
with mild hyperphenylalaninemia (79% to 83% responders), mild PKU (49% to 60% respond-
ers), and classical PKU (7% to 10% responders). About 46% of all HPA patients were respond-
ers 24 hours post loading (Fiege and Blau 2007). Extending the loading test to 48 hours (Fiege 
et al. 2005) or to one week (Shintaku et al. 2004) may detect additional patients who need 
longer to time to show the decreased phenylalanine levels. Several studies observed a similar 
high percentage of BH4-responsiveness: 62% by Leuzzi et al. (Leuzzi et al. 2006), 46% by 
Mitchell et al. (Mitchell et al. 2005), 85% by Fiori et al. (Fiege et al. 2005), 38% by Bélanger-
Quintana et al. (Bélanger-Quintana et al. 2005), 58% by Matalon et al. (Matalon et al. 2005), 
44% by Pérez-Duenas et al. (Pérez-Dueñas et al. 2004), and 66% by Muntau et al. (Muntau et al. 
2002). 
Our findings reveal several features common to different patient groups; both the frequency of 
potentially BH4-responsive alleles and genotypes is higher than initially assumed from the load-
ing test studies; the BH4-responsiveness is characterized by a substantial residual PAH activity 
of at least one mutant allele; most of the BH4-responsive mutant alleles are located in the cata-
lytic domain of the PAH subunit; and using the Hardy-Weinberg formula, BH4-responsiveness 
is higher than the effective distribution of potentially BH4-responsive genotypes. 
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The PAH locus knowledgebase PAHdb is the largest database with 3173 alleles reported in 
patients with various degrees of HPA (ca. 28% MHP, 36% mild PKU, and 56% classic PKU). 
Based on the alleles and genotype information, about 58% of patients are potentially BH4-
responders, an estimate higher than the information observed from the BH4 loading test (46% 
responders in a population with a similar proportion of various HPA patients) (Fiege and Blau 
2007). By comparing the estimated frequency of BH4-responsiveness in different European 
countries, we found that BH4-responsiveness is much higher (>75%) in southern regions of 
Europe with a high frequency of BH4-responsive alleles p.R261Q, p.V388M, p.I65T, p.R158Q, 
or p.L48S, than in central Europe (50-70%), or in some eastern European countries (<40%) 
with frequent severe alleles p.R408W, p.R252W, or IVS12+1G>A (Zschocke 2003) (Table 3). 
Similar frequencies of BH4-responsiveness were also estimated for the northern part of China 
and for South Korea (50-60% responders). 
Several authors reported inconsistency of BH4-responsiveness within the same genotypes and 
questioned the genotype-phenotype correlation. In addition it has been reported that some pa-
tients who responded in the single loading test did less well on a continuous supplementation 
with BH4 (Lambruschini et al. 2005). Inconsistency of BH4-responsiveness in patients with the 
same genotype is frequently reported, particularly in patients harboring p.L48S, p.I65T, 
p.R158Q, p.R261Q, and p.Y414C mutations (Desviat et al. 2004; Fiori et al. 2005; Leuzzi et al. 
2006; Muntau et al. 2002; Nielsen et al. 2005; Pérez-Dueñas et al. 2004; Yildirim et al. 2007). It 
is also interesting that some splicing mutations are reported as BH4-responsive (e.g. IVS4-
5C>G, AF 0.8% and IVS10-3C>T, AF 0.5%). Although, as already mentioned in some of them 
splicing may be affected only to a minor extend and/or resulting in a partially active expressed 
proteins, other factors like dietary fluctuation during the test and spontaneous may be 
responsible for responsiveness. 
In summary, from the evaluation of the data contained in the BIOPKUdb we would expect 
BH4-responsiveness in about 50% of all patients with PAH deficiency. As discussed above, this 
number may vary from country to country and is higher than the BH4 loading test data. It also 
needs to be shown to what extent genotype information can be used to predict in vivo BH4-
responsiveness. Different factors like initial blood Phe levels, age of the patient, BH4 
pharmacokinetics, the length of time of the BH4 test, and possibly BH4 stabilizers like ascorbic 
acid or a second mutation on the same allele may influence the outcome of the test. Thus, al-
though there is no absolute genotype-phenotype correlation, mutation analysis provides useful 
information on potential non-responders in patients harboring two null alleles and may, to some 
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extent, predict possible BH4-responders. Further investigations are necessary in order to esti-
mate the optimal BH4 loading test conditions (amount of BH4 and time of blood Phe monitor-
ing), and genotype analysis may help to select target populations. 
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Abstract 
We describe the treatment, the clinical, and biochemical findings and the outcome of 26 patients 
with 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency and 10 patients with 
dihydropteridine reductase (DHPR) deficiency. These are the two most common forms of the 
autosomal-recessively inherited tetrahydrobiopterin (BH4) deficiency. Time of diagnosis, 
dosage of BH4 and neurotransmitter precursors, folinic acid substitution, and levels of 5-
hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) 
are essential parameters in the follow-up of patients. Unfortunately, treatment protocols vary 
greatly among patients and clinical centers, and CSF investigations and outcome assessments 
are not always available. Seventeen patients with PTPS deficiency and four patients with DHPR 
deficiency were diagnosed within 2 months after birth. In 14 patients with PTPS deficiency 
(54%; 9 early and 5 late diagnosed) and 2 patients with DHPR deficiency (20%; all early 
diagnosed) no developmental delay is observed, while in 10 patients with PTPS deficiency 
(38%; 6 early and 4 late diagnosed) and 8 patients with DHPR deficiency (80%; 2 early and 6 
late diagnosed) development was delayed. Two PTPS-deficient patients died in the newborn 
period. DHPR deficiency seems to be more severe than PTPS deficiency and it is clearly the 
onset of treatment that determines the outcome. Our data suggest that diagnosis within the first 
month of life is essential for a good outcome and that low CSF5 HIAA and HVA values in CSF 
could be an indicator for the ongoing developmental impairment, even in the absence of 
neurological symptoms. 
Copyright © 2008 Elsevier Inc. All rights reserved. 
 
Introduction 
Tetrahydrobiopterin (BH4) deficiency represents a heterogeneous group of metabolic disorders 
caused by autosomal recessively inherited enzyme defects of the BH4 synthesis or regenerating 
pathway (Blau et al. 2001). BH4 is the cofactor for phenylalanine hydroxylase (PAH) (EC 
1.14.16.1), tryptophan hydroxylase (TPH) (EC 1.14.16.4), tyrosine hydroxylase (TH) (EC 
1.14.16.2) and nitric oxide synthase (NOS) (EC 1.14.13.39) (Kaufman 1987; Marletta 1993). It 
is synthesized in a three-step pathway from guanosine triphosphate (GTP) trough GTP 
cyclohydrolase I (EC 3.5.4.16), 6-pyruvoyl-tetrahydropterin synthase (PTPS) (EC 4.6.1.10), and 
sepiapterin reductase (SR) (EC 1.1.1.153). After coupling as an active cofactor to the aromatic 
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amino acid hydroxylases, it is regenerated by pterin-4α-carbinolamine dehydratase (PCD) (EC 
4.2.1.96) and dihydropteridine reductase (DHPR) (EC 1.6.99.7) (Thöny et al. 2000). 
BH4 deficiency, formerly known as malignant or atypical phenylketonuria (PKU), results in 
hyperphenylalaninemia (HPA), and decreased neurotransmitter and folate levels in 
cerebrospinal fluid. Infants affected by PTPS deficiency, the most common form of BH4 
deficiency, are frequently born small for gestational age (Smith and Dhondt 1985). In the 
neonatal period they may show abnormal signs such as poor sucking, impaired tone and 
microcephaly. Later they present characteristic extrapyramidal symptoms due to lack of 
dopamine in the basal ganglia (Allen et al. 1990) including truncal hypotonia, increased limb 
tone, postural instability, hypokinesia, choreatic or dystonic limb movements, gait difficulties, 
hypersalivation due to swallowing difficulties, and oculogyric crises. Ataxia, hyperreflexia, 
hypothermia as well as episodes of hyperthermia (in the absence of infections), drowsiness, 
irritability, disturbed sleep patterns, and convulsions (grand mal or myoclonic) are often seen 
(Ozand 1998; Blau et al. 1996). The clinical course of illness in DHPR deficiency is similar to 
that seen in severe forms of PTPS deficiency. In addition, extensive neuronal loss, calcifications, 
and abnormal vascular proliferation were noted in cortex, basal ganglia, and thalamus 
(Kaufman et al. 1975). 
Screening tests for BH4 deficiencies are available (urinary pterins, DHPR activity in dried blood 
(Arai et al. 1982), and BH4 loading test) and performed in most developed countries in patients 
with HPA detected in newborn screening (Dhondt 1991; Blau 2006). 
The treatment of BH4 deficiency consists of regulating phenylalanine (Phe) levels in blood 
either by oral administration of BH4 (in GTPCH and PTPS deficiency) or low Phe diet (mainly 
in DHPR deficiency) and substitution of the neurotransmitter precursors l-dopa and 5-
hydroxytryptophan (5HTRP) (Ponzone et al. 2006). It has been shown that addition of 
Selegiline (MAO-B inhibitor) or Entacapone (COMT inhibitor) allowed a lower dosage of l-
dopa and 5HTRP, preventing overdosing (Schuler et al. 1995, 2000; Spada et al. 2001). Folinic 
acid substitution is essential in DHPR-deficient patients and also in some PTPS-deficient 
patients with low 5-methyltetrahydrofolate (5MTHF) levels in cerebrospinal fluid (CSF). 
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Reports of long-term follow-up of patients with BH4 deficiency are still scarce (Dudesek et al. 
2001; Chien et al. 2001; Wang et al. 2006) and therapeutic strategies or treatment guidelines are 
vague and far from clinically based evidence. In this article we describe the long-term follow-up 
and outcome of 26 patients with PTPS deficiency and 10 patients with DHPR deficiency. 
CHAPTER 5 
 
 
Materials and methods 
Case reports 
Detailed information about BH4-deficient patients is tabulated in the BIODEF database 
(www.bh4.org). All patients presented with elevated blood Phe levels at newborn screening or 
at the time of the diagnosis. Initial biochemical data are summarized in Table 1. Mutation analy-
sis was performed in very few patients (Table1). The clinical information is illustrated in Table 
2. Additional information is included in following reports: 
BIODEF ID#47 (PTPS deficiency) Despite different treatment protocols symptoms were 
difficult to control in this patient; motor development was delayed and expressive language 
development was grossly retarded. At the age of 10 years he achieved an IQ of 71 (WISC-R) 
(Valsasina et al. 1989). 
BIODEF ID#62 (PTPS deficiency) In this boy a MAO-B inhibitor, Selegiline (0.4 mg/kg/d) 
was introduced at the age of 8 years and at the age of 146/12 years a COMT inhibitor, 
Entacapone, (17 mg/kg/d) was added. Mental and motor development was always good, with 
limited episodes of tremors. He was able to attend normal school classes, to drive a car, to make 
sports, and at the age of 20 years he started working as a civil servant (Oppliger et al. 1997). 
BIODEF ID#64 (PTPS deficiency) This boy presented with severe axial hypotonia, 
hypertonia, and hyperreflexia of the limbs, irritability, and myoclonic seizures in the first 10 
months of life. In addition to the standard treatment, at the age of 12 years Selegiline was 
introduced at a dosage of 0.2 mg/kg/d and at the age of 19 years Entacapone (9 mg/kg/d) was 
added. He attended normal school classes with good results, without motor or cognitive 
disabilities. He is now 25 years old and works as a barman (Oppliger et al. 1997; Niederwieser 
et al.). 
BIODEF ID#65 (PTPS deficiency) Despite the early treatment and possibly due to the severe 
fetal damage, this girl presented with hypotonia, spastic movements, irritability and convulsions 
in the neonatal period. Motor and intellectual development remained always severely impaired. 
At the age of 7 years Selegiline (0.28 mg/kg/d) was introduced, resulting in marginal clinical 
improvement (Oppliger et al. 1997). 
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BIODEF ID#89 (PTPS deficiency) This boy suffered from severe postnatal infection and 
showed hypoacusis in brainstem auditory evoked potentials (BAEP). His development was 
severely retarded despite the early treatment: at the age of 13 years he achieved an IQ of 43. In 
addition, he has micro adenoma of the pituitary resulting in high prolactin levels (max: 
560.8 ng/ml at 21 years) which is well suppressed by Bromocriptine treatment (prolactin: 7.5–
12.2 ng/ml; normal 5–15 ng/ml). At the age of 21 years (IQ 62) the young man works as an 
unskilled worker. 
BIODEF ID#90 (PTPS deficiency) At the age of 6 years this boy started normal school and at 
the age of 9 years he achieved an IQ of 83. A MRI image taken at 15 years showed a 10 mm 
diameter lesion in the right superior temporal gyrus superior for a low grade astrocytoma which 
did not grow during the last two years. At present he is being neurologically examined for 
sporadic headache and balance disturbances. Furthermore he presents unexplained hypertension 
(130/90 mmHg) (Schuler et al. 1995). 
BIODEF ID#96 (PTPS deficiency) This boy was born at full term from non-consanguineous 
parents by caesarean section because of pathologic CTG, placental insufficiency, and 
intrauterine dystrophy. At the age of 19 years he is mentally disabled and attends a sheltered 
workshop. 
BIODEF ID#124 (PTPS deficiency) This boy achieved an IQ of 89 at the age of 7 years, 
language development was particularly delayed. At the age of 13 years he presented with an 
articulation disorder and showed difficulties in mathematics. 
BIODEF ID#125 (PTPS deficiency) This girl was initially treated with BH4 monotherapy (3 
mg/kg/d). Neuromotor development was normal. At the age of 410/12 years, 5HIAA in CSF 
dropped and 5HTRP substitution (5 mg/kg/d) was introduced, despite the absence of symptoms. 
Physical and mental development is totally normal. 
BIODEF ID#235 (PTPS deficiency) This boy presented with cerclage of the umbilical cord, 
meconium aspiration, and underwent neonatal reanimation. Selegiline (0.1 mg/kg/d) was 
introduced at 6 years of age, resulting in an increase of neurotransmitter metabolites in CSF and 
folinic acid substitution was started because of low 5MTHF levels in CSF. Two years later the 
neurological symptoms disappeared. At the age of 14 years he achieved an IQ of 100, and he 
followed a normal school program. 
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BIODEF ID#236 (PTPS deficiency) This child developed a transient tyrosinaemia following 
the BH4 loading test, which was positive (Blau et al. 1996). The neurological and mental 
development is normal, but she suffers from a delayed puberty due to huge hyperprolactinemia 
with prolactin levels decreasing only for several hours after l-dopa/Carbidopa administration. 
Therefore, the treatment with a slow release l-dopa/Carbidopa preparation was initiated. 
BIODEF ID#251 (PTPS deficiency). At the age of 6 years this boy presented with anxiety 
psychosis and stuttering. After 6 months of treatment anxiety improved and stuttering was 
resolved. He attended normal school. At the age of 19 years he achieved an IQ of 90. During the 
last 5 years he developed several pigmented nevi. 
BIODEF ID#281 (PTPS deficiency) At 6 years this girl achieved an IQ of 98. Motor 
language function was slightly impaired and the girl attended classes at a school for speech 
therapy for the next 4 years and then changed back to normal school. At the age of 8 years a 
language free test of basic intelligence (CFT-1) showed an IQ of 118. She has a persisting 
variable mild dystonic movement disorder particularly regarding her oral motor activity. 
BIODEF ID#301 (PTPS deficiency) At the age of 1 month pterins in urine were in the 
normal range. For this reason this girl was treated with a phenylalanine-restricted diet. At the 
age of 15 months she presented with hypotonia, irritability, convulsions, developmental 
retardation and failure to thrive. She was diagnosed with BH4 deficiency and treatment was 
initiated. Muscle tonus and development improved. At the age of 7 years she achieved an IQ of 
58. 
BIODEF ID#333 (PTPS deficiency) The younger brother of patient #124 was born at full 
term after intrauterine Escherichia coli infection. He died of bronchopneumonia with 
Pseudomonas aeruginosa at the age of 5 months. 
BIODEF ID#343(PTPS deficiency) This girl is the HIV negative daughter of HIV positive 
mother and was diagnosed with mild PTPS deficiency at the age of one month. The girl was 
treated with BH4 alone. She never presented any neurological symptoms and her development 
was always normal. She attends normal school. 
BIODEF ID#346(PTPS deficiency) In this boy overall motor development was normal, but 
language motor function was retarded. At the age of 5 years he achieved an IQ of 79, his gait 
was ataxic and his speech stumbling. 
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BIODEF ID#350 (PTPS deficiency) This boy is the elder brother of patient ID#346. He 
presented with severe mental retardation at the age of 6 years, severe axial hypotonia, 
hypersalivation and oculogyric crisis. Six months after the start of treatment hypotonia 
improved and the IQ was 43. At the age of 11 years his IQ was 60. 
BIODEF ID#363(PTPS deficiency) In this boy treatment was started at the age of 3 weeks. 
Folinic acid substitution was introduced because of low 5MTHF levels in CSF. Psychomotor 
development was always in the normal range. 
BIODEF ID#365 (PTPS deficiency) This boy suffered from intrauterine dystrophy, perinatal 
asphyxia, and respiratory distress syndrome. The boy died at 7 months at home under 
unexplained circumstances. 
BIODEF ID#372 (PTPS deficiency) This girl had a perinatal respiratory distress syndrome 
and hypoglycaemia. She presented with truncal hypotonia, poor sucking, and increased 
sweating. At the age of 5 years her developmental age was at the level of a 4-year-old child. 
BIODEF ID#378 (PTPS deficiency) At the age of 8 years physical and mental development 
of this boy was normal and no abnormality was detected during neurological examination. 
BIODEF ID#410 (PTPS deficiency) This child never presented with neurological symptoms 
and he developed normally. 
BIODEF ID#450 (PTPS deficiency) This son of unrelated parents suffered neonatal 
hypoglycaemia. At the age of 2 years he had a developmental age of 18 months on the Denver 
developmental scale. At the age of 3 years he showed delayed language and cognitive 
development, and mixed (ataxic dystonic) cerebral palsy. 
BIODEF ID#457 (PTPS deficiency) At the age of 28/12 years this girl has gained a normal 
developmental age without any pathologic neurological findings. 
BIODEF ID#478 (PTPS deficiency) This is a case of severe PTPS deficiency diagnosed at 
the age of 27 years in a patient with a normal IQ. The patient was diagnosed at birth with 
classical PKU and treated with low-phenylalanine diet until the age of 3 years, when the diet 
was stopped because of good metabolic control. At the age of 14 years he presented with 
dystonia of the mouth and neck muscles, episodes of tremor of the hands, apertured mouth, and 
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inability to speak. These episodes were diagnosed as panic attacks. Under treatment the 
symptoms improved. 
BIODEF ID#151 (DHPR deficiency) No neonatal screening tests were obtained in this girl. 
At 14 months, DHPR deficiency was diagnosed and a brain CT showed calcifications of the 
basal ganglia (Longhi, Valsasina, et al. 1985; Longhi, Riva, et al. 1985; Dianzani et al. 1998). 
The woman is now 24, has spastic tetraparesis, severe epilepsy, necessitating Phenobarbital and 
Valproate anticonvulsive therapy, and she is severely mentally retarded. 
BIODEF ID#165 (DHPR deficiency) Neuroimaging performed in this boy at the age of 2 
years revealed cerebral atrophy (Cotton et al. 1986). He is now 23 years old and shows spastic 
tetraparesis, epilepsy requiring anticonvulsive therapy, and mental disability. 
BIODEF ID#167 (DHPR deficiency) A brain CT performed at the age of 10 months showed 
calcifications of the basal ganglia in this girl (Biasucci et al. 1990). Folinic acid (10 mg/d) was 
introduced. The symptoms and development improved. However, retardation persisted and 
epilepsy always required anticonvulsive medication. She developed an ataxic gait and 
inarticulate speech with poor vocabulary. At the age of 17 years the girl is mentally and 
physically disabled, needs a wheelchair, and attends a disability assistance program. She has 
several epileptic seizures and hypotonic crises per day. 
BIODEF ID#174 (DHPR deficiency) The boy never presented with neurological symptoms 
and developed normally. 
BIODEF ID#255 (DHPR deficiency) The girl is now 17 years old; she is severely mentally 
retarded and shows aggressive behavior. Epilepsy still necessitates anticonvulsive medication. 
BIODEF ID#287 (DHPR deficiency) At the age of 3 years and 7 months this boy had the 
developmental age of 2.5 years on the Denver development scale; at the age of 7 years he 
achieved an IQ of 65. At the age of 11 years he attends classes in a school for mentally 
handicapped children. 
BIODEF 334 (DHPR deficiency) Besides a slight intention tremor this boy showed no 
neurological symptoms. He developed normal according to his age. At 8 years ADHS was 
diagnosed and treated with methylphenidate. 
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BIODEF 339 (DHPR deficiency) In this girt treatment had been periodically discontinued by 
parents. At 11 years she is severely retarded and mentally disabled. 
BIODEF ID#423 (DHPR deficiency) The girl was born at full term after pregnancy with 
gestational diabetes. The newborn period was uneventful. At the age of 4 years she had 
achieved an IQ of 82. 
BIODEF 474 (DHPR deficiency) At the age of 2 years neuroimaging revealed diffuse 
calcifications of the basal ganglia in this girl. At the age of 4 years the girl continues to show 
serial severe convulsions despite a combined therapy with antiepileptic drugs and 
neurotransmitter precursors. 
 
Biochemical methods 
Diagnosis of BH4 deficiency was established by measurement of urinary pterins (Curtius et al. 
1991), DHPR activity in dried blood, and by the BH4 loading test (Ponzone et al. 1991). 
Therapy monitoring was done by measuring the neurotransmitter metabolites 5-
hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) (Blau et al. 1999), 5-
methyltetrahydrofolic acid (5MTHF), and neopterin and biopterin in cerebrospinal fluid (CSF) 
(Blau et al. 2003), beside by clinical observation. Amino acid analysis was performed either 
using the classical ion exchange chromatography or tandem mass-spectrometry. 
Patients’ biochemical and clinical data are tabulated in the International Database of 
Tetrahydrobiopterin Deficiencies (BIODEF) URL: http://www.biopku.org. 
 
Results 
We retrospectively investigated the medical records of 36 patients with the diagnosis of BH4 
deficiency (26 with PTPS deficiency and 10 with DHPR deficiency). The patients originate 
from Germany, Italy, Hungary, Turkey, Saudi Arabia, Georgia, Afghanistan, Pakistan, Sri 
Lanka, and Albania and they were diagnosed between one week (#372, #450) and 27 years 
(#478) of age. Only 11 patients had consanguineous parents. Mean birth weight was 2841 g and 
6 patients were born prematurely between 33 and 37 weeks of gestation. The results from the 
newborn screening for PKU, BH4 loading test, analysis of urinary pterins, PTPS or DHPR 
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activity, as well as initial 5HIAA and HVA concentrations in CSF are listed in Table 1. Table 2 
summarizes the initial clinical information and current therapy protocols. The course of the CSF 
neurotransmitter metabolites 5HIAA and HVA in relation to the treatment and clinical 
manifestations is presented for patients with at least 9 follow-up investigations in Fig. 1 A–N. 
 
PTPS deficiency 
Among the patients with PTPS deficiency, there are 8 girls and 18 boys. Four patients from two 
gipsy families are siblings (#346, #350 and #124, #333). Seventeen of the PTPS-deficient 
patients were diagnosed within the first two months of life, 5 within the first two years (#47, 
#62, #64, #124, #301), 3 between 3 and 7 years (#89, #251, #350), and one at the age of 27 
years (#478). Two of the PTPS patients died in the infancy period (#333 and #365). All patients 
were treated with BH4 orally, doses ranging from 2 to 12 mg/kg/d. Neurotransmitter precursors 
were substituted in all patients except #343 who was diagnosed with the mild phenotype of 
PTPS deficiency. l-Dopa/Carbidopa dosage ranged from 4 to 18 mg/kg/d. Two patients who 
were treated with Selegiline did not receive l-Dopa (#251 and #333). 5HTRP dosage ranged 
from 3 to 10 mg/kg/d. Eleven patients received Selegiline at doses up to 0.4 mg/kg/d in addition 
to neurotransmitter precursors. Entacapone was introduced in patients #62 and #64 at 14 and 19 
years of age, respectively. Folinic acid was substituted in patient #235, #363, #372, #410, and 
#457. Only one of the patients, who received folinic acid, is actually delayed in development. 
Tonus abnormalities (truncal hypotonia, hypertonia of the limbs, spasticity, and dystonic 
movements) were present in 20 patients, in 10 patients the abnormalities have been classified as 
mild and in the other 10 patients as moderate. In 4 patients (#125, #343, #378, #410) no tonus 
abnormalities were reported. Five patients (#64, #96, #124, #235, #350) showed sporadic 
oculogyric crises or myoclonic convulsions, while 5 patients (#47, #65, #89, #90, #346) 
presented with convulsions necessitating anticonvulsive therapy; all of the latter present at this 
time with moderate developmental delay. Other neurological symptoms reported in these 26 
patients were irritability, tremor, ataxia, choreoathetosis, hyperthermia and hypersalivation. 
Three patients (#343, #378, #410) never presented with any neurological symptoms and 
developed completely normally. In 12 patients developmental delay was observed, 7 of them 
(#47, #65, #89, #96, #301, #346, #350) presenting with marked delay requiring a special 
environment (special school or sheltered workshop), and 3 present with slight delay allowing 
attendance of normal school or kindergarten (#236, #372, #450), 2 (#90, #281) were delayed in 
the early childhood, but do present without delay. In 12 patients no developmental delay was 
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observed. Data from CSF analysis of 16 patients are available, 13 patients had abnormally low 
5HIAA and HVA levels at diagnosis, and in 6 patients the values remained below the lower 
normal range. Two PTPS-deficient patients died (#333 and #365). 
 
DHPR deficiency 
Among the DHPR patients there were 6 girls and 4 boys. Four patients were diagnosed within 
the first month of life, while the other 6 were diagnosed at the age between 6 months and two 
years. Four Patients were treated with BH4 orally, with doses ranging from 2 to 20 mg/kg/d; all 
patients except #167 received a phenylalanine-restricted diet. All patients received 
neurotransmitter substitution from the time of diagnosis. l-dopa/Carbidopa dosages ranged from 
5 to 13 mg/kg/d and 5HTRP dosages ranged from 3 to 11 mg/kg/d. All patients were 
supplemented with folinic acid throughout the course of treatment. In four patients (#151, #165, 
#174, #339) Selegiline was introduced at doses up to 0.6 mg/kg/d. In Patient #174 Entacapone 
was given from the age of 13 years. The patients who were diagnosed early (in the first month 
of life) did not present with tonus abnormalities or seizures, except for a slight tremor observed 
in patient #334 and a slight hypotonia in the first year of life in patient #287. Other patients 
presented with moderate to severe hypotonia and suffer from epilepsy which is difficult to 
control despite anticonvulsive treatment. Two of the patients with early diagnosis developed 
normally according to their age (#174 and #334), one presents with slight developmental delay 
at present (#423), and one presents with moderate developmental delay (#287). The 6 patients 
whose onset of treatment was after the age of 6 months are severely retarded and not able to 
attend classes. CSF data are available from almost all patients (except #151). Nine patients 
presented with 5HIAA and HVA levels below the normal range at the time of diagnosis and in 
7 of them CSF values remained low despite treatment. 
 
Outcome 
In some PTPS-deficient patients low-normal CSF values of 5HIAA and HVA correlate with a 
beneficial outcome (#90, #125), while in others normal CSF values of 5HIAA and HVA did not 
guarantee normal development (#372, #450, #96). In patients #281, #363, #236, and #378 
5HIAA and HVA were in the middle range of normal and they developed normal. Patients #90 
and #281 demonstrate clearly, that a developmental delay can be reversed under treatment. 
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Dosage of medications was very different from patient to patient, probably because adjustment 
of dosage was done according to the clinical presentation and personal experience. The addition 
of Selegiline does not seem to influence the outcome; however, in patients who receive 
Selegiline, dosage of l-Dopa and 5HTRP can be reduced. 
In patients with DHPR deficiency it is clearly the onset of therapy which makes the difference 
between good and very bad outcome. There is no evidence that once severely delayed and 
affected child could regain normal developmental age, even under correct treatment and normal 
CSF values (#167). Patient #423 presented without any symptoms despite low HIAA and HVA 
values in CSF, but a developmental delay was noted. Similarly, patient #287 presented with 
occasionally low or low-normal CSF values and rarely presented with any symptoms; however, 
development is delayed. This indicates that in DHPR patients with early onset of treatment 
development is delayed even in the absence of neurological symptoms, implicating that 
medication should be dosed according to CSF values and not only according to presence or 
absence of symptoms. One exception is patient #334 whose CSF values are partly below the 
lower limit of normal, nevertheless, the boy developed according to his age. Generally, late 
diagnosis and very low CSF values led to severe mental retardation and epilepsy. 
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Figures and Tables 
Table 1 
Laboratory data of patients with BH4 deficiency at the time of diagnosis. 
 
Phe (B) 
new-
born 
screen-
ing 
Neo 
(U) 
Bio 
(U) 
PTPS 
activity 
in RBC 
5-
HIAA 
(CSF) 
HVA 
(CSF) 
5-
MTHF 
(CSF) 
Genotyp* 
B
IO
D
EF
 ID
# 
Age at 
diagnosis 
µmol/l 
BH4 
Load-
ing 
Test mmol/mol 
creat. µU/g Hb nmol/l 
 
 
PTPS deficiency 
 
47 5 m 910 pos. 2.0 0.04 4.3 89 276 n.d. n.d. 
62 5 m 1331 pos. 27.0 0.09 1 21 158 n.d. delV47/ delK29-S32 
64 11 m 1314 pos. 13.4 <0.01 <0.1 38 134 n.d. T67M/D136V 
65 1 m 1210 pos. 27.8 <0.01 2 57 0 n.d. T67M/? 
89 3 y 1815 pos. 9.2 0.24 1.4 n.d. n.d. n.d. n.d. 
90 1 m 3 w 670 pos. 15.4 0.07 <0.1 163 421 22 n.d. 
96 1 m 540 pos. 35.9 <0.01 0.92 32 73 n.d. n.d. 
124 6 m 420 pos. 40.0 0.56 1.3 68 344 n.d. n.d. 
125 2 w 1331 pos. 21.8 <0.01 <.01 210 592 n.d. n.d. 
235 3 w 1210 pos. 9.6 0.10 2.4 38 117 15 n.d. 
236 1 m 720 pos. 40.5 <0.01 <.01 35 135 117 W115X/A12G 
251 6 y 360 pos. 6.8 0.20 <.01 36 218 n.d. n.d. 
281 1 m 3 w 303 pos. 28.7 <0.01 0.96 144 293 103 E35G/T67M 
301 1 y 2 m 2117 pos. 6.7 <0.01 2.5 64 253 75 n.d. 
333 1 m 363 pos. 4.7 0.20 0.3 n.d. n.d. n.d. n.d. 
343 1 m 605 pos. 15.5 0.17 1.72 235 553 n.d. n.d. 
346 2 w 360 pos. 18.6 0.26 0.22 n.d. n.d. n.d. n.d. 
350 5 y 10 m 180 n.d. 4.1 0.32 0.42 n.d. n.d. n.d. n.d. 
363 3 w 1260 pos. 38.0 <0.01 0.21 31 81 49 n.d. 
365 1 m 726 pos. 4.6 <0.01 <0.1 4.5 5 n.d. n.d. 
372 1 w 375 pos. 25.5 <0.01 0.44 138 125 12.6 n.d. 
378 1 m 420 pos. 21.7 <0.01 3.1 174 361 n.d. n.d. 
410 1 m 707 pos. 5.7 <0.01 0.06 153 231 25.3 N52S/N52S 
450 1 w 1031 pos. 19.0 <0.01 <0.1 307 486 68.4 T67M/T67M 
457 1 m 1264 pos. 21.6 <0.01 <0.1 231 415 77.9 n.d. 
478 27 y 381 n.d. 6.5 0.17 <0.1 8 25 13.7 n.d. 
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Table 1 cont. 
 
Phe (B) 
new-
born 
screen-
ing 
Neo 
(U) 
Bio 
(U) 
PTPS 
activity 
in RBC 
5-
HIAA 
(CSF) 
HVA 
(CSF) 
5-
MTHF 
(CSF) 
Genotype* 
B
IO
D
EF
 ID
# 
Age at 
diagnosis 
µmol/l 
BH4 
Load-
ing 
Test mmol/mol 
creat. µU/g Hb nmol/l 
 
 
DHPR deficiency 
151 1y 2m 1210 pos. 2.2 12.5 <0.05 n.d. n.d. n.d. G17V/R221X 
165 1y 1m 1210 pos. 2.8 13.2 <0.05 7 51 n.d. H158Y/H158Y 
167 7m 1797 neg. 1.9 7.9 <0.05 64 225 n.d. n.d. 
174 1m 1997 n.d. 12.6 9.2 <0.05 4 59 n.d. n.d. 
255 1y 1m 151 pos. 2.0 8.0 <0.05 15 112 n.d. R221X/R221X 
287 3w 480 pos. 5.7 3.8 <0.05 35 179 12 n.d. 
334 3w 360 pos. 12.1 3.1 <0.05 21 118 37 W90X/W90X 
339 6m 240 pos. 4.2 5.0 <0.05 16 130 20 n.d. 
423 1m 768 pos. 9.0 3.5 <0.05 21 94 18 n.d. 
474 2y 2m 847 pos. 3.0 19.5 <0.05 8 64 40.6 n.d. 
Phe (B) = phenylalanine in blood; Neo (U) = neopterin in urine; Bio (U) = biopterin in urine; 5HIAA (CSF) = 
5-hydroxyindoleacetic acid in cerebrospinal fluid; HVA (CSF) = homovanillic acid in cerebrospinal fluid; 
5MTHF (CSF) = 5-methyltetrahydrofolic acid in cerebrospinal fluid; RBC = red blood cells; n.d.: not done. 
*source BIOMDBdb (www.bh4.org) (Ponzone et al. 2004) 
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Fig. 1. A-F (continued on next page) 
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OUTCOME AND LONG-TERM FOLLOW-UP 
 
 
 
 
 Fig. 1. Follow-up of CSF neurotransmitter metabolites 5HIAA and HVA and clinical signs and symptoms 
in relation to treatment modalities and age in patients with PTPS deficiency (A-I) and DHPR deficiency (J-
N).  
Metabolite levels: 5-hydroxyindoleacetic acid (5HIAA) -x----x----x-; homovanillic acid (HVA) -z--z--z-
treatment regimen: tetrahydrobiopterin (BH4) ; L-Dopa/Carbidopa ; 5HTRP: 5-hydroxytryptophan .  
clinical symptoms: HH = Hypotonia/Hypertonia (including dystonia, spasticity): - normal muscle tone, + 
slight, ++ moderate, +++ severe; CON = convulsions: - no convulsions, + sporadic oculogyric or 
myoclonic crises, ++ frequent convulsions or epilepsy controlled by anticonvulsive therapy, +++ severe 
epilepsy, difficult to control; NEU = other neurological symptoms: - none, + one, ++ two, +++ three or 
more of the following: hypersalivation, tremor, ataxia, choreoathetosis, hyperthermia, irritability; DD = 
developmental delay: - normal child, + slight delay, attending normal classes, ++ marked delay, attending 
special school, working in sheltered workplace, +++ severely retarded, needing daily care; ?: not reported. 
 
Normal values Newborns <1 yr 2-4 yr 5-10 yr 11-16 yr >16yr 
5HIAA (CSF) nmol/l 144-800 114-336 105-299 88-178 74-163 66-141 
HVA (CSF) nmol/l 300-1000 295-932 211-871 144-801 133-551 115-488  
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Discussion 
Today selective screening for BH4 deficiencies is performed in most parts of the world in 
patients with even slight HPA detected in PKU screening. By means of a BH4 loading test and 
measurement of urinary pterins and DHPR activity an exact diagnosis of the type of BH4 
deficiency can be made in the first weeks of life (Dhondt 1991; Blau 2006). This led in most 
countries to an early onset of therapy and prevention of the severe mental and physical 
disability reported of untreated patients (al Aqeel et al. 1991; Lee et al. 2006). Early diagnosis is 
associated with better outcome (Dhondt 2006). Treatment consisting of oral administration of 
commercially available synthetic BH4 to regulate phenylalanine levels in blood and substitution 
of neurotransmitter precursors and folinic acid, has been shown to be effective in reducing 
neurological symptoms and developmental delay (Ponzone et al. 2006). However, treatment 
guidelines are vague; reports of long-term follow-up and outcome are rare and inconsistent. It is 
not yet known whether early therapy can completely prevent developmental delay in all patients 
with BH4 deficiency. Since selective screening is performed, and more and more patients are 
detected early, it is a central concern to expand the knowledge about the course of the treated 
disease. 
 
Problems of the data collection 
This is a multicenter observational study, with patients spread all over Europe. The population 
is very heterogeneous with respect to age, some of the patients being very young. There is no 
general treatment or assessment scheme. It is not stated whether physical therapy, logopedia, or 
other supportive measures were taken. Records of IQ assessments were not always found. 
 
PTPS 
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PTPS deficiency occurs in two distinctive forms: a peripheral/mild form (approximately 20%) 
and a central/severe form (Niederwieser et al. 1987). The mild form is commonly easy to treat 
with BH4 administration alone and development is normal, as is shown in patient #343 (see case 
reports). The severe form necessitates neurotransmitter and sometimes folinic acid substitution 
in addition to BH4 administration and the outcome differs greatly. For instance patient #65, does 
not present with a satisfying outcome despite early diagnosis and treatment possibly because the 
fetal damage, while patient #64 was diagnosed after the onset of sever neurological symptoms 
OUTCOME AND LONG-TERM FOLLOW-UP 
 
and today presents with a good outcome. Among the 15 early diagnosed (before 2 months of 
life) 9 are without developmental delay, while among 9 late diagnosed patients we found 5 
without developmental delay, one of them being diagnosed in adult age (#478). In our patient 
population there is no clear correlation between any one factor and a good outcome. It is 
interesting that out of the 5 patients who received folinic acid, 4 do not present with a 
developmental delay. It has been reported that long-term l-Dopa/Carbidopa therapy may result 
in low 5MTHF levels in CSF, probably due to the methyl-group loss during the catabolism of l-
dopa to vanillactic acid (Bräutigam et al. 2000). This might indicate the importance of CSF 
folates monitoring and folinic acid substitution in PTPS-deficient patients. This study does not 
allow establishing benefits of MAO-B and COMT inhibitors in the treatment of BH4 deficiency. 
However, the addition of Selegiline in some cases allowed lower dosage of neurotransmitter, 
thus not only the on-off effects and the daily fluctuations diminished or disappeared, but 
probably the known side effects of the long-term treatment either. We found no clear correlation 
between CSF 5HIAA and HVA values and clinical outcome. This study reflects the 
heterogeneity of PTPS deficiency ranging from the mild form #343 over an intermediate form 
#125, #378, #410 to a severe form with developmental delay despite early diagnosis, 
administration of BH4, and neurotransmitter substitution (#65, #90, #96, #236, #346, #372, 
#450). In some patients in which CSF sampling was not possible (#89, #90, #124, #235, #251, 
#346, #350), dopamine production was monitored by blood prolactin levels (Spada et al. 1996). 
Initially high blood prolactin levels normalized in all patients under standard treatment (data not 
shown). 
Early diagnosis and correct, closely monitored therapy can reduce symptoms and prevent 
catastrophic outcome; however, it remains uncertain, which factor decides whether a child will 
experience delayed development and which not. It has been discussed that prenatal brain 
damage might be the cause for the most early onset neurological presentations (Dhondt 2006). 
 
DHPR 
The natural course of DHPR deficiency has been previously described (Ponzone et al. 2004). In 
DHPR deficiency an early diagnosis and early introduction of therapy in the first months of life 
is crucial, as permanent brain damage (cerebral atrophy, neuronal loss, calcification of basal 
ganglia) occurs early in the course of the untreated disease, and development cannot be regained. 
Analysis of the medical records of our 10 patients supports this, suggesting a cut-off time limit 
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for the therapeutic intervention of one month of life. Doubtless, the diagnosis should be settled 
before the irreversible brain damage occurs. The course of the early-diagnosed and well-treated 
disease is characterized by very good control of neurological symptoms. However, it is not clear 
why patients #287 and #423 do present with developmental delay. Possibly the partly low 
HIAA and HVA values in CSF led to impaired development in the absence of other symptoms. 
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 C h a p t e r  6  
GENE EXPRESSION OF BH4 STIMULATED CELLS 
 
Introduction 
The first enzyme in the BH4 de novo biosynthesis is GTPCH, mainly active in the liver. It is 
believed to be the rate limiting enzyme in the pathway and converts GTP to NH2TP. In several 
cell types it can be stimulated by the cytokines IFN-γ and TNF-α, and on the other hand its 
activity can be inhibited by DAHP (Thöny et al. 2000; Xie et al. 1998). The second enzyme in 
the cascade is PTPS. It produces 6PTP from NH2TP and is considered to be constitutively 
expressed and active in most cells. In several human cells, a splicing polymorphism had been 
found that leads to skipping of exon 3, indicating that alternative splicing may have a regulatory 
function (Thöny et al. 1994). The third and last enzyme in the pathway of BH4 de novo 
biosynthesis is SR. This enzyme converts, under NADPH consumption, 6PTP into BH4. 
Dicumarol was found being an effective inhibitor of SR. Lack of this enzyme can be partially 
compensated by alternative carbonyl reductases and by aldose reductase. This alternative – 
together with the salvage pathway – can circumvent parts of the negative effects of inborn 
defects in SR (namely the hyperphenylalaninemia) (Iino et al. 2003). 
The homeostasis of BH4 is controlled by a feedback regulatory circuit through interaction with a 
protein termed GFRP, that forms a complex with GTPCH. At high concentration, BH4 
decreases its own biosynthesis through negative feedback control, whereas on the other hand, 
phenylalanine has the opposite effect. Using cell cultures, it has been observed that this control 
mechanism not only takes place on the level of enzyme activity but also on a transcriptional 
level, as the expression of the genes GCH1 and GCHFR are either down regulated or up 
regulated respectively, depending on the condition. Phenylalanine not only stimulates the 
biosynthesis of BH4 by reversing the negative feedback inhibition of GTPCH, but also by 
increasing the mRNA level of GCH1 (Gesierich et al. 2003). 
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The metabolic disorders correlated with BH4, provide a direct insight into the metabolism of 
BH4. The understanding of the metabolism is not only of academic interest but is also highly 
important for an early diagnosis and a possible treatment of patients. The goal of the here 
presented study was to further investigate the metabolism and particularly the regulation of BH4 
biosynthesis and regeneration using different cell cultures as model, based especially on the 
level of gene expression. 
To reach this goal we examined the effects of BH4 (either exogenously supplemented or by 
increasing de novo synthesis with cytokine induction) on enzymes and pathways which 
participate in the BH4 system or which are dependent on BH4 as a cofactor in different cell 
models. 
We compared fibroblasts of patients, suffering from specific BH4-deficiencies (GTPCH-
deficiency and SR-deficiency) with normal fibroblasts following BH4 supplementation. The two 
approaches used were stimulation of GTPCH with cytokines or adding BH4 to culture medium. 
As it had been shown, that BH4 supplemented in the culture medium is inefficiently able to 
increase the intracellular BH4 pool (it is quickly excreted in form of BH2 after being taken up by 
the cells), we used its precursor sepiapterin. Sepiapterin was found to be taken up quickly into 
cultured cells, converted to BH2 by SR and reduced to BH4 by DHFR (Hasegawa et al. 2005). 
Improved uptake and elevated BH4 concentrations in tissues was also found in vitro, feeding 
mice with sepiapterin. Thus sepiapterin could potentially serve as an alternative to BH4 in 
patients with BH4-deficiency or BH4-responsive PKU (Sawabe et al. 2004). 
 
Results 
Different cell lines were analysed for expression of BH4-metabolism related enzyme activity 
(Table 1). Being the rate determining enzyme in the BH4-pathway, activity of GTPCH was 
tested first. Certain cells, e.g. fibroblasts, need stimulation with cytokines for the induced 
expression of GTPCH, whereas cells of hepatic origin are supposed to express GTPCH 
constitutively and stimulation with cytokines usually does not lead to a significantly increased 
activity. Cell lines which did not express activity or only marginal levels of all the enzymes 
analysed in the enzyme assays, were not considered for further examination as well as cells 
which grew weakly. Two cell lines, expressing considerable amount of GTPCH-, PTPS-, 
DHPR and SR activity, were the neuroblastomal SK-N-BE and the liver carcinoma cell line 
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HepG2. Additionally we had decided to have a closer look at different fibroblasts of patients 
with a BH4 deficiency and healthy controls. 
Table 1 
Enzymes activity in different cell lines 
Cell Line Enzyme Treatment Activity* unit 
CCF-STTG1 GTPCH CK 0 µU/mg 
 PTPS - 0.72±0.83 µU/mg 
 SR  - 201.63±156.59 µU/mg 
 DHPR - 4.23±0.85 mU/mg 
Fibroblasts GTPCH CK 0.43±0.63 µU/mg 
 PTPS - 0.26±0.12 µU/mg 
 SR - 78.84±33.22 µU/mg 
 DHPR - 4.68±1.59 mU/mg 
HepG2 GTPCH CK 0.03±0.03 µU/mg 
 GTPCH - 0.02±0.01 µU/mg 
 PTPS - 0.38±0.5 µU/mg 
 SR - 178.69±229.45 µU/mg 
 DHPR - 6.83±0.8 mU/mg 
KB  GTPCH - 3.15±1.62 µU/mg 
 PTPS - 436.26±132.87 µU/mg 
 SR  - 3.03±0.62 mU/mg 
 DHPR - 0 µU/mg 
SK-N-BE GTPCH - 0.16±0.1 µU/mg 
 PTPS - 5.09±3.05 µU/mg 
 SR  - 129.98±93.16 mU/mg 
 DHPR - 3.49±1.56 µU/mg 
HHI-16 GTPCH - 0.17±0.03 µU/mg 
HHL-17 GTPCH - 0.06±0.07 µU/mg 
Huh7 GTPCH - 0 µU/mg 
THLE-3 GTPCH - 0 µU/mg 
 PTPS - 9.19±2.12 µU/mg 
Enzyme assays performed in different cell lines; Treatment: - ; 
untreated; CK = cytokines (TNF-α, IFN-γ); * = mean activity ± 
standard deviation, (n = 4-12). For more details on the cell cultures, 
please refer to the appropriate section in Materials and Methods. Page 
133 
 
Primary rat hepatocytes 
Cell culture models are widely used in studies of metabolisms, toxicology, and 
pharmacokinetics, however due to the nature of many cell lines, being isolated and cultured 
from cancer tissues, enzymes of interst may not be expressed anywhere. Therefore, we decided 
to test primary cells. As the liver is the major site of phenylalanine catabolism, liver cells can 
serve as a promising model, for studies of phenylalanine respectively BH4 metabolism. We used 
primary rat hepatocytes, which were cultured in a first experiment in two different kinds of 
culture dishes; in Falcon dishes coated with collagen or in pre-coated Sarstedt plates. Using 
collagen-coated dishes was reported enhancing the attachment and spreading of primary 
hepatocytes on the culture plate. PAH and GTPCH activity was measured on day one after 
isolation (prior to plating cells), on day two, three and four. PAH activity rapidly diminished 
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and fell within 48 under 5% of the original activity. Culturing primary rat hepatocytes in 
presence of 100 µM sepiapterin did not change the activity substantially, neither of PAH nor of 
GTPCH. On day two, cells on Sarstedt plates showed a slightly higher activity (Figure 1). These 
plates were used in further experiments. Primary rat hepatocytes were cultured for 24 hours in 
presence or absence of 100 µM sepiapterin. GTPCH activity was measured before seeding the 
cells (-3 h), after 3 hours at the time marked by the change of WME A medium to WME B, 
after 18 and 24 hours (Figure 2). Measured activity declined within 18 hours significantly. Rat 
liver lysate was used as a control for the assay. 
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 Fig. 1. PAH activity of primary rat hepatocytes on day 1 to day 4:  untreated cells cultured on Falcon 
plates;  cells incubated with 100 µM sepiapterin.  Untreated cells cultured on precoated Sarstedt plates; 
+ control: rat liver; results given as mean activity and  standard deviation, (n = 3). 
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 Fig. 2. PAH activity of primary rat hepatocytes cultured for 24 hours in Sarstedt plates:  untreated cells;  
cells incubated with 100 µM sepiapterin (supplementation with sepiapterin at 0 hours); + control : rat liver; 
results given as mean activity and  standard deviation, (n = 3). 
 
 
Primary rat hepatocytes were cultured in the presence of 100 µM sepiapterin, to see whether 
sepiapterin is taken up by the cells. HepG2 cells were incubated for 24 hours in 25 µM 
sepiapterin and its concentration in the culture medium was determined spectrophotometrically 
(Figure 3). Concentrations of 25 µM sepiapterin appeared to be sufficient for an incubation time 
of 24 hours as about 19 µM sepiapterin were consumed within this time. As sepiapterin is 
sensitive to light and is rapidly degraded, cells were handled at dim light and otherwise kept in 
the dark (Figure 4). 
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 Fig. 3. Consumption of sepiapterin by primary rat hepatocytes, mean values with standard deviation: 
 25 µM sepiapterin incubated in cell free medium;  25 µM sepiapterin incubated in the presence of 
primary rat hepatocytes. ∆[SP]/24 h ≈ 19 µM. Absorption at 420 nm, ελ = 10400 M-1 cm-1.; results given as 
mean activity and  standard deviation, (n = 3). 
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 Fig. 4. Decomposition of 1.25 mM sepiapterin stock solution when left at daylight and room temperature:  
sepiapterin solution stored in the dark at 37°C; { sepiapterin solution kept at daylight and room 
temperature. [SP] measured in 1:20 dilution at 420 nm, ελ = 10400 M-1 cm-1. 
 
 
To test whether culturing primary rat hepatocytes sandwiched between two layers of collagen, 
forming an environment similar to the one in the liver, would increase the life span of the cells 
and helping to maintain the activity of the enzymes involved in BH4 synthesis, sandwich 
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cultures were prepared at different time points after plating the cells. In the control experiment, 
without collagen double layer, activity of GTPCH diminished significantly within 96 hours; 
sepiapterin (25 µM) had no influence on the enzyme activity (Figure 5). The same hold also true 
when the hepatocytes were grown in sandwich cultures. Neither, bedding the cells after 4 hours 
(Figure 6), nor after 24 hours after seeding (Figure 7) could stop the steadily decline of GTPCH 
activity. The sandwiched cells appeared to retain morphologically healthy structure for a longer 
period. Also, in a test for uptake of bile salts (Figure 8), indicating functional activity of the bile 
acid transporters, typical for functional hepatocytes, sandwiched cultures performed slightly 
better (Student’s t test; p ≤ 0.05). As the activity of the central enzyme of BH4 biosynthesis 
could not be maintained for a longer period, which would allow investigating effects of BH4 
after repeated administration, the use of primary rat hepatocytes and sandwich cultures was not 
further explored. 
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 Fig. 5. GTPCH activity of primary rat hepatocytes: mean values and standard deviation,  untreated cells; 
 cell incubated with 25 µM sepiapterin (supplementation at 3, 24, 48, 72, 96, 120, 144 hours);  + control: 
rat liver; results given as mean activity and  standard deviation, (n = 3). 
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 Fig. 6. GTPCH activity of primary rat hepatocytes: sandwich culture after 4 h; mean values and standard 
deviation;  control cells;  cells incubated with 25 µM sepiapterin (supplementation at 4, 24, 48, 72, 96, 
120, 144 hours);  + control: rat liver. All significantly reduced after 96 h (p ≤ 0.05); results given as mean 
activity and  standard deviation, (n = 3). 
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 Fig. 7. GTPCH activity of primary rat hepatocytes: sandwich culture after 24 h; mean values and standard 
deviation;  control cells;  cells incubated with 25 µM sepiapterin (supplementation at 3, 24, 48, 72, 96, 
120, 144 hours);  + control: rat liver. All significantly reduced after 96 h (p ≤ 0.05); results given as mean 
activity and  standard deviation, (n = 3). 
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 Fig. 8. Uptake study of taurocholate by primary rat hepatocytes:  control cells, 3 hours 
after seeding;  controls cells, 96 hours after seeding;  cells cultured sandwiched 
between two collagen layers prepared 4 hours after seeding, measured after 96 hours. At 
96 hours bile acid uptake in control cells is significantly reduced compared with controls at 
3 hours (*: p ≤ 0.05). No significant reduction was observed for 96 hour-sandwich 
cultures; results given as mean activity and  standard deviation, (n = 3). 
 
 
Gene expression in fibroblasts and different cell lines 
In next series of experiments, fibroblasts and other different cell lines were analysed for gene 
expression after either stimulation with cytokines (IFN-γ; 1250 U and TNF-α; 500 U), 
sepiapterin (25 µM; 100 µM), phenylalanine (2 mM), all three agents were used to increase 
intracellular BH4 concentration. The first approach was used to stimulate GTPCH, the second to 
convert supplemented sepiapterin to BH4, and the third to activate the GTPCH·GFRP complex 
via positive feedback control. Results of gene expression were acquired using Micro Fluidic 
Cards (mini arrays relying on RT-PCR) (Table 2). 
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Table 2 
Micro Fluidic Card 2, gene expression assay 
Gene 
symbol Gene name 
ABI assay 
number 
Chromosomal 
location NCBI RefSeq Function 
18S Eukaryotic 18S rRNA Hs99999901_s1 -   
GAPDH glyceraldehyde-3-phosphate 
dehydrogenase 
Hs99999905_m1 12p13 NM_002046.2 Control 
ACTB actin, beta Hs99999903_m1 7p15-p12 NM_001101.2 Control 
GCH1 GTP cyclohydrolase I Hs00609198_m1 14q22.1-q22.2 NM_00102402
4.1 
Synthesis 
GCHFR GTP cyclohydrolase I 
feedback regulator 
Hs00193360_m1 15q15 NM_005258.2 Synthesis 
PTS 6-pyruvoyltetrahydropterin 
synthase 
Hs00609393_m1 11q22.3-q23.3 NM_000317.1 Synthesis 
SPR sepiapterin reductase Hs00268403_m1 2p14-p12 NM_003124.3 Synthesis 
PCBD1 pterin-4α-carbinolamine 
dehydratase/dimerization 
cofactor of hepatocyte 
nuclear factor 1 alpha 1 
Hs00165396_m1 10q22 NM_000281.2 Recycling 
PCBD2 pterin-4α-carbinolamine 
dehydratase/dimerization 
cofactor of hepatocyte 
nuclear factor 1 alpha 2 
Hs00259792_m1 5q31.3 NM_032151.3 Recycling 
QDPR quinoid dihydropteridine 
reductase 
Hs00165610_m1 4p15.31 NM_000320.1 Recycling 
AKR1B1 aldo-keto reductase family 1, 
member B1 (aldose 
reductase) 
Hs00739326_m1 7q35 NM_001628.2 Altern. 
AKR1C3 aldo-keto reductase family 1, 
member C3 
Hs00366267_m1 10p15-p14 NM_003739.4 Altern. 
CBR1 carbonyl reductase 1 Hs00156323_m1 21q22.13 NM_001757.2 Altern. 
AKR1A1 aldo-keto reductase family 1, 
member A1 (aldehyde 
reductase) 
Hs00195992_m1 1p33-p32 NM_153326.1 Altern. 
AKR1C1, 
AKR1C2 
aldo-keto reductase family 1, 
member C1 (dihydrodiol 
dehydrogenase 1) 
Hs00413886_m1 10p15-p14 NM_001353.5 Altern. 
AKR1C4 aldo-keto reductase family 1, 
member C4 (chlordecone 
reductase) 
Hs00559542_m1 10p15-p14 NM_001818.2 Altern. 
DHFR dihydrofolate reductase Hs00758822_s1 5q11.2-q13.2 NM_000791.3 Altern. 
NOS1 nitric oxide synthase 1 
(neuronal) 
Hs00167223_m1 12q24.2-
q24.31 
NM_000620.1 BH4 req. 
NOS2A nitric oxide synthase 2A 
(inducible, hepatocytes) 
Hs00167248_m1 17q11.2-q12 NM_153292.1 BH4 req. 
NOS3 nitric oxide synthase 3 
(endothelial cell) 
Hs00167166_m1 7q36 NM_000603.3 BH4 req. 
PAH phenylalanine hydroxylase Hs00609359_m1 12q22-q24.2 NM_000277.1 BH4 req. 
TH tyrosine hydroxylase Hs00165941_m1 11p15.5 NM_199292.1 BH4 req. 
TPH1 tryptophan hydroxylase 1 Hs00188220_m1 11p15.3-p14 NM_004179.1 BH4 req. 
TPH2 tryptophan hydroxylase 2 Hs00542783_m1 12q21.1 NM_173353.2 BH4 req. 
Information about the genetic transcripts detected by real-time RT-PCR. The NCBI reference sequence (RefSeq) 
was provided by ABI with each TaqMan Gene Expression Assay. Gene symbols and chromosomal locations are 
listed according to the most recent NCBI data (http://www.ncbi.nlm.nih.gov/). (*)ABI TaqMan Gene Expression 
Assays are under proprietary license and the exact primer and probe sequences are not available. 
Function: Control = endogenous control; Synthesis = enzyme involved in BH4 de novo biosynthesis; Recycling = 
proteins involved in the regeneration of BH4; Altern = enzymes of the alternative and of the salvage pathway; 
BH4 req. = enzyme that require BH4 as a cofactor. 
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Following cell lines were analysed; Fibroblasts: FB Ko 1 and FB Ko 2 (normal control), 
FB SRdef (SR-deficient patient), FB GCHdef 1 and FB GCHdef 2 (GTPCH-deficient patients); 
liver derived cells: HepG2, HHL-17 and HHI-16 (a kind gift from A. Patel; (Clayton et al. 
2005), and brain, bone marrow neuroblastoma SK-N-BE.  
Gene expression analysis of single cell lines resulted in significant difference of expression only 
in limited cases (Figure 9). The most significant up-regulations of gene expression were gained 
from stimulation with the cytokines (TNF-α and IFN-γ; CK) on the GCH1 gene and AKR1B1. 
Nevertheless a cluster of up and down-regulation was recognisable amongst other genes, after 
stimulation with cytokines or other agents. Expression patterns of all cell lines were compared 
to the endogenous control GAPD with reference to the chosen stimulant. The combined 
cytokines TNF-α and IFN-γ tended to stimulate expression of GCH1, SPR and AKR1B1. On the 
other hand the gene expression of AKR1C1, AKR1C2 and DHFR appeared to be down regulated 
by cytokines. Phenylalanine generally tended to up-regulate the expression of GCH1, and 
QDPR; AKR1B1 expression was repressed. The effects of 25 µM sepiapterin were not as 
prominent as the ones of the cytokines and changes of gene expression were smaller by an order 
of magnitude. Sepiapterin had rather the opposite effect on QDPR compared to phenylalanine 
and would either also lead to a repression of CBR1 or else leave the expression level unchanged. 
The strongest change of expression was observed for GCH1 especially with fibroblasts where 
gene expression could exceed 1000-fold up-regulation, for AKR1B1 a maximal change of 100-
fold was seen. All other genes showed in general much lower changes on the transcriptional 
level. 
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FB Ko 1 100 100 100 100 100 100 100 n.d. n.d. n.d. 100 n.d. n.d. 100 n.d. n.d.
FB Ko 2 100 100 n.d. n.d. 100 100 100 n.d. n.d. n.d. 100 n.d. n.d. 100 n.d. n.d.
FB SRdef n.d. 100 n.d. 100 100 100 100 n.d. n.d. n.d. 100 n.d. n.d. 100 n.d. n.d.
FB GCHdef 1 100 100 100 100 100 100 100 n.d. n.d. 100 100 100 n.d. 100 n.d. n.d.
FB GCHdef 2 100 100 100 100 n.d. 100 100 100 100 n.d. 100 100 100 100 n.d. n.d.
HHL 17 100 100 100 100 100 100 100 100 100 100 100 100 100 100 n.d. n.d.
HHI 16 n.d. 100 100 100 100 100 100 100 100 100 100 n.d. 100 100 n.d. n.d.
HepG2 100 100 100 100 100 100 100 n.d. n.d. n.d. 100 n.d. 100 100 100 100
SK-N-BE 100 100 n.d. 100 100 100 100 n.d. n.d. n.d. 100 n.d. 100 100 n.d. n.d.
FB Ko 1 89 11524 50 106 77 47* 111 n.d. n.d. n.d. 303* n.d. n.d. 87 n.d. n.d.
FB Ko 2 122 10195* n.d. n.d. 193 33 138 n.d. n.d. n.d. 613 n.d. n.d. 79 n.d. n.d.
FB SRdef n.d. 8937* n.d. 44 138 30 203 n.d. n.d. n.d. 975* n.d. n.d. 29 n.d. n.d.
FB GCHdef 1 107 9514 62 60 170 44 65 n.d. n.d. 80 746* 47 n.d. 96 n.d. n.d.
FB GCHdef 2 83 628* 234 42 n.d. 68 72 177* 77 n.d. 83 73 31 79 n.d. n.d.
HHL 17 130 530* 91 25 162 109 122 59 62 113 145 30 108 176 n.d. n.d.
HHI 16 n.d. 1179* 12 163 67 106 84 51 53 142 244 n.d. 129 n.d. n.d. n.d.
HepG2 107 149* 96 79 115 102 105 n.d. n.d. n.d. 151* n.d. 65 123 95 60
SK-N-BE 131 137 n.d. 165 144 139 95 n.d. n.d. n.d. 113 n.d. n.d. 258 n.d. n.d.
HHL 17 99 74 n.d. 25 151 98 134 69 69 76 78 36 100 75 n.d. n.d.
HHI 16 n.d. 101 18 169 65 118 97 207 102 72 108 n.d. 109 42 n.d. n.d.
FB Ko 1 82 161 72 89 73 126 138 n.d. n.d. n.d. 58* n.d. n.d. 50 n.d. n.d.
FB Ko 2 97 190 n.d. n.d. 95 141 48 n.d. n.d. n.d. 88 n.d. n.d. 161 n.d. n.d.
HepG2 102 134 106 90 109 92 112 99 100 87 107 104 102 149 86 166
FB Ko 1 92 113 60 131 74 106 78 n.d. n.d. n.d. 82 n.d. n.d. 74 n.d. n.d.
FB Ko 2 90 131 n.d. n.d. 126 85 56 n.d. n.d. n.d. 89 n.d. n.d. 95 n.d. n.d.
FB SRdef n.d. 235 n.d. 34 50 34 123 n.d. n.d. n.d. 74 n.d. n.d. 28 n.d. n.d.
FB GCHdef 1 65 53 46 74 93 101 66 n.d. n.d. 43 133 31 n.d. 71 n.d. n.d.
FB GCHdef 2 96 164 142 27 n.d. 59 126 175* 79 n.d. 108 39 242 56* n.d. n.d.
HHL 17 103 67 78* 43 149 102 154 107 112 125 103 118 132 96 n.d. n.d.
HHI 16 n.d. 34 6 146 64 82 62 79 80 63 181 n.d. 88 66 n.d. n.d.
HepG2 101 89 100 50 102 73* 115* n.d. n.d. n.d. 88 n.d. 96 104 108 166
SK-N-BE 77 67 n.d. 97 716 67* 123 n.d. n.d. n.d. 221 n.d. 225 55 n.d. n.d.
24 h SP
24 h -
24 h CK
24 h Phe
6 h Phe
 
 Fig. 9. Gene expression study of different cell cultures. Relative expression numbers 
(%); numbers marked with (*): statistically significantly modified gene expression 
(Student’s t-test; p ≤ 0.05); green, turquoise colours: up-regulated expression; red and 
yellow colours: down-regulated gene expression, grey: nearly unchanged expression 
levels, n.d.: not detected. For percentage and colour code, refer to the list on the right 
hand. Treatment: 24 h - = untreated control cells (were set to 100% expression and all 
other expression numbers were relative to them); 24 h CK = cells supplemented for 
24 hours with cytokines (TNF-α and IFN-γ) 24 h Phe resp. 6 h Phe = cells incubated with 
2 mM phenylalanine for 24 hours, respectively 6 hours prior to harvesting. 24 h SP = 
cells incubated with sepiapterin (25 µM). For more details on the cell cultures, please 
refer to the appropriate section in Materials and Methods. 
% 
< 50
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> 200
n.d. 
  
 
 
In parallel to the gene expression profile, the main metabolites, neopterin and biopterin, were 
measured in the cells and in the cell culture medium, and enzyme assays for GTPCH, the rate 
limiting enzyme of the biosynthesis of BH4, known to alter activity upon cytokine stimulation, 
and SR, the principle enzyme in reduction of exogenous sepiapterin to BH2, were performed. In 
contrast to the PTPS and GTPCH which were measured close to the detection limit, SR assay 
resulted in better reproducible measurements, with smaller standard deviations than the two 
other assays. As expected, stimulation with cytokines, lead to the strongest change in the 
metabolism of BH4, especially in fibroblast which normally do not show GTPCH activity but 
upon stimulation with cytokines, enzyme activity became measurable. Further, intracellular 
concentration of biopterin and neopterin were increased upon stimulation. In unstimulated cells 
these two metabolites generally remained undetected (Table 3). Supplementation of the cell 
culture medium with sepiapterin, in concentrations between 25 µM and 100 µM had no 
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influence on the activity of neither GTPCH nor SR. However, addition of sepiapterin to 
cultured cells led to a massive increase in intracellular biopterin (Table 3). The reason for this is 
fast uptake of sepiapterin and its conversion to BH2, and subsequent reduction to BH4. 
Incubations with phenylalanine did not lead to a significant change of the metabolism. 
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Table 3 
GTPCH and SR activity assay and intracellular and extracellular neopterin and biopterin concentrations in 
fibroblasts and HHL-17, HHI-16, and HepG2 cells cultured under different conditions. 
 
  x±SD x±SD x ±SD x ±SD x ±SD x ±SD 
  GTPCH neopterin biopterin ex neo ex bio SR 
Cell line Treatment µU/mg prot pmol/mg pmol/mg pmol/mL pmol/mL µU/mg prot 
FB Ko 1 24h - 0 0 0 10.1±9.7 17.5±5.8 150.3±41.8
 24h SP 0 0 183.1±88.6* 10.5±11.9 52.6±10 167.6±65.9
 24h CK 0.46±0.21* 7.2±7.8* 111.2±37.4* 11.3±2.9 33.4±7.1* 157.6±40 
 6h 2mM Phe 0 3.1±4.3 0 n.d. n.d. n.d. 
 24h SP100 0 2±2.8 411.6±25 n.d. n.d. n.d. 
FB Ko 2 24h - 0 0 0.6±1.1 5.8 21.2 152.4±0.9 
 24h SP 0 0 129.3±74.5* 7.2 73.1 215.1±8.5 
 24h CK 0.61±0.45 22.1±22.1* 102.1±24.2* 11.2 29.4 189.4±11.4
 6h 2mM Phe 0 0 0 n.d. n.d. n.d. 
 24h SP100 0 0 340.5±21.8* n.d. n.d. n.d. 
FB SRdef 24h - 0 0 2.2±4.9 8.9 21.4 0 
 24h SP 0 0 8.8±10.5 3.5 31.4 0 
 24h CK 3.35±0.39 101.2±74.6* 16.6±20.6 n.d. 23.6 0 
FB GCHdef1 24h - 0 0 0 16.8±11.8 16±3 100.8±30.6
 24h SP 0 0.4±0.9 208.1±29.9* 29.3±21.7 80.9±2.2* 109.2±2.9 
 24h CK 0.03 2.4±4.1 44.9±42.1* 20.5±14.7 37.8±1.7* 103±14.4 
FB GCHdef2 24h - 0.05 1.2±2.6 3.4±6.3 16.7±5.3 16.4±2.7 88±2.4 
 24h SP 0.04 1.4±2.8 578.5±321.7* 34±0 216±0 58.5±8.6 
 24h CK 0.15 16.9±9.9* 40.4±16.4* 17.3±3.8 29.6±6.4 62.7±6.4 
FB GCHdef3 24h - n.d. 0 0 11.5±0 23±0 n.d. 
 24h SP n.d. 1.2±1.7 2.6±3.7 6.4±0 37.4±0 n.d. 
 24h CK n.d. 0 6.5±0.2* 10±0 37±0 n.d. 
HHL-17 24h - 0.12±0.17 3.7±5 7.9±10.9 16.9±20.9 27.6±27.5 210.6±36.3
 24h SP 0.17±0.19 0 435.4±225.3* 121.9±111.9 1181.4±1200.6 234±27.5 
 24h CK 0.26±0.24 5.3±1.6 19.7±2.4* 12.8±15.1 32.4±19.7 173.4±35.2
 6h 2mM Phe n.d. 1.7±2.4 2±2.8 n.d. n.d. n.d. 
 24h SP100 n.d. 0 1746.3±51.4* n.d. n.d. n.d. 
HHI-16 24h – n.d. 0 4.3±6.1 n.d. n.d. n.d. 
 24h SP n.d. 0 0 n.d. n.d. n.d. 
 24h CK n.d. 4.3±0.2* 2046.3±86.8* n.d. n.d. n.d. 
 24h Phe 2mM n.d. 0 44.9±5.9 n.d. n.d. n.d. 
HepG2 24h - 0.29±0.11 5.8±6.3 9±1.6 33.7±7.2 100.9±73.4 399.5±23.6
 24h SP100 0.22±0.07 546.8±39.2* 3017.5±2276.5* 891.2±421.7 5735.3±595.1* 404±5.3 
 24h CK 0.33±0.10* 4.3±0.1 13.3±2.5 31.1±4.5 98.2±30.9 425.8±5.7 
 6h 2mM Phe 0.29±0.01 3±2.6 11.9±1.3 27±0.8 84.1±76.1 n.d. 
SK-N-BE 24h - 0.35±0.16 0 82.4±4.7 8±2.4 141.8±88.8 110.9±12.5
 24h SP 0.32±0.2 0.5±0.9 844±135.8* 89.6±126.8 1130.9±1493.8 125.8±17.7
 24h CK 0.32±0.08 1.2±1.7 69±6.6* 19.8±28 424±528.7 118.8±28.8
Treatment: 24h - = untreated control cells; 24h CK = cells supplemented for 24 hours with cytokines (TNF-α 
and IFN-γ); 24h SP = cells incubated for 24 hours in 25 µM sepiapterin, respectively 24h SP100, incubated 
with 100  µM sepiapterin; 24h Phe = cells incubated in 2 mM phenylalanine for 24 hours. ex bio resp. ex neo = 
extracellular biopterin/neopterin measured in used culture medium samples. Results given as mean values ± 
standard deviation. For details on cells, see Materials and Methods.  
 
 
Gene expression analysis in patients’ fibroblasts 
In a next step we investigated fibroblasts, to explore whether there were differences in the 
regulation of genes in fibroblasts of BH4 deficient patients compared with healthy controls. We 
  112 
 
GENE EXPRESSION OF BH4 STIMULATED CELLS 
 
selected seven different fibroblast samples of patients with a known GTPCH-deficiency, one 
with SR-deficiency; and three samples from healthy subjects. Using conventional RT-PCR we 
focused on the expression of GCH1 and GCHFR after stimulation with cytokines (IFN-γ: 
1250 U and TNF-α: 500 U). In all samples that we analysed a strong induction of GTPCH 
expression following cytokine treatment was observed (Figure 10). Expression levels and 
enzyme activity did not necessarily correlate, as also GTPCH deficient cells showed a high 
induction of mRNA production which did not lead to measurable amounts of functional enzyme. 
Cytokines seemed to reduce GCHFR production in the fibroblasts, at least in the BH4 deficient 
cells, where levels of GCHFR were significantly reduced compared to untreated cells 
(Figure 10). In the normal cells, no significant reduction or increase of the gene expression was 
found. Reduction of GCHFR levels along with induction of GCH1 appears to be another 
mechanism by which GTPCH activity seems to be regulated in the cells. To show whether the 
same holds true for non-BH4-defiecient fibroblasts further investigations need to be done. 
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 Fig. 10. Relative gene expression of A) GCH1 in different human fibroblast of patients with BH4 deficiency; 
(FB Ko = normal control (n = 6), FB GCHdef: = GTPCH deficiency (n = 16)), results given as mean activity and  
standard deviation:  unstimulated cells (no cytokines);  incubated for 24 hours in presence of cytokines (IFN-
γ: 1250 U and TNF-α: 500 U). Cytokines stimulated GTPCH expression significantly (p ≤ 0.01). B) Relative 
expression of the gene GCHFR in different human fibroblast of patients with BH4 deficiency; (FB Ko = normal 
control (n = 6), FB GCHdef: = GTPCH deficiency (n = 16)):  unstimulated cells (no cytokines);  incubated 
for 24 hours in presence of cytokines (IFN-γ: 1250 U and TNF-α: 500 U). Expression of GCHFR in BH4 
deficient patient is significantly reduced after stimulation with cytokines (p ≤ 0.05). For details on cell types; 
refer to section Materials and Methods. 
 
 
Gene expression profile in HepG2 cells 
PAH is almost exclusively a hepatic enzyme and thus, liver cells are most promising for the 
study of phenylalanine catabolism and also for BH4 metabolism. We selected the HepG2 cell 
line, which provided active DHPR, SR, PTPS, PAH and GTPCH enzyme. The latter was also 
  113 
 
CHAPTER 6 
 
constitutively expressed. The cell culture medium was supplemented either with cytokines 
(IFN-γ; 1250 U and TNF-α; 500 U), sepiapterin (100 µM), phenylalanine (2 mM), all three 
expected to increase intracellular BH4 levels; or dicumarol (100 µM) or DAHP (10 mM), both 
with inhibiting effect on the BH4 biosynthesis, and combinations of these. Gene expression was 
studied after a 24-hour incubation. Phenylalanine was added 6 hours prior to cell harvesting. 
Dicumarol is a know inhibitor of SR activity and DAHP inhibits BH4 synthesis at the level of 
GTPCH. 
The different agents had variant effects on the genes. The gene expression of AKR1B1 (the gene 
encoding for aldose reductase, AR) was significantly induced after cytokine treatment but also 
after supplementation with the GTPCH-inhibitor DAHP and by dicumarol. These results are 
rather contradictory. The gene expression of the aldo-keto reductase AKR1C3 was induced by 
dicumarol and down regulated by any combinations containing cytokines, except the mixture of 
dicumarol and CK. For the carbonyl reductase gene CBR1 even more controversial results were 
observed. Its transcription was either induced by CK, phenylalanine or DAHP but any 
combinations of those had rather a tendency for the opposite effect, even though no significant 
change was found with combined treatment. Dicumarol alone or in combination with other 
agents significantly induced expression of GCH1. GCHFR gene expression was significantly 
down regulated by virtually all combinations of the reagents used, except when treated with the 
mixture DAHP/SP. PCBD1 expression was slightly induced by sepiapterin and somewhat 
stronger by a cytokine/phenylalanine mixture. Concerning PTS, the gene expression was 
significantly down-regulated by sepiapterin and most mixtures containing it. QDPR expression 
was reduced by several agents, namely by sepiapterin, DAHP and combinations of these two. 
The expression of the gene encoding sepiapterin reductase, SPR, was induced by DAHP and 
mixtures of it. Surprisingly it was induced by the notedly inhibitor of SR, dicumarol. Dicumarol 
had also a distinct effect on several other genes. Especially the expression of iNOS and eNOS 
were markedly induced by dicumarol alone and mixtures of the other reagents. The significance 
of this finding is not clear. Increased expression of eNOS and iNOS is often mentioned in the 
context of liver or hepatocyte damage (Koti et al. 2005; McNaughton et al. 2002). In adipocytes, 
NOS activity was found to be reduced by dicumarol, most likely due to inhibition of the 
cofactor biosynthesis (BH4). In this study, cytotoxicity, as reason for the observed effects of 
dicumarol, was ruled out (Linscheid et al. 2003). Results of the experiments are summarised in 
Figures 11-16. 
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 Fig. 11. Gen expression of HepG2 cells: A =  untreated contr., B = 24 hour incubation with cytokines; 
C = 24h incubation with 100 µM sepiapterin; D =  24 hour incubation in DMEM with addition of 2 mM 
phenylalanine 6 hours before harvesting; E = 24 hour incubation with 10 mM DAHP; F = 24 hour 
incubation with dicumarol; G = 24 hour incubation of a mixture of C and E (SP/DAHP); H = mixture of B 
and E (CK/DAHP); I = mixture of D and E (Phe/DAHP); J = mixture of C and F (SP/Dic); K = mixture of B 
and F (CK/Dic); L = mixture of D and F (Phe/Dic); M = mixture of B and D (CK/Phe); N = mixture of C 
and D (SP/Phe); O = mixture of B and C (CK/SP);  significantly reduced expression compared to A, 
(p ≤ 0.05);  significantly increased expression compared to A, (p ≤ 0.05);  reduced expression, 
respectively  increased expression. 
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 Fig. 12. Gen expression of HepG2 cells: after 24 hours of incubation with cytokines (IFN-γ: 1250 U and 
TNF-α: 500 U);  significantly changed expression compared to untreated HepG2 cells (relative expression 
of untreated HepG2 = 100 %, p ≤ 0.05); results given as mean activity and  standard deviation, (n = 4). 
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 Fig. 13. Gen expression of HepG2 cells: after 24 hours of incubation with 100 µM sepiapterin;  
significantly changed expression compared to untreated HepG2 cells (relative expression of untreated 
HepG2 = 100 %, p ≤ 0.05); results given as mean activity and  standard deviation, (n = 4). 
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 Fig. 14. Gen expression of HepG2 cells: after 6 hours of incubation with 2 mM phenylalanine;  
significantly changed expression compared to untreated HepG2 cells (relative expression of untreated 
HepG2 = 100 %, p ≤ 0.05); results given as mean activity and  standard deviation, (n = 4). 
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 Fig. 15. Gen expression of HepG2 cells: after 24 hours of incubation with 10 mM DAHP, an inhibitor of 
GTPCH;  significantly changed expression compared to untreated HepG2 cells (relative expression of 
untreated HepG2 = 100 %, p ≤ 0.05); results given as mean activity and  standard deviation, (n = 4). 
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 Fig. 16. Gen expression of HepG2 cells: after 24 hours of incubation with 100 µM dicumarol an inhibitor of 
SR;  significantly changed expression compared to untreated HepG2 cells (relative expression of untreated 
HepG2  = 100 %, p ≤ 0.05); results given as mean activity and  standard deviation, (n = 4). 
 
 
We compared gene expression with the enzyme activity of GTPCH and SR and with 
intracellular biopterin/neopterin production. Most remarkable changes were achieved by 
treatment of HepG2 with sepiapterin which led to significant raise of the metabolites of the 
BH4-metabolism (Figure 17). Intracellular neopterin and biopterin concentration were increased 
by more than 100-fold, as well was the concentration of these two metabolites in the cell culture 
medium. But the enzyme activities of the SR and GTPCH were not affected by culturing 
HepG2 in presence of sepiapterin neither was the relative gene expression of these two enzymes 
(Figure 17). With exception of dicumarol treatment (inhibitor of SR) the activity of SR was not 
changed significantly by culturing the cells in presence of cytokines, sepiapterin, phenylalanine 
or DAHP. Neither was the activity of GTPCH significantly altered by treatment with any of 
above-named other than GTPCH inhibitor DAHP. No significant effects on the level of enzyme 
activity were observed using phenylalanine (results not shown). 
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 Fig. 17. Enzyme activity assays and neopterin and biopterin measurements in HepG2; results given as 
mean activity and standard deviation, (n = 3).;  untreated controls;  cells incubated for 24 hours 
with 100 µM sepiapterin; and  HepG2 stimulated with TNF-α and IFN-γ. A) GTPCH activity; B) SR 
activity; C) intracellular neopterin; D) intracellular biopterin; E) extracellular neopterin; F) extracellular 
biopterin. 
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Materials and Methods 
Following methods and reagents are mentioned in this chapter: 
 
 
 
Enzyme assays and measurement of pterins ............................................................................................... 120 
GTP cyclohydrolase I (GTPCH) assay ...................................................................... 120 
6-Pyruvoyltetrahydropterin synthase (PTPS) assay................................................... 123 
Sepiapterin reductase (SR) assay ............................................................................... 125 
Dihydropteridine reductase assay............................................................................... 127 
Phenylalanine hydroxylase (PAH) assay ................................................................... 129 
Neopterin and biopterin measurement of cell extracts and cell culture medium ....... 131 
Taurocholate uptake in sandwich-cultured hepatocytes ............................................. 132 
Cell culture and treatment with different reagents ...................................................................................... 133 
Cell lines..................................................................................................................... 133 
Thawing of cells ......................................................................................................... 134 
Freezing cells.............................................................................................................. 134 
Passaging.................................................................................................................... 134 
Cell counting .............................................................................................................. 135 
DME Medium ............................................................................................................ 135 
Mycoplasma staining.................................................................................................. 135 
Reagents used to treat cultured cells .......................................................................... 136 
Isolation primary hepatocytes .................................................................................... 137 
Cultivation of primary rat hepatocytes....................................................................... 137 
Sandwich cultures using hepatocytes......................................................................... 138 
Animals ...................................................................................................................... 140 
Gene expression experiments...................................................................................................................... 140 
Total RNA isolation from cultured cells .................................................................... 140 
First-strand cDNA synthesis ...................................................................................... 141 
Real time RT-PCR (TaqMan) .................................................................................... 141 
Real-time PCR using Micro Fluidic Cards ................................................................ 142 
Protein analysis ........................................................................................................................................... 142 
Bradford spectrophotometric method for protein determination ............................... 142 
General buffers, solutions and reagents ...................................................................................................... 142 
 
 
Enzyme assays and measurement of pterins 
Following enzyme assays and measurements of metabolites were performed: 
GTP cyclohydrolase I (GTPCH) assay 
This assay was performed as described in (Hatakeyama and Yoneyama 1998) with some 
modifications (Bonafé et al. 2001). It measures the conversion of the substrate GTP to neopterin 
triphosphate by GTPCH; neopterin triphosphate was detected by HPLC after oxidation and 
dephosphorylation as neopterin.  
  120 
 
GENE EXPRESSION OF BH4 STIMULATED CELLS 
 
Cultured cells from confluent 10 cm dishes were trypsinized and centrifuged at 200×g for 4 min, 
washed by resuspending the cell pellets in 5 mL PBS, then again centrifuged at 200×g for 4 min. 
The pellets were either kept at −20°C or were quick-frozen in liquid nitrogen and kept at −80°C 
for longer storage. 
The frozen cell pellets were suspended in 200 µL of 1 × homogenization-buffer and lysed by 6 
freeze-thaw cycles. Samples were centrifuged at 15000×g (tabletop centrifuge; Biofuge, 
Heraeus AG) for 5 min at 4°C. Each 150 µL of the recovered supernatant was loaded onto a 
pre-equilibrated MicroSpin G-25 sephadex column (Amersham Biosciences UK Ltd.) to desalt 
and remove ATP. They were centrifuged at 735×g for 2 min at 4°C. 50 µL of the filtrate was 
used in the assay the rest was kept for protein concentration determination according to 
Bradford method (Bradford 1976). The MicroSpin columns were prepared according to 
manufacturers instructions, in brief, the resin was resuspended and the bottom closure was 
snapped off. The column, in a 1.5 mL microfuge tube, was pre-spun for 1 min at 735×g and 
then equilibrated with 150 µL homogenization-buffer. Shortly before usage, the column was 
centrifuged again at 735×g for 2 min at 4°C, then loaded with the 150 µL recovered cell lysate 
and centrifuged as described above. 
The enzyme assay was performed as follows; 50 µL of the filtrate were mixed with 148 µL of 
1 × reaction buffer and 2 µL of 100 mM GTP in a 1-mL microcentrifuge tube on ice. For 
duplicates with half amount of protein, 25 µL of filtrate were used. The missing 25 µL were 
substituted with 25 µL 1 × homogenization buffer. The total volume of 200 µL was divided into 
two parts of 100 µL. One half was used as test sample the other half was used as blank sample. 
The test samples were incubated for 1 hour at 37°C in the dark. Additionally a cell-extract-free 
sample (containing 25 µL of 1 × homogenization buffer plus 1 µL of 100 mM GTP and 74 µL 
1 × reaction mixture) was incubated and treated like the test samples. After the incubation, the 
sample tubes were placed on ice and 10 µL oxidising solution was added. They were incubated 
for 1 hour at room temperature in the dark. To stop the reaction, 10 µL of ascorbic acid solution 
were added and mixed with the samples. In contrast to this, blank samples were directly 
oxidised with 10 µL oxidising solution as above without prior incubation. After 1 hour at room 
temperature in the dark, oxidation was stopped as well by addition of 10 µL of ascorbic acid. 
After this step, 14 µL of 1 M NaOH (to adjust the pH to 8.5) plus 20 µL of alkaline phosphatase 
solution B was added to all samples and blanks. This mixture was incubated for 1 hour at 37°C. 
The reaction was stopped by adding 5 µL of 2 M HCl. The samples (total volume 159 µL) were 
transferred to an Ultrafree-MC Centrifugal Filter Unit (Millipore Corporation USA, 10000 
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NMWL) and centrifuged for 15 min at 5000×g at 4°C in a tabletop centrifuge (Biofuge, 
Heraeus AG). Alternatively samples were centrifuged with YM-10 Microcon Centrifugal Filter 
Devices (Millipore Corporation USA, 10000 MWCO) at 14000×g for 15 min instead of 
Ultrafree-MC. The filtrate was stored either at −20°C until analysis or directly analysed for 
neopterin content using HPLC (liquor-system HPLC, injection volume 10 µL) as described in 
(Curtius et al. 1991; Zurflüh et al. 2005). 
Calculation of the activity: At 37°C one unit of GTPCH produces 1 mol of neopterin per minute. 
Measured neopterin values [nmol/L] of corresponding blank samples and of the cell-extract-free 
sample were subtracted from the test samples, then multiplied by 0.106 and divided by the 
protein concentration [mg/mL] in the desalted lysate. The result was given as µU per mg protein. 
Following solution and reagents were used: 
• 10 × reaction mixture (diluted to 1 × reaction mixture before use): 50 mL of 1 M Tris-
HCl (Fluka), pH 7.5 was mixed with 7.5 g KCl, 2 mL 0.5 M EDTA (Sigma) and 
100 mL H2O. 
• 1 × homogenization buffer (freshly prepared before usage): 2 µL 200 mM PMSF (Fluka) 
were mixed with 1 µL 2 mM leupeptin (Fluka), 1 µL pepstatin (Fluka) and 2 µL 1 M 
DTT (Fluka) in 2 mL 1 × reaction mixture. 
• 200 mM phenylmethanesulphonylfluoride (PMSF; (Fluka)): 34 mg per mL was 
dissolved in propan-2-ol (Fluka) and stored at room temperature. 
• 2 mM leupeptin (Fluka): 1 mg per mL was dissolved in ddH2O and stored at −20°C. 
• 2 mM pepstatin (Fluka): 1.4 mg per mL was dissolved in methanol (Fluka) and stored at 
−20°C. 
• 1 M dithiothreitol (DTT (Fluka)): 15.4 mg was dissolved per 100 µL ddH2O and stored 
at −20°C. 
• 100 mM GTP Li- salt (Roche): aliquots of 10 µL were stored at −20°C. 
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• Oxidizing solution: (0.5% iodine / 1% potassium iodide in 1 M HCl): 0.5 g potassium 
iodide (KI; Fluka) was mixed with 600 µL 1 M HCl and 0.25 g iodine (I2; Fluka). This 
mixture was diluted in 50 mL 1 M HCl. 
• 2% ascorbic acid solution (Fluka): 2 mg per 100 µL ascorbic acid were dissolved in 
ddH2O. This solution was freshly prepared. 
• Alkaline phosphatase solution B: 220 µL alkaline phosphatase, calf intestine, grade II 
(Roche Diagnostics GmbH) was mixed with 10 µL 1 M MgCl2, 10 µL 100 mM ZnCl2 
and 760 µL 0.1 M Tris-HCl, pH 8. Alternatively 220 µL alkaline phosphatase, calf 
intestine, grade I (Roche Diagnostics GmbH) diluted 1:10 in 3.2 M ammonium sulphate, 
2 mM MgCl and 0.1 M ZnCl2, pH = 7, was used instead. This solution was freshly 
prepared before usage. 
• 100 mM ZnCl2 (Fluka): 13.6 mg ZnCl2 per mL were dissolved in ddH2O. 
• Tris/MgCl2-solution: 1 M Tris-HCl, pH 9.6, 80 mM MgCl2: 46 mL 1 M Tris-HCl, 
pH 9.6, were mixed with 4 mL 1 M MgCl2 and stored at room temperature. 
6-Pyruvoyltetrahydropterin synthase (PTPS) assay 
This assay was performed as described in (Shintaku et al. 1988) with modifications (Bonafé et 
al. 2001). 
Cultured cells from a confluent 10 cm plate were harvested by trypsinization, then centrifuged 
at 200×g (Rotina 46, Hettich Zentrifugen) for 4 min, resuspended in 5 mL PBS and centrifuged 
again 200×g for 4 min. Cell pellets were either kept at −20°C or quick-frozen in liquid nitrogen 
and kept at −80°C for longer storage. 
The cell pellets were resuspended in 150 µL lysis buffer. After 6 times freeze-thaw-lysis, 
samples were centrifuged at 15’000×g for 5 min at 4°C in a tabletop centrifuge. Supernatant, 
containing the cell extract, was recovered. 
Samples were prepared in 1-mL microcentrifuge tubes on ice as follows: 50 µL of the cell 
extract plus 5.5 µL of 200 mM MgCl2 (10 mM final concentration), 5.5 µL 20 mM NADPH 
(1 mM final), 5.5 µL 20 mM NADH (1 mM final) and 2 µL SR (3 mU), 4.4 µL 50 mU/µL 
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DHPR (220 mU final), 13 µL NH2TP (60 µM final) and 24.1 µL of 0.1 M Tris-HCl, pH 7.4 
were mixed. 
The remaining cell extract was used for protein concentration determination according to 
Bradford method (Bradford 1976). 
Additionally a cell-extract-free blank was produced by mixing the same reagents as above but 
the 50 µL cell extract were replaced with 50 µL lysis buffer. 
Of this mixture each 50 µL were used for the test samples and 50 µL for the blank samples. Test 
samples were first incubated for 2 hours at 37°C, and then placed on ice. Blank samples were 
directly placed on ice. The procedure for the remaining steps of the assay was the same for all 
samples. 15 µL of 30% TCA was added to the samples, which were then centrifuged at 
15’000×g for 5 min. After this step 50 µL of the supernatant were recovered and oxidised with 
10 µL of a 1% I2-solution, then incubated for 1 hour at room temperature in the dark. The 
reaction was stopped by adding 15 µL 1% ascorbic acid to the mixture. 
The 75 µL reaction mixture was diluted 1:4 with 225 µL ddH2O, incubated for 2 hours at 60°C. 
Afterwards the samples were deproteinized by centrifugation (at 5000×g for 10 min) through 
Millipore Ultrafree-MC Centrifugal Filter Unit (10000 NMWL). 
Diluted samples were analysed by HPLC (Curtius et al. 1991; Zurflüh et al. 2005) for biopterin 
content (liquor system, 10 µL injection volume). 
Calculation of the enzyme activity: One unit of PTPS produces 1 µmol biopterin per min at 
37°C. After subtraction of corresponding sample blank and cell-extract-free blank, measured 
biopterin [nmol/L] concentration was multiplied by 0.036×4 (1:4 dilution) and divided by the 
protein concentration [mg/mL] leading to the enzyme activity [µU/mg protein]. 
Following solution and reagents were used: 
• Lysis buffer: 0.1 M Tris-HCl, pH 7.4 was diluted 1:10 with ddH2O and then mixed with 
1 mL per 100 mL Triton® X-100 (Fluka) and stored at room temperature. 
• 200 mM MgCl2 (Fluka): 4.07 g MgCl2·6 H2O was dissolved ad 100 mL with ddH2O and 
stored at room temperature. 
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• 20 mM NADPH (Roche Diagnostics AG): 16.7 mg NADPH was dissolved per 1 mL 
0.1 M Tris-HCl, pH 7.4, freshly prepared and kept on ice. 
• 20 mM NADH (Roche Diagnostics AG): 14.2 mg NADH was dissolved per 1 mL 
0.1 M Tris-HCl, pH 7.4, freshly prepared and kept on ice. 
• 3 mU sepiapterin reductase (SR): purified recombinant rat SR (Rec-rSR-His), approx. 
1.5 mU/µL stored at −80°C. 
• 220 mU dihydropteridine reductase (DHPR; Sigma): sheep liver DHPR, 50 U/mL, 
stored at −20°C. 
• 500 µM dihydroneopterin triphosphate (NH2TP): produced by using an immobilised 
GTPCH column, stored at −80°C. 
• 0.1 M Tris-HCl, pH 7.4, Fluka: diluted 1:10 with ddH2O from 1 M Tris-HCl buffer, 
pH 7.4. 
• 1 M Tris-HCl, pH 7.4 (Fluka): 12.1 g Tris were dissolved in ddH2O ad 100 mL and 
adjusted to pH 7.4 with HCl. 
• 30% trichloroacetic acid (TCA; Fluka): 3 g TCA was dissolved ad 10 mL in ddH2O. 
• 1% iodine (I2) solution: 2 g potassium iodide (KI; Fluka) and 1 g of iodine (I2; Fluka) 
were dissolved in 100 mL ddH2O and stored at room temperature in the dark. 
• 1% ascorbic acid (Fluka): 10 mg ascorbic acid were diluted per 1 mL ddH2O. Freshly 
prepared. 
Sepiapterin reductase (SR) assay 
This assay was performed as described in (Ferre and Naylor 1988) with modifications (Bonafé 
et al. 2001), it bases on the measurement of the conversion of sepiapterin to dihydrobiopterin 
(BH2) by SR. BH2 is detected as its oxidation product biopterin. 
Cultured cells from a confluent 10 cm plate were harvested (1% trypsin), centrifuged at 200×g 
(Rotina 46, Hettich Zentrifugen) for 4 min, resuspended in 5 ml PBS and then centrifuged again 
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(200×g, 4 min). Cell pellets were either stored at −20°C for some days or shock frozen in liquid 
nitrogen and stored at −80°C. 
Pellets were resuspended in 1 mL of lysis buffer and lysed by 6 cycles of freezing and thawing. 
The cell suspension was centrifuged at 15’000×g for 5 min at 4°C in a tabletop centrifuge. The 
cell extract (supernatant) was recovered. 
The assay was performed as follows: Samples were prepared in 1-mL microfuge tubes on ice; 
20 µL of the cell extract were mixed with 30 µL ddH2O and 50 µL of 2 × reaction buffer. This 
mix was divided into two portions of 50 µL. One half was used for the test samples, the other 
half for blank samples. In addition to this, a cell-extract-free blank was prepared, containing 
10 µL lysis buffer plus 15 µL ddH2O and 25 µL reaction buffer. A part of the cell extract was 
used for protein determination in accordance with the Bradford method (Bradford 1976). 
The test samples and the cell-free-blank were incubated at 37°C for 30 min in the dark. Then 
10 µL oxidising solution were added. Blank samples were immediately oxidised in this way 
without prior incubation. The oxidation reaction was stopped after a 30 min-incubation at room 
temperature in the dark by addition of 10 µL 1% ascorbic acid solution. 
All samples were diluted 1:2 with 70 µL ddH2O, then transferred to a Millipore Ultrafree-MC 
Centrifugal Filter Unit (10000 NMWL) and centrifuged at 5000×g for 15 min. Alternatively 
they were centrifuged using Millipore YM-10 Microcon Centrifugal Filter Devices at 14000×g 
for 15 min instead of Ultrafree-MC. 
The filtrate was stored at −20°C until analysis with HPLC (urine-system HPLC, injection 
volume 20 µL), as performed in (Curtius 1991; Zurflüh et al. 2005). 
The enzyme activity was calculated as follows: One unit of SR produces 1 µmol of biopterin 
per min at 37°C, i.e. measured blank sample and cell-extract-free blank values [µmol/L] were 
subtracted from measured test sample value and then multiplied with 233×2 (1:2 dilution) and 
divided by the protein concentration [mg/mL]. This resulted in the relative activity of SR 
[µU/mg protein]. 
Following solution and reagents were used: 
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• Lysis buffer: 20 mL 1 M potassium phosphate buffer, pH 6.4 was mixed with 2.2 g KCl 
(Fluka), 12.5 g glycerol (Fluka), 1 mL 0.5 M EDTA (Sigma) and 200 mL ddH2O and 
stored at room temperature. 
• 2 × reaction buffer: 100 µL 1 M potassium phosphate buffer, pH 6.4 was freshly mixed 
before use with 100 µL 1.25 mM sepiapterin (Schircks Laboratories, Switzerland), 
100 µL 250 µM NADPH and 200 µL ddH2O. 
• 1 M potassium phosphate buffer, pH 6.4 was prepared by mixing 1 M KH2PO4 (Fluka) 
with 1 M K2HPO4 (Fluka) to pH 6.4. 
• 1.25 mM sepiapterin: 3 mg sepiapterin (Schircks Laboratories, Switzerland) was 
dissolved in 10 mL ddH2O. Concentration was verified using a photometer (ελ at 
420 nm = 10400 M-1cm-1); aliquots of 100 µL in microfuge tubes aerated with N2 were 
stored at −80°C. 
• 250 µM NADPH (Roche Diagnostics AG): 2.1 mg NADPH were dissolved per mL 
0.1 M potassium phosphate buffer, pH 6.4, freshly prepared and kept on ice. 
• Oxidation solution: 0.5 g potassium iodide (KI, Fluka) dissolved in 600 µL 1 M HCl 
was mixed with 0.25 g iodine (I2, Fluka) and diluted with 50 ml 1 M HCl. It was stored 
at room temperature in the dark. 
• 1% ascorbic acid (Fluka): 10 mg ascorbic acid were diluted per 1 mL ddH2O. The 
ascorbic acid solution was freshly prepared before use. 
Dihydropteridine reductase assay 
This assay was performed as previously described in (Milstien et al. 1976) with some 
modifications, see (Bonafé et al. 2001). 
Cultured cells from 1 confluent 10 cm plate were trypsinized, then centrifuged at 200×g (Rotina 
46; Hettich Zentrifugen) for 4 min, resuspended in 5 mL PBS and centrifuged again 200×g for 
4 min. Cell pellets were kept either at −20°C or quick-frozen in liquid nitrogen and stored at 
−80°C within a few days. 
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Cell pellets were resuspended in 150 µL lysis buffer and disrupted by freezing and thawing six 
times. The lysate was centrifuged for 5 min at 15’000×g at 4°C in a table top centrifuge. 
Supernatant was recovered and used in the assay. 
Samples were prepared in 1 mL microfuge tubes as follows: 780 µL 50 mM Tris-HCl, pH 7.2 
was mixed with 10 µL 2500 U/mL peroxidase (25 U final), 10 µL 880 mM H2O2 (8.8 mM final), 
100 µL 10mM NADH (1 mM final) and 100 µL of the cell lysate. The remaining lysate was 
used for the measurement of the protein concentration according to (Bradford 1976). 
For each test sample a sample blank was prepared by mixing 880 µL 50 mM Tris-HCl, pH 7.2 
with 10 µL 2500 U/mL peroxidase, 10 µL 880 mM H2O2 (8.8 mM final) and 100 µL 10 mM 
NADH (1 mM final). Positive control contained 5 mU sheep liver DHPR (96 U/mL, Sigma) in 
880 µL 50 mM Tris-HCl, pH 7.2, 10 µL 2500 U/mL peroxidase, 10 µL 880 mM H2O2 (8.8 mM 
final) and 100 µL 10 mM NADH (1 mM final). 
After a 5 min pre-incubation at 25°C the absorbance of NADH at 340 nm of the test and blank 
samples was measured. Subsequently, 15 µL of 1 mM 6.7-dimethyltetrahydropterin was added 
as substrate for the DHPR. The samples were quickly mixed and the absorbance against 
corresponding blanks was measured at 25°C and 340 nm for 5 min. The change in absorption 
reflexes the consumption of NADH due to the reduction of the substrate 6.7-
dimethyltetrahydropterin catalysed by DHPR. 
Calculation of the enzyme activity: One unit of DHPR oxidises 1 µmol of NADH per minute at 
25°C. The difference of the absorbance was multiplied by 331 and divided by the protein 
concentration [mg/mL] leading to the relative enzyme activity [mU/mg protein]. 
Following solution and reagents were used: 
• Lysis buffer: 1.49 g KCl was dissolved in 20 mL 50 mM Tris-HCl, pH 7.4, diluted with 
ddH2O ad 200 mL and stored at 4°C (all Fluka). 
• 880 mM H2O2 (Fluka): 5 µL 35% H2O2 was mixed with 55 µL 50 mM Tris-HCl, pH 7.2. 
• 10 mM NADH: 7.09 mg NADH (Roche Diagnostics AG) was dissolved per mL 50 mM 
Tris-HCl, pH 7.2. The solution was freshly prepared and kept on ice. 
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• 5 mU DHPR: 2 µL 96 U/mL sheep liver DHPR (Sigma) were diluted in 998 µL 50 mM 
Tris-HCl, pH 7.2. Of this dilution 26 µL were mixed with 854 µL 50 mM Tris-HCl, pH 
7.2 to get a 5 mU/880 µL DHPR solution. 
Phenylalanine hydroxylase (PAH) assay 
This assay was adapted from the radiometric PAH assay (Ledley et al. 1987) 
Cultured cells from a confluent 10 cm plate were trypsinized, then centrifuged at 200×g (Rotina 
46, Hettich Zentrifugen) for 4 min, resuspended in 5 mL PBS and centrifuged again 200×g for 
4 min. Cell pellets were either kept at −20°C or quick-frozen in liquid nitrogen and kept at 
−80°C for longer storage. 
Cell pellets were resuspended in 200 µL lysis buffer (adapted from (Christensen et al. 2000)). 
After 6 times freeze-thaw-lysis, samples were centrifuged at 15’000×g for 5 min at 4°C in a 
tabletop centrifuge. Supernatants were recovered. 
Protein concentration in the supernatants was determined according to Bradford method 
(Bradford 1976). For the assay generally 50-100 µg of protein was used. 
Samples were prepared in microfuge tubes as follows: Blank samples; cell lysates (50-100 µg) 
were diluted with H2O to a final volume of 104 µL. They were incubated for 5 min at 95°C in a 
heating block.  
Test samples: The same amount of cell lysate as in the blank samples was diluted with H2O to a 
final volume of 77.5 µL. 1 µL 60 mM phenylalanine, 1.5 µL catalase (3.6 U final), 10 µL 2 M 
potassium-phosphate buffer and 10 µL 1.5 M potassium chloride were added. This mixture was 
pre-incubated at room temperature for 5 min, then 2 µL 0.1 M dithiothreitol plus 2 µL 4.5 mM 
6-MePH4 was added, followed by a 1-hour incubation at 25°C. The reaction was stopped by 
placing the samples for 5 min in a 96°C heating block. Thereafter they were put on ice for 5 min. 
Test samples and blank samples were spun down at 10’000×g in a tabletop centrifuge. 
Supernatants were transferred into a Millipore Ultrafree-MC Centrifugal Filter Unit (10000 
NMWL) and centrifuged at 5000×g for 10 min. 
Phenylalanine and tyrosine levels in the filtrate were measured using an amino acid analyzer 
(Biochrom 20 Plus; Amersham Pharmacia-Biotech). The PAH activity was calculated as 
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(∆[tyrosine] (test sample − blank sample) [µmol/L] × 104 divided by (µL lysate / assay × 
incubation time [min] × mg/mL protein) = mU PAH / mg protein. 
Following solution and reagents were used: 
• Lysis buffer: 200 uL 2 M potassium phosphate buffer was mixed with 200 µL 1.5 M 
KCl, 2 µL 200 mM PMSF, 1 µL 2 M leupeptin, 1 µL 2 M pepstatin and filled up to 
2 mL with ddH2O. The buffer was freshly prepared and kept on ice (all Fluka) 
• Homogenisation buffer: 1.15 g potassium chloride (KCl, Fluka) was dissolved in 
100 mL ddH2O, mixed with 5 µL β-SH-EtoH (Fluka) and stored at room temperature. 
• 60 mM L-phenylalanine (Fluka): 50 g L-phe was dissolved in 5 mL ddH2O. 
• 4000 U/mL catalase (Sigma): C-100 bovine liver catalase (approx. 50’000 U/mg) was 
diluted to 4000 U/mL in 10 mM Tris, pH 7.4 and aliquoted into single use tubes. 
Storage at −20°C. 
• 2 M potassium phosphate buffer, pH 6.8: 13.6 g KH2PO4 (Fluka) and 22.8 g K2HPO4 
(Fluka) were dissolved in 100 mL ddH2O. The buffer was stored at room temperature. 
• 1.5 M potassium chloride: 11.18 g KCl (Fluka) was dissolved in 100 mL H2O. 
• 4.5 mM 6-methyltetrahydropterin (Schircks Laboratories): 11.4 mg 6-MePH4 was 
dissolved in 10 mL degased H2O. Single use aliquots were stored at −20°C. 
• 0.1 M dithiothreitol (Fluka): 15.4 mg DTT was solved in 1 mL ddH2O and stored in 
aliquots at −20°C. 
• 200 mM phenylmethanesulphonylfluoride (PMSF; Fluka): 34 mg per mL was dissolved 
in propan-2-ol, Fluka, and stored at room temperature. 
• 2 mM leupeptin (Fluka): 1 mg per mL was dissolved in ddH2O and stored at −20°C. 
• 2 mM pepstatin (Fluka): 1.4 mg per mL was dissolved in methanol (Fluka) and stored at 
−20°C. 
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Neopterin and biopterin measurement of cell extracts and cell culture medium 
Cell extracts were prepared as follows: Cells from 1 confluent 10 cm plate of were trypsinized 
and centrifuged at 200×g for 4 min then washed by resuspending the cell pellet with 5 mL PBS 
and again centrifuged at 200×g for 4 min. The pellet was either kept at −20°C or was quick 
frozen in liquid nitrogen and kept at −80°C for longer storage until use. 
The frozen cell pellets were suspended in 200 µL of TED-buffer and lysed by 6 freeze-thaw 
cycles. Samples were centrifuged at 15000×g (tabletop centrifuge) for 5 min. at 4°C and the 
supernatants were recovered. 100 µL of the lysate were used in the assay the rest was kept for 
protein concentration determination according to Bradford method (Bradford 1976). 
Samples were prepared as follows: In a 1 mL microcentrifuge tube 100 µL lysate were mixed 
with 6 µL 1 M HCl and 20 µL 1% I2 solution and incubated at room temperature for 15 min in 
the dark (alternatively only 50 µL of lysate plus 50 µL of additional TED-buffer for duplicates 
with half amount of protein or 50 µL of supernatant cell culture medium plus 50 µL TED-buffer 
for the measurement of excreted pterins were used). After incubation 20 µL of 1% ascorbic acid 
solution and 12 µL 1 M Tris-HCl (pH 9.6), 80 mM MgCl2 were added. Following a 1 hour 
incubation at 37°C, 7 µL 2 M HCl were added and the mixture was transferred to a Millipore 
Ultrafree-MC Centrifugal Filter Unit (10000 NMWL) and centrifuged for 15 min at 5000×g at 
4°C in a tabletop centrifuge. Alternatively samples were centrifuged with Millipore YM-10 
Microcon Centrifugal Filter Devices at 14000×g for 15 min instead of Ultrafree-MC. The 
filtrate was stored either at −20°C until analysis or directly analysed for pterins with the HPLC, 
urine-system HPLC, injection volume 20 µL as described in (Curtius et al. 1991; Zurflüh et al. 
2005). 
Calculations: Measured neopterin and biopterin values (in µmol/L) were multiplied by 1750 and 
divided by the protein concentration in the lysate (in mg/mL). The result was given as pmol per 
mg protein. In the case of measurement of pterins in the cell culture medium the HPLC result 
(in µmol/L) was multiplied by 3500 and given as pmol per mL. 
Following solution and reagents were used: 
• TED-buffer (50 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 mM DTE): 0.5 mL 1 M Tris-
HCl, pH 7.4; 20 µL 0.5 M EDTA (Sigma) plus 1.5 mg DTE (Fluka) were dissolved in 
10 mL ddH2O. 1 mL aliquots were stored at −20°C.  
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• 1% iodine: 2 g potassium iodide (KI; Fluka) and 1 g of iodine (I2; Fluka) were dissolved 
in 100 mL ddH2O and stored at room temperature in the dark. 
• 1% ascorbic acid: 1 mg L-ascorbic acid (Fluka) per 100 µL H2O was prepared freshly 
before use. 
• 1 M Tris-HCl, pH 9.6, 80 mM MgCl2: 46 mL 1 M Tris-HCl, pH 9.6, were mixed with 
4 mL 1 M MgCl2 and stored at room temperature (all Fluka). 
• Alkaline phosphatase solution B: 220 µL alkaline phosphatase, calf intestine, grade II 
(Roche Diagnostics GmbH) were mixed with 10 µL 1 M MgCl2, 10 µL 100 mM ZnCl2 
and 760 µL 0.1 M Tris-HCl, pH 8. Alternatively 220 µL alkaline phosphatase, calf 
intestine, grade I (Roche Diagnostics GmbH) diluted 1:10 in 3.2 M ammonium sulphate, 
2 mM MgCl and 0.1 M ZnCl2, pH = 7, was used instead. This solution was freshly 
prepared before usage. 
• 2 M HCl (Fluka): 16.7 mL 37% HCl was mixed with 100 mL ddH2O and stored at room 
temperature. 
• DTE: 1,4-Dithioerythritol (Fluka) 
Taurocholate uptake in sandwich-cultured hepatocytes 
The uptake assay of bile acid (taurocholate) into hepatocytes was performed as described in 
(Liu et al. 1998; McRae et al. 2006) with modifications. 
Adherent hepatocytes on culture plates were washed 3 times with warm choline buffer (3 mL 
each, 37°C), and then the cells were incubated in 2 mL taurocholate/choline solution (37°C) for 
10, 20, and 30 min at 37°C. For the blank value (0 min incubation) 2 mL cooled (4°C) 
taurocholate/choline solution was added and aspired immediately after. 
The reaction was stopped by 3 times washing the cells with ice-cold choline buffer. Cells were 
lysed with 2 mL/plate 1% Triton X-100. After a 10 min incubation, cells were detached with a 
rubber policeman and 1 mL lysate was transferred into a counter vial (the remaining lysate was 
used for determination of the protein content according to (Bradford 1976)). 5 mL Ultima Gold 
cocktail (PerkinElmer) were added and the cell lysates were analysed by liquid scintillation 
spectroscopy. 
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In parallel the same assay was performed replacing the choline buffer in all steps with a sodium 
buffer. 
As a negative control for the uptake choline buffer containing 1 µM saquinavir with or without 
100 µM estrone-3-sulfate were used. 
Following solution and reagents were used: 
• Sodium buffer: 400 mg KCl, 150 mg KH2PO4, 200 mg MgSO4 ×7 H2O, 265 mg 
CaCl2 ×2 H2O (Merck), 2.0 g D-glucose (Merck), 4.76 g hepes and 6.8 g NaCl were 
solved in H2O to 1 L. pH was adjusted to 7.4. 
• Choline buffer: 400 mg KCl, 150 mg KH2PO4, 200 mg MgSO4 ×7 H2O, 265 mg 
CaCl2 ×2 H2O, 2.0 g D-glucose, 4.76 g hepes and 16.20 g choline chloride were solved 
in H2O to 1 L. pH was adjusted to 7.4. 
• Taurocholate/choline solution: 2.8 µL [3H]taurocholate stock solution (1 mCi/mL) was 
mixed with 7 µL cold taurocholate stock solution (10 mM) and diluted with 14 mL 
choline buffer (0.2 Ci/mL and 5 µM final). 
• Taurocholate/sodium solution: 2.8 µL [3H]taurocholate stock solution (1 mCi/mL) was 
mixed with 7 µL cold taurocholate stock solution (10 mM) and diluted with 14 mL 
sodium buffer (0.2 Ci/mL and 5 µM final). 
 
Cell culture and treatment with different reagents 
Cell lines 
Following cell lines were employed: 
• CCF-STTG 1; homo sapiens brain-, astrocytoma cells (ATCC) 
• HCN-1A; homo sapiens brain-, cortical neuron cells (ATCC) 
• HepG2; homo sapiens, liver hepatocellular carcinoma (kind gift from Gerd A. Kullak-
Ublick Klinische Pharmakologie und Toxikologie) 
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• HHL-17/HHI-16; Homo sapiens; primary hepatocytes, immortalised with Moloney's 
mouse leukaemia virus (kind gift from Dr. Arvind Patel MRC Virology Unit, Institute 
of Virology Glasgow). 
• KB; homo sapiens, HeLa contaminant 
• SK-N-BE; homo sapiens; bone marrow, neuroblastoma (ATCC) 
• THLE-3; Homo sapiens; liver; left lobe; epithelial; immortalised with SV40 large T 
antigen (ATCC); derived from normal liver cells. 
• Fibroblasts; homo sapiens, connective tissue: 
FB Ko 1; normal control fibroblasts 
FB Ko 2; normal control fibroblasts 
FB SRdef, SR deficiency 
FB GCHdef 1, GTPCH deficiency 
FB GCHdef 2, GTPCH deficiency 
 
Thawing of cells 
Cells were quickly thawed in a 37°C water bath. Shortly before all ice was gone, cells were 
suspended usually in 10 mL fresh DMEM medium in a 10 cm plate. 
Freezing cells 
Adherent cells were washed once with 5 mL PBS (AMIMED, Bioconcept Switzerland) on the 
plate, then detached with 1 mL 1 × trypsin and incubated for some min at 37°C. The reaction 
was stopped by adding 5 mL medium. Cell suspension was transferred to 15 mL centrifugation 
tubes (Techno Plastic Products AG, Switzerland) and spun down at 200×g for 5 min. 
Supernatant was aspired and the pellet was resuspended in 3 mL ice-cold freezing medium. 
Aliquots of 1 mL in cryo-tubes, insulated with cotton wool, were kept at −80°C for 3 days and 
afterwards stored in liquid nitrogen. 
Passaging 
Cells were usually splitted around 90% confluency. First the cells were washed once with 3 to 
5 mL PBS per dish, and then detached with 1 mL trypsin (incubation for approx. 5 min at 37°C). 
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Cells were splitted into several portions depending on requirements and resuspended each in 
10 mL medium per plate. 
Cell counting 
Confluent cells of one 10 cm plate were trypsinized and suspended in 10 mL medium, then 
200 µL of the cell suspension was mixed with 300 µL PBS and 500 µL trypan blue (Bio 
Whittaker) and incubated for 5 to 15 min at room temperature, then pipetted onto the Neubauer-
counting chamber. Cells on 1 big square (1 mm2 ↔ 0.1 mm3) were counted and the 
concentration was calculated: Number of cells per square multiplied by 5 (dilution factor) × 104 
= Number of cells per mL cell suspension. 
DME Medium 
One dose of Dulbecco’s modified eagle medium (Gibco) plus 18.5 g NaHCO3 (Fluka) were 
dissolved in 5 L ddH2O. The pH was adjusted to 7.2 with HCl. The medium was sterile filtered 
(MediaKap-5 0.2 µm Microgon) which changed the pH to 7.4. Then the DMEM was bottled in 
500 mL portions and stored at 4°C. Before use, 50 mL foetal bovine serum (FBS; Gibco) plus 
5 mL penicillin/streptomycin was added. Storage at 4°C in the dark. 
Mycoplasma staining  
Cells were analysed for mycoplasma contamination; cells were cultured on 60 mm plates to 
approx. 70% confluency. Culture medium was removed and the adherent cells were washed 2 
times with 2 mL PBS, then cells were fixed by incubation with 1 mL formaldehyde solution at 
37°C for 20 min. The formaldehyde solution was aspirated and cells were permeabilised by 
washing with cold methanol (−20°C) one time and were then soaked again in 2 mL cold 
methanol. After an incubation of 30 min at room temperature, the methanol was removed and 
the culture plate was washed 10 times with H2O. The cells were dyed with 2 mL staining 
solution for 15 min at 37°C in the dark, then washed again 10 times with H2O. Cells were 
analysed using a fluorescence microscope, 25 × objective immersed in water. Normal cells 
would show nuclear fluorescence, infected cells a dotted fluorescence in the cytoplasm. 
Following solution and reagents were used: 
Formaldehyde solution: 0.5 mL 37% formaldehyde (Fluka) and 5 µL 1 M MgCl2-solution were 
diluted with 4.5 mL 1×PBS. 
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Staining solution: 1 µL of Hoechst stain stock solution was diluted with 10 mL aqueous 0.9% 
NaCl-solution. The staining solution was freshly prepared before usage. 
Reagents used to treat cultured cells 
Cultured cells from a ~90% confluent 10 cm dish were incubated for 24 hours with following 
agents and various mixtures thereof in 5 mL fresh DMEM or other appropriate cell culture 
medium: 
• 2.5 µL IFN-γ (1250 U; Sigma) 
• 2.5 µL TNF-α (500 U; Sigma) 
• 10-100 µM sepiapterin (Schircks Laboratories) from a 1.25 mM stock solution (stored at 
–80°C). During handling with sepiapterin, light was dimmed in the working area and 
cells and sepiapterin were protected from light until the cells were harvested. 
• 2-4 mM phenylalanine (Sigma) from a 100 mM stock solution (stored at 4°C) was either 
incubated for 24 or preferably 6 hours. 
• 10 mM 2,4,-diamino-6-hydroxypyrimidine (DAHP; Aldrich) was added from a freshly 
prepared 20 mM DMEM/DAHP stock solution. 
• 100 µM 3.3’-methylene-bis(4-hydroxycoumarin) (dicumarol; Sigma) were added from a 
freshly prepared 167 µM DMEM/dicumarol stock solution. 
Penicillin/streptomycin (penstrep; Gibco): aliquots of 10 mL containing 5000 U penicillin/mL 
and 5000 µg streptomycin/mL were stored at −20°C. 
10 × Trypsin-EDTA (5% trypsin, 5.3 mM EDTA·4 Na; Gibco): 10 × trypsin was diluted 1:10 
with ddH2O, aliquoted in 10 mL and stored at −20°C. 
1 × PBS: 10 × PBS (Gibco) was diluted 1:10 with ddH2O and stored at room temperature. 
Freezing Medium (DMEM/10% DMSO/20% FBS): freezing medium was produced by mixing 
80 mL DMEM (containing 10% FBS and penstrep) was mixed with 10 mL FBS (Gibco) and 
10 mL DMSO (Sigma). Storage at 4°C in the dark. 
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Interferon-γ human (IFN-γ; Sigma): 1×106 U/vial were dissolved in 2 mL PBS (1250 U/2.5 µL). 
Aliquots of 100 µL were stored at −20°C. 
Tumour necrosis factor-α (TNF-α; Sigma): 2×105 U/vial were diluted in 1 mL PBS 
(500 U/2.5 µL) and aliquots of 100 µL were stored at −20°C. 
Isolation primary hepatocytes 
Liver perfusion was performed using a modified method for a two-step collagenase perfusion 
(Berry and Friend 1969; Boelsterli et al. 1995; Sidler Pfändler et al. 2004). In short; rats were 
narcotised with Nembutal (Abbott Laboratories), (0.15 mL/100 g rat). 0.25 mL heparin 
(500 U/100 g rat) was injected into the femoral vein. The liver was in situ perfused with pre-
perfusion solution for 5 min at 37°C. Then the liver was carefully removed and perfused with 
recycling perfusion solution for 12 min at 37°C. After the liver got soft the liver was placed in a 
Petri dish with 10 mL ice-cold WME solution A to stop collagenase activity. Thereafter the 
perfused lobes of the liver were opened and the liver was swivelled in the solution to release the 
hepatocytes. The cell suspension was filtered twice through a metal sieve (first: 280 µm, 50 
mesh; second: 190 µm, 80 mesh) and distributed to 4×50 mL centrifugation tubes. The 
suspension was filled up to 50 mL with ice-cold WME A medium and centrifuged for 2 min at 
4°C and 20×g. Supernatant was aspired, the cells were carefully resuspended with 50 mL ice-
cold WME medium A and the centrifugation step was repeated. The supernatant was aspired 
again and the cell pellet was depending on yield resuspended in 20 mL cold WME medium A. 
After isolation of the primary hepatocytes, the number and the vitality of the cells in the 
suspension were determined using a haemocytometer (Neubauer-counting chamber). 100 µL 
cell suspension was diluted 1:10 with 0.9% NaCl solution. 450 µL of the dilution were mixed 
with 50 µL trypan blue (Bio Whittaker) and incubated for exactly 2 min. Thereafter the 
suspension was pipetted onto the Neubauer-counting chamber. Each 100 cells in three different 
quadrants were counted and the vitality was given as percentage of unstained (viable) cells to 
totally counted cells. Then all unstained cells on 4 big squares were counted and the total 
number of vital cells was calculated (average number of cells per square × 106 = number of 
viable cells in the undiluted suspension/mL). 
Cultivation of primary rat hepatocytes 
Cells were diluted with WME medium A to a concentration of 0.7×106 cells/mL and 3 mL of 
this suspension was plated per 6 cm collagen coated culture dish (2.1×106 cells per dish). 
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During the first 3 hours the cells were incubated in WME medium A (5% CO2 (vol/vol), at 
37°C) then the medium was changed to WME medium B (3 mL). The WME medium B was 
thereafter changed daily. 
Sandwich cultures using hepatocytes 
Hepatocytes sandwich cultures were prepared in a modified version as previously published by 
Berthiaume et al. and Wang et al. (Berthiaume et al. 1996; Wang et al. 2004). Freshly isolated 
hepatocytes were plated on 6 cm collagen coated culture dishes as described above. The cells 
were allowed to attach and 2 hours after the change from WME medium A to B, the medium 
was aspired, and cells were covered with 150 µL/plate, ice-cold, neutralised collagen solution. 
After a 1 hour incubation at 37°C to jelly, 3 mL fresh WME medium B was added. WME 
medium B was renewed daily. 
Following solution and reagents were used: 
• Hank’s balanced salt (HBS) solution: 0.4 g KCl, 0.06 g KH2PO4, 8 g NaCl, 0.35 g 
NaHCO3 (Gibco), 0.048 g Na2HPO4 ×2 H2O, 1 g D-glucose solved in ddH2O to 1 L, pH 
adjusted to 7.4. The solution was sterile filtered and stored at 4°C (all other chemicals; 
Merck) 
• 50 mM Ethylene glycol tetraacetic acid (EGTA; Sigma) stock solution: 19.03 g/L 
EGTA was solved in ddH2O; pH was adjusted to 7.4 with 10 mM NaOH. The solution 
was sterile filtered and stored in 10 mL aliquots at −20°C. 
• 1 M HEPES (Sigma): 238.3 g/L HEPES was solved in ddH2O, pH was adjusted to 7.4 
using 10 M NaOH. The solution was sterile filtered and stored in 10 mL aliquots at 
−20°C. 
• Heparin (Sigma) 500 U/100 g rat: Heparin was diluted with 0.9% NaCl to a 
concentration of 500 U/250 µL 0.9% NaCl. Pre-perfusion solution (400 mL): 4 mL 
50 nM EGTA (final 500 µM) was mixed with 8 mL 1 M (final 20 mM), filled up to 
400 mL with Hank’s (HBS)and sterile filtered. 
• Perfusion solution (250 mL) 438.17 mg NaHCO3 was dissolved in 200 mL Hank’s 
(HBS) and mixed with 125 mg BSA (Sigma). 184.42 mg CaCl2 × 2 H2O was dissolved 
in 30 mL Hank’s (HBS) and slowly mixed with above NaHCO3 solution. The mixture 
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was filled up to 250 mL with Hank’s, sterile filtrated and aerated with a 
95% O2/5% CO2 mixture. 83.3 mg collagenase (25’00 U/250 mL; Type 2 CLS 2; 
Worthington) was dissolved in 10 mL perfusion solution. Immediately before use, the 
collagenase was added to the remaining perfusion solution through a 0.45 µm filter. 
• Williams medium for hepatocytes (AMIMED, Bioconcept AG): to 500 mL WME, 
5 mL L-glutamine (2 mM final; Gibco), 5 mL penicillin/streptomycin (Gibco), 
100 U/mL final) and 50 mL FCS (10% final) were added. Storage at 4°C. 
• Insulin stock solution (250 U/mL; bovine pancreas; Sigma): 100 mg (24.5 U/mg) was 
dissolved in 10 mL 0.01 M HCl and stored at 4°C. 
• Insulin solution A (25 U/mL): insulin stock solution was diluted 1:10 with 0.01 M HCl 
– storage at 4°C. 
• Insulin solution B (2.5 U/mL): insulin solution A was diluted 1:10 with 0.01 M HCl and 
kept at 4°C. 
• Dexamethasone (0.1 mM; Sigma): a bottle of dexamethasone (1 mg) was dissolved in 
277 µL EtOH and diluted with 25.203 mL H2O. The solution was stored at 4°C. 
• WME medium A (seeding medium): 400 mL WME medium (L-Glu/Pen/Strep/FCS) 
was mixed with 40 µL insulin solution A (2.5 mU/mL final) and 4 mL dexamethasone 
(1 µM final). The medium was stored and used ice cold. 
• WME medium B (culture medium): 500 mL WME medium (L-Glu/Pen/Strep/FCS) was 
mixed with 50 µL insulin solution B (250 µU/mL final) and 500 µL dexamethasone 
(0.1 µM final). The medium was stored at 4°C and warmed up to 37°C before use. 
• Collagen coated culture plates: collagen R (Serva) parent solution (2 mg/mL) was 
diluted 1:160 with ddH2O (12.5 µg/mL final). For 3 cm dishes 1 mL of the above 
solution was used and for 6 cm plates 2 mL were used. Collagen was poured onto 
Falcon Primaria plates (BD Biosciences) and incubated for 1 h at 37°C. Afterwards 
plates were washed 3 times with sterile 0.9% NaCl (2 mL for 3 cm plates and 3 mL for 
6 cm, respectively) and stored in a sterile hood overnight. Alternatively pre-coated 6 cm 
plates from Sarstedt were used. 
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• Neutralised collagen solution (1 mg/mL): 500 µL collagen R parent solution (2 mg/mL) 
was diluted with 500 µL 1 M HEPES buffer pH 7.2-7.5 (GIBCO) Ascorbic acid 2-
phosphate (Sigma): 
Animals 
Male Sprague-Dawley rats (RCC) weighing between 210 g and 300 g were used for the 
isolation of the hepatocytes. The animals had free access to water, were fed ad libitum and 
housed in a constant alternating 12-hour light (6.30 am to 6.30 pm) and dark cycle. They 
received human care in accordance with the local animal protection authorities (Sidler Pfändler 
et al. 2004). 
 
Gene expression experiments 
Total RNA isolation from cultured cells 
Total RNA was isolated from adherent cultured cells using QIAamp® RNA Blood Mini Kit 
(QIAGEN) according to supplier’s recommendations (QIAGEN 1999). In brief, culture 
medium was aspirated; cells were washed with 5 mL PBS and then harvested. The cells were 
either trypsinized or detached using a rubber policeman (only primary rat hepatocytes). 3 mL 
culture medium was added to the cells, then they were transferred to a 15-mL centrifugation 
tubes (Sarstedt), and pelleted by centrifugation at 300×g for 5 min. Supernatant was aspirated 
and the pellet quickly washed with 3 mL PBS (centrifuged again at 300×g for 3 min., 
supernatant was discarded). Cells were disrupted by mixing with 350-600 µL RLT buffer, 
containing β-SH-EtOH. The cell lysate was transferred on a QIAshredder spin column and 
homogenised. 1 volume of 70% ethanol was added to the cell lysate, which was pipetted onto a 
QIAamp spin column. 350 µL of RW1 buffer was pipetted onto the column and centrifuged. 
Then, DNA was digested according to appendix D (QIAGEN 2006) in the protocol using 80 µL 
RNase-free DNase I in RDD buffer (QIAGEN). After a 15-min incubation at room temperature, 
samples were washed again with 350 µL RW1 buffer. Thereafter 500 µL RPE buffer was 
pipetted into the column, centrifuged and another 500 µL RPE buffer was added. Samples were 
centrifuge and to eliminate any chance of possible RPE buffer carryover, columns were 
transferred into new collection tubes and centrifuged again (optional step 8a in the protocol). 
Samples were eluted with 30 µL RNase-free H2O.  
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Total RNA of the samples quantity was measured in accordance with appendix B (QIAamp® 
RNA Blood Mini Handbook) carried out with RNA-dilutions in nuclease-free H2O) and the 
purity was assessed using RNA-dilution in 10 mM Tris-HCl, pH 7.5, also according to 
appendix B. A260/A280 ratios of 1.9-2.3 were assumed as acceptable. 
Total RNA samples were stored at −20°C.  
All solutions and reagents were supplied with the QIAamp® RNA Blood Mini Kit. 
First-strand cDNA synthesis 
cDNA was produced using the Reverse Transcription System (Promega) according to 
manufacturer’s instructions. In brief, samples containing 1 µg total RNA per 9.75 µL nuclease-
free H2O were incubated at 70°C for 10 min in a microfuge tube, then briefly spun down and 
placed on ice. PCR-tubes containing following mix were prepared: 4 µL 25 mM MgCl2, 
10 × reverse transcription buffer, 2 µL 10 mM dNTP mixture, 0.5 µL recombinant RNasin 
ribonuclease inhibitor, 0.75 µL 20 U/µL AMV reverse Transcriptase (15 U final), 1 µL 
500 µg/mL random primers plus 9.75 µL of the before prepared total RNA samples in nuclease 
free H2O (50 ng/µL final). The reaction was first incubated for 10 min at room temperature 
(22°C), then at 42°C for 15 min. After this step, samples were heated to 95°C for 5 min, then 
cooled down to 4°C for 5 min. All incubation steps were performed on a GeneAmp PCR 
System 9700 (Applied Biosystems). Synthesised first-strand cDNA was stored at −20°C until 
use. 
All solutions and reagents were supplied with the Reverse Transcription System. 
Real time RT-PCR (TaqMan) 
TaqMan samples were prepared as follows in 96-well optical plates (MicroAmp Optical 96-
Well Reaction Plate; Applied Biosystems): per well 12.5 µL 2 × TaqMan PCR Master Mix 
(Applied Biosystems) was mixed with 1.25 µL of the appropriate 20 × Assay mix (Biosystems) 
and 11.25 µL first-strand cDNA in nuclease-free H2O (25 µL final reaction volume). Usually 
30-50 ng cDNA per well were used. All samples were measured in triplicates. The 96-well plate 
was closed with optical foil (MicroAmp Optical Adhesive Film; Applied Biosystems) briefly 
spun down at 1500 rpm and then analysed with a ABI Prism 7700 (Applied Biosystems) 
TaqMan device according to manufacturer’s instructions; thermal cycling conditions used were 
2 min at 50°C, 10 min at 95°C, (15 s at 95°C, 1 min at 60°C) × 40 cycles. Ct values were 
exported to MS excel and difference in expression (∆∆Ct-value) of the various genes of the 
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samples were calculated according to the comparative ∆Ct-method. Expression was normalised 
using an endogenous control (either GAPDH or 18S-RNA). 
Real-time PCR using Micro Fluidic Cards 
RT-PCR was performed according to supplier’s guidelines, in brief: first strand cDNA samples 
were diluted with nuclease-free H2O to 10 ng/µL. In a 1.5-mL microfuge tube usually 100 ng of 
first strand cDNA was then diluted with nuclease-free H2O to a total volume of 50 µL per 
sample. 50 µL 2×TaqMan Universal PCR Mix (Applied Biosystems) was added and the 
samples were thoroughly mixed by gentle vortexing. The microfuge tubes were quickly spun 
down. Then the Micro Fluidic Cards were loaded with the samples; 100 µL of the solution per 
fill reservoir, eight samples at a time per card. 
The Micro Fluidic Card was centrifuged 2 × at 1200 rpm for 1 min (Sorvall Legend T 
Centrifuge with Sorvall/Heraeus custom buckets and card holder). After centrifugation it was 
closed using a Micro Fluidic Card Sealer. Filling reservoirs were cut off and the card was run on 
an ABI Prism 7900HT real-time PCR device (Applied Biosystems). The RT-PCR was 
performed under following conditions for relative quantification: 2 min at 50°C, 10 min at 
94.5°C, then 40 cycles of 30 s at 97°C and 1 min at 59.7°C. 
Datasets from the SDS enterprise database were exported as Ct values to MS excel and 
differences in expression (∆∆Ct-value) of the various genes of the samples were calculated 
according to the comparative ∆Ct-method. Expression was normalised using an endogenous 
control (either GAPDH, 18S-RNA or ACTB (β-actin)). 
 
Protein analysis 
Bradford spectrophotometric method for protein determination 
Protein concentrations in cell lysates were determined by Biorad Microassay according to 
(Bradford 1976) and using bovine γ-globulin as a calibrator. 
 
General buffers, solutions and reagents 
2 M HCl (Fluka): 16.7 mL 37% HCl were diluted in 100 mL ddH2O. 
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1% ascorbic acid (Fluka): 1 mg L-ascorbic acid per 100 µL H2O was freshly prepared before 
use. 
Alkaline phosphatase (Roche Diagnostics GmbH), 10 mg/mL containing 1400 U/mL or 
alkaline phosphatase, calf intestine, grade I (Roche Diagnostics GmbH) diluted 1:10 in 3.2 M 
ammonium sulphate, 2 mM MgCl and 0.1 M ZnCl2, pH = 7, was used instead. The phosphatase 
was diluted shortly before usage and stored at 4°C. 
2 M HCl: 16.7 mL 37% HCl was mixed with 100 mL ddH2O and stored at room temperature. 
A 10 litre stock of 10x PBS can be prepared by dissolving 800 g NaCl, 20 g KCl, 144 g 
Na2HPO4 and 24 g KH2PO4 in 8 L of distilled water, and topping up to 10 L. The pH is ~6.8, 
but when diluted to 1x PBS it should change to 7.4. 
On dilution, the resultant 1x PBS will have a final concentration of 137 mM NaCl, 10 mM 
Phosphate, 2.7 mM KCl, pH 7.4 
50 mM Tris-HCl, pH 7.2: 6.1 g Tris was dissolved ad 1000 mL with ddH2O, pH was adjusted to 
7.2 using HCl. 
 
Discussion 
In the present study, gene expression of proteins and enzymes responsible for BH4 de novo 
biosynthesis, regeneration and regulation was investigated in different cell systems. 
Additionally several genes associated with alternative pathways of BH4 synthesis and of the 
salvage pathway had been examined. We also engaged in gene expression profile of enzymes 
which use BH4 as essential cofactor. 
In a first step we attempted to find an cell line which expresses all enzyme activities of the 
enzymes involved in synthesis and regeneration of BH4. Most promising were found to be the 
cell lines SK-N-BE and HepG2, which provided the major activities also in absence of known 
stimulants. 
Many cell lines isolated from tissues of tumour patients present with abnormal metabolism and 
not all genes of interest may be expressed. Primary rat hepatocytes may serve our purpose and 
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were investigated. Unfortunately, they proved a limited lifetime of GTPCH and PAH activity. 
We tried to overcome this drawback by culturing these cells in collagen sandwiches. It has been 
observed that primary hepatocytes, grown between such sandwich layers, expressed over 
increased periods specific hepatic functions, as the conditions are much closer to the in vivo 
environment compared to normal 2D-monolayers (Berthiaume et al. 1996; Sidler Pfändler et al. 
2004; Wang et al. 2002, 2004). In our hands, even though higher than in conventional 
monolayer controls, GTPCH activity could not be maintained employing such sandwich 
cultures as the enzyme activity was not stable over 24 hours and rapidly decayed. Also the fact 
that primary rat hepatocytes had to be cultured in presence of 0.1 µM dexamethasone and 
250 µU/mL insulin, which both interfere with BH4-synthesis, let us turn away from these cells 
(Ishii et al. 2001; Skimming et al. 2003). 
We concentrated on cell lines SK-N-BE and HepG2 but used also additional cell lines of 
hepatic origin (HHL-17 and HH-16) which were isolated from the liver of a healthy subject. 
These human primary hepatocytes were immortalised with Moloney's mouse leukaemia virus. 
Furthermore, we analysed fibroblasts of different BH4-deficient patients (SR-deficiency and 
GTPCH-deficiency) and healthy controls. We used a novel format of TaqMan RT-PCR, so-
called Micro Fluidic Cards (Applied Biosystems) to estimate gene expression. Amplification 
was measured in duplicates and single samples or samples of the same cell type and same 
treatment were measured multiple times (between 2 and 5 times) and resulted in some cases in 
considerable variations of calculated expression. Particularly genes like GCHRR, PTS, AKR1C3 
or DHFR were sometimes problematic to assess, being expressed either at the border of 
detection limit or giving inconsistent results. Strong expression was found for GCH1 (in the 
average about 50-fold induction), AKR1B1 (average induction about 3 to 4-fold compared to 
untreated controls) both induced by cytokines and a milder down-regulation of the expression, 
to 80% of levels in untreated controls, of the gene QDPR. Not only on the level of gene 
expression but also in regard of the enzyme assays and metabolite measurements were 
considerable variation observed. 
A closer look at the expression pattern of fibroblasts of patients and controls, with and without 
supplementation of cytokines revealed at least in patients with GTPCH deficiency a significant 
reduction of GCHFR expression. Whether the same holds also true for normal controls or on the 
level of protein production could not yet be verified. A similar observation was made upon 
stimulation cell cultures with lipopolysaccharide (LPS) by Werner et al. (Werner et al. 2002). 
They found a down-regulation of GCHFR expression in cultured human cells as well as in rats 
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treated with LPS in vivo. They had anticipated that GCHFR expression would be induced 
together with the protein it regulates, i.e. with GTPCH. The opposite effect was found, 
rendering GTPCH in the cells independent of the metabolic control by phenylalanine. One 
possible explanation is that in a situation where expression of GTPCH is triggered as a response 
of immunological signals (like proinflammatory cytokines or LPS) metabolic regulation, as 
accomplished by phenylalanine in the interplay with GFRP, is not necessary and can be 
circumvented by repression of GCHFR, the gene coding for GFRP. 
In a last series of experiments, we focused on HepG2 cells which were treated with cytokines, 
sepiapterin, phenylalanine, DAHP (inhibitor GTPCH via interaction with GFRP), dicumarol 
(inhibitor of SR) and virtually all possible combinations of those reagents. Gene expression was 
assessed using Micro Fluidic Cards and the cells were analysed for metabolites and enzyme 
activity of GTPCH and GFRP. As seen in the experiments above, considerable variation in gene 
expression of samples of the same type were observed. AKR1B1 responded to most agents with 
induction of gene expression and the function of activation of mRNA production remains 
unclear. In Parkinson’s patients an inverse reciprocal expression pattern of SPR and AKR1B1 
was observed (Tobin et al. 2007); such a correlation between the two could not be found in our 
study. Further, this gene was associated with potential control of stress response in experiments 
with Saccharomyces cerevisiae (Chang et al. 2003), being a general regulator of stress response 
might also serve as a potential explanation in our case. As GCH1 is constitutively active in 
HepG2 cell, the change in expression of the gene was markedly lower compared to the change 
in fibroblasts. Similarly as found in the Hep3B hepatoma cell line, biopterin and neopterin 
concentration drop in our cells closely to zero after treatment with DAHP or with dicumarol  
but in contrast to Aguado and others (Aguado 2006) we did not observe reduced gene 
expression of the PAH gene. There are additional observations concerning gene expression in 
HepG2 cell which need further investigation. 
  145 
 
 C h a p t e r  7  
DISCUSSION 
 
Outcome and Outlook 
In the here presented Ph.D. thesis, we engaged through a series of studies, metabolism, 
regulation, pharmacokinetic characteristics and implications of BH4 for patients with either 
BH4-responsive PKU/HPA or a BH4-deficiency. Chapters 2 to 6 are discussed in more detail at 
the end of the corresponding section. Here a brief summary.  
In chapter 2, Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter 
paper, we described a novel method for the analysis of pterins. Dried blood spots on filter paper 
(Guthrie cards) were introduced in the early 1960s for newborn screening, including the 
metabolic disease PKU. With the introduction of tandem mass spectrometry, a number of new 
tests were developed for blood spots. Analysis using dried blood spots became a useful 
alternative to measurements of serum, plasma or urine samples. Only minimal sample volumes 
are needed and specimens can be sent in an envelope by ordinary mail. Blood spots are used to 
measure DHPR activity in patients with HPA for the selective screening of BH4 deficiencies. 
Up to date analysis of BH4 metabolites is performed using urine. According to the profile of 
neo- and biopterin in urine, enzyme defects of BH4 metabolism can be localised. One major 
problem of analysis of pterins in body fluids is their sensitivity to light and oxygen; samples 
need to be sent frozen on dry ice or fully oxidised to the laboratory performing the analysis. In 
dried blood spots on filter paper, BH4 is already fully oxidised to biopterin and partially 
degraded to pterin. Once oxidised, pterins are stable in blood spots for about up to two weeks at 
room temperature. It was estimated that this time should be sufficient to send a sample to the 
laboratory.  
The method we developed, allows measuring amino acids, DHPR activity and pterins from a 
single Guthrie card. 
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Elution and extraction of pterins was optimised and recovery was calculated to be 63-69%. 
Concentrations of pterins from blood spots were expressed per haemoglobin, as a relatively 
high amount of neopterin and biopterin is located in erythrocytes.  
Blood spots biopterin + pterin were used to follow BH4 pharmacokinetics in healthy controls 
and patients with HPA. In a pilot study of more than 70 patients with HPA, we measured blood 
spot pterins before loading test and compared results with the standard screening method using 
urine. The profile of pterins in blood spots was identical with that found in urine collected at the 
same time. Our preliminary results suggested that blood spots on filter paper may be a practical 
alternative in differential screening of BH4 deficiencies. 
In chapter 3, Pharmacokinetics of orally administered tetrahydrobiopterin in patients with 
phenylalanine hydroxylase deficiency, we studied pharmacokinetic parameters of BH4 in PAH-
deficient patients. Even though extensive pharmacokinetic studies have been performed in 
animals, not much was known about the situation in humans. We analysed dried blood spots of 
patients after BH4 loading test. Plasma profile of total biopterin showed a first-order kinetic, 
with a fast absorption phase and a rapid decline in the distribution phase followed by a slower 
decline in the final elimination time. Similarly to what was reported in healthy controls, blood 
BH4 peaked at 4 hours in 90% of the patients. 
Data from combined Phe+BH4 loading test showed that administration of phenylalanine 
(100 mg/kg) almost doubled blood BH4 concentrations after 3 hours in about 70% of the 
patients. This is consistent with previous findings that biopterin concentration in urine or plasma 
correlates with blood phenylalanine concentrations.  
In the chapter 4, Molecular genetics of tetrahydrobiopterin-responsive phenylalanine 
hydroxylase deficiency, mutations from BH4-responsive patients (315) collected in the BIOPKU 
database were analysed for association with BH4 responsiveness. Alleles and genotypes, defined 
as BH4-responsive, were compared with data previously reported for PKU patients in several 
European countries, Northern China and South Korea. Furthermore, the PAHdb knowledgebase, 
compiling 3171 mutant alleles from all over the world, was analysed. Comparison of different 
databases and PKU studies with the BIOPKUdb allowed us to estimate both allele and genotype 
frequencies of BH4-responsiveness. 
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BH4-responsiveness seems to be multifactorial, a stabilising effect of BH4 (chaperone-like 
activity) on PAH, being probably the major mechanism. It was proposed that the responsiveness 
to BH4 in patients with PAH deficiency is probably due to suboptimal physiological 
concentrations of BH4 in hepatocytes (Kure et al. 2004). 
Our findings reveal several features common to different patient groups; both the frequency of 
potentially BH4-responsive alleles and genotypes is higher than initially assumed from the 
loading test studies; the BH4 responsiveness is characterised by a substantial residual PAH 
activity of at least one mutant allele. 
Several authors reported inconsistency of BH4-responsiveness within the same genotypes and 
questioned the genotype-phenotype correlation. Especially genotypes harbouring the mutations 
p.L48S, p.I65T, p.R158Q, p.R216Q, and p.Y414C lead frequently to controversial results. In 
addition, it has been reported that some patients who responded in the single loading test did 
less well on a continuous supplementation with BH4. 
Although there is no absolute genotype-phenotype correlation, mutation analysis provides 
useful information on potential non-responders in patients harbouring two null alleles and may, 
to some extent, predict possible BH4-responders. 
The chapter 5, Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin 
deficiency, dealt with treatment, clinical, and biochemical findings and the outcome of 26 
patients with PTPS deficiency and 10 patients with DHPR deficiency. 
Today selective screening for BH4 deficiencies is performed in most parts of the world in 
patients with even slightly increased phenylalanine levels detected in the newborn screening. 
Exact diagnosis of the type of BH4 deficiency can be made in the first weeks of life. This led to 
an early onset of therapy and prevention of the severe mental and physical disability reported of 
untreated patients. Early diagnosis is associated with better outcome. However treatment 
guidelines are vague, reports of long-term follow-up and outcome are rare and inconsistent.  
In the group of PTPS patients analysed in this study there was no clear correlation between any 
one factor and a good outcome. Indications were found that Selegiline in some cases allowed a 
lower dosage of neurotransmitter thus not only the on-off effects and the daily fluctuations 
diminished or disappeared, but probably also the known side effects of the long-term treatment. 
  148 
 
DISCUSSION 
 
Early diagnosis and correct, closely monitored therapy can reduce symptoms and prevent 
catastrophic outcome; however it remains uncertain, which factor decides whether a child will 
experience delayed development and which not. 
In the case of DHPR-deficiency an early diagnosis and early introduction of therapy in the first 
months of life appears to be crucial, as permanent brain damage occurs early in the course of the 
untreated disease. Analysis of the 10 patients supported this, suggesting a cut-off time limit for 
the therapeutic intervention of one month of life.  
In the last chapter 6, Gene expression of BH4 treated cells, preliminary results from studies 
assessing the gene expression profile of enzymes involved in the biosynthesis and in the 
recycling of the cofactor BH4 and of enzymes depending on it, are described.  
In a first step we tried to find a cell line, which expresses all enzymes involved in synthesis and 
regeneration of BH4. Most promising were the cell lines SK-N-BE and HepG2 which provided 
activities of all BH4 enzymes. 
Trying to reduce artificial effects on the level of the metabolism and gene expression, we 
investigated also in the use of primary cells, i.e. primary rat hepatocytes. As they proved a 
limited lifetime of PAH and GTPCH activity, culturing these cells in collagen sandwiches, 
which had been observed to reflect a condition much closer to the in vivo environment 
compared to normal 2D-monolayers, was tried. The GTPCH activity was slightly higher than in 
conventional monolayer controls, but could not be maintained, employing such sandwich 
cultures, for over 24 hour.  
In addition to SK-N-BE and HepG2 we used cell lines of hepatic origin (HHL-17 and HH-16) 
which were isolated from the liver of a healthy subject. Furthermore, we analysed fibroblasts of 
different BH4-deficient patients. We applied a novel format of TaqMan RT-PCR, so-called 
Micro Fluidic Cards (Applied Biosystems) to estimate gene expression. A marked change of 
expression was found for GCH1 and AKR1B1 both induced by cytokines and a milder gene 
expression down-regulation, to 80% of levels in untreated controls, of the gene QDPR by 
supplementation with sepiapterin. Not only on the level of gene expression but also in regard of 
the enzyme assays and metabolite measurements were considerable variation observed. 
A closer look at the expression pattern of fibroblasts of patients and controls, with and without 
supplementation of cytokines revealed at least in patients with GTPCH deficiency a significant 
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reduction (p ≤ 0.05) of GCHFR expression. Whether the same holds also true for normal 
controls or on the level of protein production could not yet be verified. A similar observation 
was made upon stimulation cell cultures with lipopolysaccharide (LPS). A down-regulation of 
GCHFR expression in cultured human cells was found as well as in rats treated with LPS in vivo 
(Werner et al. 2002). 
In a last series, we focused on HepG2 cells which were treated with cytokines, sepiapterin, 
phenylalanine, DAHP (inhibitor GTPCH via interaction with GFRP), dicumarol (inhibitor of 
SR) and virtually all possible combinations of those reagents. Gene expression was assessed 
using Micro Fluidic Cards and the cells were analysed for metabolites and enzyme activity of 
GTPCH and SR. As seen in the experiments before, considerable variation in gene expression 
of samples of the same type were observed. AKR1B1 responded to most agents with induction 
of gene expression and the function of activation of mRNA production remains unclear. This 
gene was associated with potential control of stress response in experiments with 
Saccharomyces cerevisiae (Chang et al. 2003), being a general regulator of stress response 
might also serve as a potential explanation in our case. As GCH1 is constitutively active in 
HepG2 cell, such a marked change in expression of the gene as in fibroblasts, was not observed. 
But by supplementation with DAHP and dicumarol the expression was increased, potentially as 
a response to increased inhibition of the enzyme through GFRP/DAHP and in the second case 
as answer to inhibition of sepiapterin reducing BH4 synthesis. Similarly as found in the Hep3B 
hepatoma cell line, biopterin and neopterin concentration drop in our cells closely to zero after 
treatment with DAHP or with dicumarol  but in contrast to Aguado and others (Aguado et al. 
2006) we did not observe reduced gene expression of the PAH gene. There are additional 
observations concerning gene expression in HepG2 cell which need further investigation. 
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Tetrahydrobiopterin (BH4) is the cofactor for phenylalanine hydroxylase (PAH) and is essential 
to treat different forms of hyperphenylalaninaemia, i.e. patients with defects in the biosynthesis 
of BH4, but also in the PAH gene (Bernegger and Blau 2002; Kure et al. 1999; Muntau et al. 
2002). Responsiveness of mutant PAH to BH4 administration relies on a chemical chaperon 
effect of BH4 preventing PAH from protein misfolding and inactivation (Thöny et al. 2004), but 
several other mechanisms may also be involved (Blau and Erlandsen 2004). Recently, we re-
ported that sublingual administration of BH4 tablets in a single control person resulted in 58%–
67% higher plasma BH4 concentrations than the usual oral route (Fiege et al. 2004). Drawbacks 
included rapid decomposition of tablets, acidic taste, and increased salivation. Since sublingual 
application could reduce therapy costs, orange flavoured artificially sweetened BH4 pastilles 
were tested on four healthy volunteers and a child with mild phenylketonuria (PKU). 
BH4 (Schircks, Switzerland) was administered to four healthy male volunteers (age 28–57 years) 
on 2 subsequent days either as tablets (50 mg) or pastilles (100 mg, con 
taining 5 mg aspartame and orange aroma) with a 1 week wash-out between the two trials. 
Blood was collected before, and 1, 2, 3, and 4 h after administration. An 8-year-old patient with 
mild PKU (genotype P281L/R261Q) who was already on regular BH4 therapy was treated with 
BH4 pastilles (sublingually, 12 mg/kg/day; bid) in addition to P-AM 2 formula for 2 weeks. 
Written consensus was obtained from the family. 
In the four healthy male volunteers, total biopterin values before and up to 4 h after oral and 
sublingual administration were compared (Fig. 1A). No statistically significant difference be-
tween oral and sublingual administration was observed. Pterin concentrations increased after 
both oral and sublingual administration, reflecting instability of BH4 in blood. The ratio of 
pterin to cumulated biopterin and pterin ranged between 22.8% and 33.5%. Summing biopterin 
and pterin instead of total biopterin did not alter the ratio between oral and sublingual 
administration (data not shown). 
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Changing from standard therapy to sublingual administration in a child with mild PKU resulted 
in almost unchanged plasma phenylalanine concentrations (Fig. 1B). After 2 weeks of twice 
daily sublingual BH4 administration, the patient complained of a painful prickling sensation at 
the tip of the tongue. He nevertheless continued the treatment for a further 10 days, moving the 
tablets in his mouth from one side to the other, which resulted in severe mucitis. His condition 
normalised rapidly upon discontinuation of the sublingual form. No mucitis appeared in healthy 
volunteers. 
APPENDIX 
 
A clinical trial with sublingual BH4 in a patient with mild PKU failed despite pharmacological 
effectiveness on blood phenylalanine levels because of an adverse pastille-related side-effect. 
Formulation of buffered tablets approaching neutral pH and further investigations on BH4 
metabolism and pharmacokinetics are needed. 
 
 
Fig. 1. (A) Comparison of total plasma biopterin levels (median ± SD) after oral or sublin-
gual administration of BH4 (2 mg/kg) in four healthy volunteers at different time points. (B) 
Dried blood spot phenylalanine (solid squares) and biopterin (open squares) measured 3 h 
after oral (15 mg/kg) or sublingual (12 mg/kg) administration of BH4 in a patient with mild 
PKU (s.l. sublingual) 
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